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1.  General Introduction  
Platelets are small, enucleated blood cells that play an important role to 
stop bleeding at the site of disrupted endothelium. This process consists of 
different steps including platelet adhesion, platelet activation and platelet 
aggregation (termed primary hemostasis), followed by activation of the 
coagulation cascade (termed secondary hemostasis). This reaction cascade is 
maintained and regulated by several receptors expressed on the platelet surface. 
Recent studies, however, indicated that platelets also contribute to innate and 
adaptive immunity (Semple et al. 2011). Consequently, low platelet count due to 
either decreased production or increased destruction (termed thrombocytopenia) 
and functional platelet dysfunction (termed thrombocytopathy) may not only lead 
to bleeding disorders but also to other immune mediated diseases (van Ommen 
& Peters 2012). 
The IIb3 integrin represents the most abundant receptor on platelets 
responsible for platelet adhesion and aggregation mediated by interaction with 
von Willebrand factor (vWF) and fibrinogen, respectively. In addition, platelets 
also express v3, which is functionally important as vitronectin receptor for the 
platelet attachment to endothelium (Gawaz et al, 1997). The IIb subunit is 
exclusively expressed in platelets and their precursor megakaryocytes (Grimaldi 
et al. 1998), whereas the v and β3 subunits are also found on endothelial 
progenitor cells (Caiado & Dias 2012), angiogenic endothelial cells  (Weis & 
Cheresh 2011), microglia (Milner 2009), astrocytes (Avalos et al, 2009), 
cytotrophoblast (Zhou et al. 1997)  and syncytiotrophoblast cells of the placenta 
(Kumpel et al. 2008). 
Several studies in the last recent decades documented that platelet 
reactive antibodies against IIb3 integrin can cause platelet destruction leading 
to immune mediated thrombocytopenia and bleeding. In addition, the hereditary 
defect of IIb3 expression on platelets can impair platelet functions associated 
with the bleeding tendency. However, little is known about the role of v3 and 
anti-v3 antibodies in this context. 
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1.1. 3 Integrins 
Integrins are a large family of heterodimeric transmembrane 
glycoproteins, which function as adhesive receptors promoting cell-cell and cell-
extracellular matrix interactions. Integrins plays a significant role in several 
biological processes such as platelet aggregation, inflammation, immune 
function, wound healing, metastasis, and tissue migration during embryogenesis. 
Currently, 18 - and 8 -subunits form 24 different integrins (Figure 1). 
Interaction of integrins with their binding partners can induce bi-directional 
signals, known as outside-in and inside-out signaling (Hynes 2002; Harburger & 
Calderwood 2009). This novel signal transduction pathway is not only important 
for the regulation of ligand binding but also for the modulation of transmembrane 
protein kinases (e.g receptor tyrosine kinases). Depending on the integrin 
regulation, specific receptor tyrosine kinases can be recruited which leads to cell 
growth, cell division, cell survival, cellular differentiation, and apoptosis 
(programmed cell death).  
The 3-integrin family consists of two members, the IIb3 and v3 
heterodimers.  The IIb3 integrin is only found in platelets and megakaryocytes. 
On platelets, IIb3 (50.000 - 80.000 copies/platelet) acts as a primary receptor 
for vWF, fibrinogen and other ligands (vitronectin, fibronectin, and 
thrombospondin) (Bennett 2005). The  and  subunits are produced 
independently. In the endoplasmic reticulum, high mannose N-linked 
oligosaccharides are assembled into the pro-IIb precursor prior to the formation 
of pro-IIb3 heterodimer. Subsequently, this complex is transported into the 
Golgi where pro-IIb undergoes further processing; conversion of mannose into 
complex oligosaccharides, and proteolytic cleavage of the pro-IIb into a 
disulfide-linked light and heavy chains. Afterwards, the mature form of IIb3 
complex is expressed on the cell surface or stored within alpha granules (Floyd & 
Ferro 2012). The v3 integrin is synthesized by a similar mechanism (Grimaldi 
et al. 1998).  However, other than IIb, v subunit does not undergo proteolytic 
cleavage. Furthermore, IIb3 complex formation is calcium-dependent, whereas 
v3 is magnesium-dependent (Bray et al. 1988).  
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Figure 1: The integrin superfamily  
The heterodimer formation of v and IIb with different  subunits is highlighted. 
Figure adapted from Chai and Chen, 2008.  
 
The v3 integrin, known as vitronectin receptor, represent as minor 
integrin on platelets (50-100 copies/platelet). However, v3 integrin is found 
abundantly on osteoclasts, on endothelium and various other tissues such as, in 
tumors (Brooks et al. 1994; Horton 1997). Likewise, v3 integrin plays an 
important regulatory role in angiogenesis (Mahabeleshwar et al. 2007; Weis & 
Cheresh 2011). In contrast to IIb, v can form heterodimers with different 
subunits (1, 35, 6, 8) (Figure 1). Interestingly, recent evidence showed the 
reciprocal involvement of v3 and v5 in angiogenesis, with v3 play a role in 
modulating VEGF (Soldi et al. 1999; Mahabeleshwar et al. 2007). In addition, the 
ligation between v3 and extracellular matrix is essential for cell survival. The 
inhibition of this interaction by monoclonal antibodies, RGD peptide or 
peptidomimetic agents will lead to cell apoptosis (anoikis) (Brassard et al. 2015; 
Eliceiri & Cheresh 1998; Brooks et al. 1994;  Montgomery et al. 1994), and 
prevents angiogenesis (Montenegro et al. 2012; Maubant et al. 2006). 
Recent structural analysis showed that both IIb and v consist of an 
amino-terminal -propeller domain followed by a thigh domain and two calf 
domains. The 3 subunit has eight domains; an amino-terminal PSI (plextrin-
General Introduction 
4 
 
semaphorin-integrin) domain, Ig-like hybrid domain containing ligand-binding site, 
A-hybrid domain, four EGF-like domains, and the β-tail domain. Under resting 
conditions, the headpiece of the integrin faces down towards the membrane and 
extends upwards in a "switchblade"-like opening upon activation (Figure 2). 
These long-range structural rearrangements of the entire integrin molecule 
involving inter-domain contacts appear closely linked to conformational changes 
within the I-like domains, which result in increased affinity and competence for 
ligand binding (Takagi & Springer 2002). 
In humans, naturally occurring SNPs leading to single amino acid 
substitutions were found on IIb and 3. By the identifications of the domains 
(see Figure 2), point mutations which are responsible for the formation of 
alloantigen determinant(s) can be located more precisely. Immunization against 
such polymorphic structure(s) expressed as human platelet antigens (HPA) may 
result in the production of platelet alloantibodies (see below).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2:  The three dimensional structure of integrin IIb3 
Schematic structure of the IIb3 on resting platelets (A) and on activated 
platelets (B). Figure adapted from Xiong et al, 2001. 
 
IIb 3 
Bent conformation Extended conformation 
activation 
Resting platelets Activated platelets 
A B 
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In some cases, SNPs can also impair IIb3 synthesis leading to platelet 
dysfunction. Some SNPs on the v subunit associated with susceptibility to 
chronic hepatitis B and hepatocellular carcinoma have been reported (Yang et al. 
2014; Mathew et al. 2016). However, alloantibodies against v3 have not been 
described so far.  
1.2. SNPs on IIb3 Integrin creating Alloantigenic Determinants  
 Integrin IIb3 is the most immunogenic integrin on platelets (Table 1). 
Among common HPA systems, HPA-1 or previously designated as PlA1/A2 or Zwa/b 
was the first HPA system implicated in FNAIT (van der Weerdt et al. 1963; 
Shulman 1962). HPA-1 system is a result of a single nucleotide change C>T that 
leads to an amino acid substitution leucine to proline at position 33. This point 
mutation is located on the PSI domain of the 3 subunit, a 13 amino acids long 
loop formed by disulfide bonds between cysteine residues 26 and 38 (Figure 3) 
(Newman et al. 1989; Calvete et al. 1991; Xiong et al. 2004). A rare mutation 
leucine into valine at position 33 has also been described (Santoso et al. 2006). 
Table 1: Common Human Platelet  Alloantigens (HPAs)  
Antigen Synonym GP 
Location 
Gene 
Name 
Nucleotide 
Substitution 
Aminoacid 
Substitution 
HPA-1a Zwa, PlA1 GPIIIa ITGB3 T176 Leu33 
HPA-1b Zwb, PlA2   C176 Pro33 
HPA-2a Kob GPIb GP1BA C482 Thr145 
HPA-2b Koa, Siba   T482 Met145 
HPA-3a Baka, 
Leka 
GPIIb ITGA2B T2621 Ile843 
HPA-3b Bakb   G2621 Ser843 
HPA-4a Yukb, 
Pena 
GPIIIa ITGB3 G506 Arg143 
HPA-4b Yuka, 
Penb 
  A506 Gln143 
HPA-5a Brb, Zavb GPIa ITGA2 G1600 Glu505 
HPA-5b Bra, Zava   A1600 Lys505 
 
Although the location of amino acid substitution could be identified, little is 
currently known about the exact structure of HPA-1a alloantigenic determinant(s). 
Synthetic peptides could not mimic HPA-1a (Flug et al. 1991)  indicating that the 
three dimensional structure of 3 integrin facilitated by multiple disulfide bonds, 
especially within the PSI domain, play an important role in the formation of HPA-
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1a alloantigenic epitopes. Furthermore, some HPA-1a epitopes need additionally 
the presence of intact hybrid/EGF1 domains (Valentin et al. 2016). Naturally 
occurring substitution of the distally located residue 93 (Arg>Gln) at the 
hybrid/PSI interface disrupts the HPA-1a epitope for some anti-HPA-1a 
antibodies (Jallu et al. 2013).  
 
 
Figure 3: The ectodomain three-dimensional structure of the 3. 
The PSI domain is harboring Leu33Pro mutation responsible for the formation of 
HPA-1a and HPA-1b, respectively. Figure adapted from Jallu et al. 2012 
 
Additionally, the HPA-3 system located on the IIb integrin subunit has 
been described (see Table 1). The HPA-3 system also known as Baka/b results 
from a T>G base substitution at position 2621 located on the calf 2 domain of 
IIb. This substitution determines the presence of isoleucine or serine at position 
843 of the mature protein (Covas et al. 2000; Lyman et al. 1990). The HPA-3 
alloantigen system is less well characterized, although it is known that anti-HPA-3 
antibodies react with 76- and 60-Kd fragments of the GPIIb heavy chain. Unlike 
the HPA-1a system, the HPA-3 alloantigenic determinants do not seem to be 
sensitive to disulfide bond reduction, suggesting that they may comprise of the 
linear peptide (Landau & Rosenberg, 2011). However, Goldberger et al. (1991) 
and Calvete & Muniz-Diaz (1993) propose that the O-glycosylation site at serine 
847 represents an additional critical component of HPA-3a epitopes. This 
carbohydrate residue seems to be a labile component; treatment of HPA-3a 
phenotyped platelets with neuraminidase reduced the binding affinity of some 
HPA-3a antibodies (Take et al. 1990). Besides common of HPAs, rare HPAs 
residing on IIb and 3 subunits have been discovered. Currently, 13 HPAs 
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located on 3 subunit (see Table 2) and only a few rare HPAs were found on the 
IIb subunit (see Table 3).  
Table 2: Rare Human Platelet Alloantigens (HPAs) residing on 3  
Antigen GP 
Location 
Gene 
Name  
Nucleotide 
Substitution 
Aminoacid 
Substitution 
Reference 
HPA-6b GPIIIa ITGB3 1544G>A Arg489Gln Wang et al. 
1993 
HPA-7b GPIIIa ITGB3 1297C>G Pro407Ala Kuijpers et al. 
1993 
HPA-7c GPIIIa ITGB3 1297C>T Pro407Ser Koh et al. 
2010 
HPA-8b GPIIIa ITGB3 1984C>G Ag636Cys Santoso et al. 
1994 
HPA-10b GPIIIa ITGB3 263G>A Arg62Gln Peyruchaud 
et al. 1997 
HPA-11b GPIIIa ITGB3 1976G>A Arg633His Simsek et al. 
1997 
HPA-14b GPIIIa ITGB3 1909-1911 
deletion 
AAG 
Lys611del Santoso et al. 
2002 
HPA-16b GPIIIa ITGB3 497C>T Thr140Ile Jallu et al. 
2002 
HPA-17b GPIIIa ITGB3 622C>T Thr195Met Stafford et al. 
2008 
HPA-19b GPIIIa ITGB3 487A>C Lys137Gln Peterson et 
al. 2010 
HPA-21b GPIIIa ITGB3 1960G>A Glu628Lys Peterson et 
al. 2010 
HPA-23b GPIIIa ITGB3 1942C>T Arg622Trp Peterson et 
al. 2012 
HPA-26b   GPIIIa ITGB3 1818G>T Lys580Asn Sachs et al. 
2012 
Khaa GPIIIa ITGB3 98C>T Thr7Met Sullivan et al. 
2015 
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Table 3: Rare Human Platelet Alloantigens (HPAs) residing on IIb  
Antigen GP 
Location 
Gene 
Name 
Nucleotide 
Substitutio
n 
Aminoacid 
Substitution 
Reference 
HPA-9b GPIIb ITGA2B 2602G>A Val837Met Noris et al. 
1995 
HPA-20b GPIIb ITGA2B 1949C>T Thr619Met Peterson et al. 
2010 
HPA-22b GPIIb ITGA2B 584A>C Lys164Thr Peterson et al. 
2012 
HPA-24b GPIIb ITGA2B 1508G>A Ser472Asn Jallu et al. 
2011 
HPA-27b GPIIb ITGA2B 2614C>A Leu841Met Jallu et al. 
2013 
HPA-28b GPIIb ITGA2B 2311C>G Val740Leu Poles et al. 
2013 
Lapa GPIIb ITGA2B 2511G>C Gln806His Wihadmadya 
tami et al. 
2015 
 
The fact that the polymorphic integrin 3 participates in the formation of 
the v3 heterodimer is underestimated. Theoretically, this condition can also 
create single and/or complex antigenic epitopes which are recognized by the 
different types of platelet alloantibodies.   
1.3 SNPs on 3 Integrin affecting Receptor Synthesis and Functions  
 
Some SNPs on IIb or 3 integrin can also affect mRNA stability and 
posttranslational processing of the proteins, and thereby impair the correct 
biosynthesis of IIb3 (Bellucci & Caen 2002; Nurden 2006). In most cases, 
mutations result in low expression or total absent of IIb3 expression on the 
platelet surface, which leads to functional defects of the receptor and, 
consequently, impaired platelet aggregation (hemostasis). Some of the mutations 
were found in the cytoplasmic domain of IIb or 3 demonstrating the importance 
of this domain in integrin signaling (Chen et al. 1992; Peyruchaud et al. 1998; 
Raborn et al. 2011; Wang et al. 1997). In addition, others mutations located in the 
EGF domain of 3 give rise to a constitutively active receptor (Chen et al. 2001; 
Ruiz et al. 2001).  
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Interestingly, no correlation was observed between the amount of residual 
platelet IIb3 and the severity of the hemorrhagic events (George et al. 1990; 
Nurden. 2006; Nurden et al. 2011). Since the 3 integrin subunit represents the 
common subunit of IIb3 and v3 heterodimer, a defect in 3 can theoretically 
alter the biogenesis and/or structure of v3 integrin as well. It is feasible to 
speculate that absence of v3 function in vascular cells contribute to 
hemorrhage (George et al. 1990; Nurden et al. 2011).  
 
1.4. Immune Mediated Thrombocytopenia  
In addition to their role in hemostasis, platelet IIb3 integrin carries antigenic 
determinant(s), which are frequently targeted by platelet reactive antibodies 
recognizing either polymorphic structure (called alloantibodies) or common 
structure (called isoantibodies). Patients or mothers receiving “alloantigen-
incompatible” platelets due to platelet transfusions and during pregnancy, 
respectively, usually produce platelet alloantibodies. Consequently, platelet 
reactive alloantibodies can cause alloimmune-mediated disorders, such as 
platelet transfusion refractoriness (PTR) and fetal neonatal alloimmune 
thrombocytopenia (FNAIT). Similarly, patients or mothers with 3 receptor 
deficiency (Glanzmann Thrombasthenia; see below) can produce platelet 
isoantibodies after platelet transfusion or pregnancy, respectively.  
1.5. Diseases associated with platelet alloantibodies 
The binding of platelet allo- or isoantibodies can induce platelet clearance 
by reticuloendothelial cells via Fc receptors. Three different disorders associated 
with this pathomechanism are known: Post Transfusion Purpura (PTP), Platelet 
Transfusion Refractoriness (PTR) and Fetal Neoanatal Alloimmune 
Thrombocytopenia (FNAIT).  
1.5.1. Post Transfusion Purpura (PTP) 
Post-transfusion purpura (PTP) is a rare transfusion reaction leading to 
severe thrombocytopenia which occurring approximately seven until ten days 
after blood transfusions. Its incidence is 1 in 50.000–100.0000 blood transfusions 
and occurs more commonly in multiparous women (Padhi et al. 2013). This 
disorder is mediated by alloantibodies against specific platelet antigens, most 
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commonly HPA-1a. However, the exact mechanism of PTP is unclear. Some 
studies have proposed that HPA-1a and HPA-1b share certain antigens, and thus 
could induce an alloantibody response, leading to platelet destruction. In addition 
was also proposed, the involvement of immune complexes (Schulman et al. 
1961; Kaplan 2002). Intravenous immunoglobulin (IVIG) with and without 
corticosteroids has been used as first-line therapy (Kaplan 2002).  
1.5.2. Platelet Transfusion Refractoriness (PTR) 
PTR is defined as a failure of multiple platelet transfusions from random 
donors to improve the recipients platelet counts. Alloantibodies against human 
leucocyte alloantigen (HLA) class I as well as against HPAs have been 
documented (Kiefel et al. 2001). Transfusion of HLA and/or HPA compatible 
platelets is the treatment of choice (Hod and Schwartz,2008).  
1.5.3. Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT) 
Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding 
disorder of the fetus and newborn caused by binding of maternal platelet 
alloantibodies to the infant’s platelets, leading to their destruction during 
pregnancy or after birth (see Figure 1). Thrombocytopenia in the fetus/neonate is 
defined as platelet count <150 × 109/L (Ghevaert, et al. 2007; Kjeldsen-Kragh et 
al. 2007). FNAIT is estimated to occurs in around 1:1,500-2,000 live births  
(Kjeldsen-Kragh et al. 2007; Kaplan 2006; Bussel et al. 2005) The occurrence of 
FNAIT in primiparous women is surprisingly high, more than 50% of all FNAIT 
cases. Antibodies against HPA-1a are the most frequent cause of FNAIT (80%) 
in Caucasians (Symington & Paes 2011). The clinical consequences of FNAIT 
include petechiae, hematoma, urogenital bleeding, intrauterine growth restriction, 
and fetal demise (Kaplan 2006).  
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Figure 4:  Mechanism of Fetal Neonatal Alloimmune Thrombocytopenia  
During pregnancy, a HPA-1b positive mother (blue) develops anti-HPA-1a 
alloantibodies against HPA-1a positive platelets of the fetus (red). This IgG 
alloantibody can cross the placenta, binds to fetal platelets, leads to platelet 
destruction, and induces thereby thrombocytopenia and sometimes bleeding.  
 
The most devastating risk of FNAIT is intracranial hemorrhage (ICH) 
leading to death or persistent neurological sequelae in approximately 10% of the 
clinically symptomatic cases (Figure 2) (Giers et al. 1996; Mueleler-Eckhardt et 
al. 1989.; Bussel et al. 2005; Spencer & Burrows 2001). It is currently unclear 
which factors determine whether ICH will occur. Modality of birth, birth weight, 
and the presence of other bleeding symptoms are not associated with ICH, and 
the association between low platelet counts and ICH is loose (Kroll et al. 2005; 
Thude et al. 2006). In subsequent pregnancies of mothers immunized against 
HPA-1a, only sibling history, but no laboratory test has been shown to be 
predictive for the risk of ICH (Birchall et al. 2003; Radder et al. 2003). 
  
Fetus Mother 
HPA-1a HPA-1b 
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Figure 5: Clinical presentation of neonates with severe FNAIT 
Generalized petechiae (upper) and cerebral bleeding (below) as shown by 
Magnetic Resonance Image. Figure adapted from Silva et al, 2011. 
 
Routinely, the diagnosis of suspected FNAIT cases is approved by 
incompatibility between the HPA genotype of the mother and the child/father and 
by the identification of the corresponding platelet alloantibodies. To date, HPA 
typing is mainly performed by molecular-based methods (such as, PCR-SSP). 
Several methodological approaches for the detection of platelet alloantibodies 
exist. However, antigen capture assay (such as MAIPA; monoclonal antibody 
immobilization platelets specific alloantigens) is currently being used as the gold 
standard in platelet antibody detection (Kiefel et al. 1987).  
 
In the prenatal period, treatment to maintain fetal platelets counts and to 
prevent bleeding during pregnancy are recommended including administration of 
intravenous IgG (IVIG) with and without corticosteroid in mothers, intrauterine 
transfusion with HPA-compatible platelets, fetal blood sampling (McQuilten et al. 
2011), and fetal early delivery (Bussel 1997). Among these, IVIG seems to be 
most effective. It does not impair the maturation of the neonatal immune system 
(Rayment et al. 2011; Berkowitz et al. 2006). 
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Postnatal treatment aims to increase the platelets counts of the infant. 
Infusion of IVIG can be used although up to three days are required to reach a 
normal platelet count. Transfusion with HPA-matched platelets is recommended 
(McQuilten et al. 2011; Paterson et al. 2012). This approach shows higher 
platelet increment when compared to random platelets. Silent ICH in neonates 
with severe FNAIT has been observed (Bussel et al. 2005). Since the clinical 
diagnosis from ICH is not straight forward for all of neonates with suspected 
FNAIT, brain imaging is recommended especially for the neonates with the 
platelet count less than 50x109 ⁄ L. 
 
1.6. Disease associated with platelet isoantibodies 
Mutations based on genetic defects of IIb or 3 are responsible for 
lacking, diminished expression, or functional defects of IIb3 associated with a 
life long bleeding tendency, as observed in patients with Glanzmann 
Thrombasthenia. Transfusion of these patients with normal platelets from healthy 
donors can lead to the production of isoantibodies against IIb3 integrin. 
1.6.1. Glanzmann Thrombasthenia  
Glanzmann Thrombasthenia (GT) is an inherited rare autosomal 
recessive bleeding disorder caused by a quantitative and/or qualitative deficiency 
of IIb3. Laboratory analysis shows normal platelet count and morphology, but 
absent platelet aggregation responses to different platelet agonists (adenosine 
diphosphate, collagen, arachidonic acids, epinephrine) (Nair et al. 2016). 
However, platelets respond normally to ristocetin. GT patients are categorized 
into three types according to the number of IIb3 expressed on the platelet 
surface. Type I GT patients express <5% IIb3, type II GT patients express 5-
20% IIb3 and type III GT (variant) patients express a normal amount of IIb3, 
but with functionally defects (Ambo et al. 1998; Siddiq et al. 2011). GT are found 
in several ethnic groups including Caucasians, Indians, Iranians, Iraqi Jews,  
Jordanian, Arabs and French Gypsies (Nurden et al. 2011; Chandrakala et al. 
2012). Clinical symptoms of this disease occur early after birth and include 
episodic severe mucocutaneous or gastrointestinal bleeding, unprovoked 
bruising, epistaxis  and  prolonged bleeding after trauma or surgical interventions. 
In a woman, copious menstrual hemorrhage accompanies this disorder. 
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Recently, around 250 naturally occurring mutations in the IIb (ITGA2B) or 3 
(ITGB3) genes affecting biosynthesis and/or structure of the IIb3 complex 
leading to GT disease  have been reported; 138 mutations on ITGA2B (138 
mutations), and 101 mutations on ITGB3 (see http:// sinaicentral. mssm. edu/ 
intranet/ research/ glanzmann) (Fiore et al. 2012; Tokgoz, et. al., 2015).  
Treatment of GT patients depends in disease severity. Mild bleeding is 
treated conventionally by compression, local haemostatic agents, hormonal 
therapy and anti-fibrinolytics. Treatment with platelet transfusion(s) can be 
necessary in more severe bleeding. It however, may provoke isoimmunisation 
against IIb3, which in turn can lead to platelet transfusion refractoriness. To 
overcome this problem, treatment with recombinant factor VII, especially for 
refractory patients, is recommended (Poon et al. 2015). Mother with GT may 
develop isoantibodies directed against IIb3 expressed of foetal platelets 
leading to the development FNAIT (Leticee et al. 2005; Siddiq et al. 2011).  
 
1.7. Anti-HPA-1a alloantibodies may react with endothelial cells  
Endothelial cells are the thin layer of cells that lines the basal surface of 
blood vessels. Therefore, alterations at the level of the endothelium are crucial to 
understand the nature of vascular diseases and organ damage (Hernandez et al. 
2012). Naturally, the v3 integrin is found on endothelial cells and plays an 
important role in angiogenesis and vasculogenesis during blood vessel 
development. Furthermore, upregulation of endothelial v3 is observed during 
inflammation which is mediated by vascular endothelial growth factor (VEGF) and 
fibroblast growth factor (FGF). 
 
Anti-endothelial antibodies were detected in tissues of kidney biopsies 
and sera of patients with rheumatic diseases and Systemic Lupus Erythematosus 
(SLE) (Lindqvist et al, 1971; Renaudineau et al. 1999). In addition, several 
investigations reported the presence of anti-endothelial antibodies in systematic  
autoimmune and vascular disorders such as Rheumatoid Arthritis, Wegener 
Granulomatosis (Sebastian et al, 2007), Kawasaki Disease (Grunebaum et al. 
2002), Behcet’s Disease (Cervera et al. 1994), Takayasus Arteritis, Microscopic 
Polyangitis (Chanseaud et al. 2003) and Inflammatory Bowel Diseases (Aldebert 
et al, 1995). Recently, our group could demonstrate that alloantibodies against 
General Introduction 
15 
 
neutrophil antigen (HNA-3a) cross-react with endothelial cells,  thereby interfere 
with endothelial function, leading to transfusion related acute lung injury (TRALI) 
(Bayat et al. 2015; Sachs et al. 2006). Furthermore, accumulated evidence 
shows that alloantibodies against HLA expressed on endothelial cells are 
responsible for organ transplant rejection (Valenzuela & Reed 2014). 
 
Some studies investigating the effect of maternal anti-HPA-1a 
alloantibodies on the endothelial cells were performed in the past. Radder et al. 
(2004) described that anti-HPA-1a alloantibodies did not cause activation and 
damage of endothelial cells In contrast, Gils et al. (2009) found that HPA-1a 
alloantibodies could inhibit endothelial cell spreading and interfere with 
endothelial cell monolayer integrity. It has also been speculated that anti-HPA-1a 
antibodies may affect placental development (Tiller et al. 2012).  
 
More recently, Yougbaré  and coworkers (2015) demonstrated in an 
animal model that anti-3 integrin antibodies can impair angiogenesis in the fetal 
brain, indicating that anti-HPA-1a antibodies reactive with endothelial cells may 
be responsible for the development of ICH. The question why and how only some 
anti-HPA-1a alloantibodies are capable of inducing ICH was the focus of our 
investigation. 
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2. The Objectives of the Study 
 
This study arose from the following questions and considerations: 
 
Although HPA-1a alloantibodies as a cause of FNAIT in Caucasian 
population are well established, little is currently known about the relevance of 
platelet antibodies in Southeast Asian population, especially in Malays (Malaysia 
and Indonesia). Consequently, analysis of platelet alloantibody specificities in 
suspected FNAIT among Malays is mandatory to approach this question (see 
manuscript # 1).  
 
In Caucasians population, most of the FNAIT cases are provoked by 
platelet alloantibodies against HPA-1a. In some severe FNAIT cases, maternal 
anti-HPA-1a antibodies can induce intracranial hemorrhage in the fetus during 
the pregnancy, leading to disability or death. The mechanism how these 
antibodies can cause severe bleeding in the fetal brain is not well understood. 
Also, little is known about the prediction and specific treatment of this severe 
FNAIT. Several studies indicate that neither platelet counts nor platelet antibody 
titer seem to be reliable predictors for the occurrence of ICH. Recent data from 
our center and others suggest that endothelial disturbance caused by endothelial-
reactive antibodies can trigger bleeding. In this study, the effects anti- HPA-1a 
antibodies on endothelial cells was investigated (see manuscript #2). 
Furthermore, studies on other related diseases should confirm the existence of 
such endothelial-reactive antibody (see manuscript #3).  
 
More recently, our group has demonstrated that a de-glycosylated mouse 
monoclonal IgG antibody against HPA-1a (called SZ21) can prevent platelet 
destruction and can be transported through the placenta making (rendering) 
prenatal treatment of FNAIT feasible. Meanwhile, this monoclonal antibody is 
humanized (called 813) and can be produced as a recombinant protein in 
mammalian cells. We analyzed the effect of de-glycosylated 813 (called d-813) 
on endothelial function and asked the question whether d-813 could prevent 
endothelial dysfunction caused by maternal anti-HPA-1a antibodies (see 
manuscript # 4). 
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Besides HPA-1a, several rare HPAs associated with FNAIT have been 
discovered in the last two decades. Although most rare HPAs are found among 
Caucasian, some are detected exclusively in the Asian population. Hence, 
characterization of new platelet alloantigen is important to augment the role of 
platelet alloantibodies in the pathomechanism of FNAIT (see manuscript # 5). 
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3. Manuscripts 
3.1. Manuscript #1 
Platelets Reactive Alloantibody Responsible for Immune Thrombocytopenia 
in Malay Population  
Mohamad Ismail Armawai, Afifah Hasan, Hevi Wihadmadyatami and Sentot 
Santoso. 
Medical Journal of Indonesia, 2014; volume 23, pages 158 – 162; see attachment 
1. 
 
Abstract 
Background: Alloantibodies against human platelet alloantigens (HPAs) are 
responsible for the development of platelet transfusion refractoriness (PTR) in 
patients receiving random platelets and bleeding disorder in babies with fetal 
neonatal alloimmune thrombocytopenia (FNAIT). Recently, our results based on 
the analysis of the allelic distribution of HPAs indicated that immunization may 
occur among Malay. In this study, we sought to analyze the frequencies of 
platelet reactive alloantibodies responsible for FNAIT and PTR in Malaysia.  
Methods: Sera from suspected FNAIT (n = 295) and PTR (n = 74) were collected 
in five years period (2008- 2013) and tested for the presence of platelet reactive 
antibodies by the use of antigen capture assay.  
Results: In 5/74 (5.41%) platelet specific antibodies against HPA-2b (n = 1), 
HPA-5a (n = 1), HPA-5b (n = 1), HPA-15b (n = 2) could be identified in our PTR 
cohort. In FNAIT cohort, platelet specific alloantibodies could be detected in 18 
sera (6.10%) consisting anti-HPA-1a (n = 1), anti-HPA-3a (n = 3), anti-HPA-5a (n 
= 6), anti-HPA-5b (n = 6), anti-HPA-15a (n = 1), and anti-HPA-15b (n = 1).  
Conclusion: Our study indicates that anti-HPA-3, -HPA- 5 and -HPA-15 
antibodies seem to be the most platelet specific antibodies involved in FNAIT and 
PTR cases in Malaysian population. Since similar HPA allelic distribution among 
Malaysian and Indonesian populations have been observed, immunization 
against these three HPA systems are expected to be the most potential risk of 
alloimmune mediated platelet disorders in Indonesia.  
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3.2. Manuscript #2 
Anti-endothelial v3 Antibodies are a Major Cause of Intracranial Bleeding 
in Fetal/ Neonatal Alloimmune Thrombocytopenia.  
Sentot Santoso, Hevi Wihadmadyatami, Tamam Bakchoul, Silke Werth, Nadia Al-
Fakhri, Gregor Bein, Peter J. Newman, Jieqing Zhu, Volker Kiefel, Behnaz Bayat 
and Ulrich J. Sachs  
Atherosclerosis, Thrombosis, and Vascular Biology, Thrombosis, and Vascular 
Biology, 2016, volume 36, pages 1517-24; see attachment 2. 
 
Abstract 
Objective - Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a severe 
bleeding disorder which can result in intracranial hemorrhage (ICH), leading to 
death or neurological sequelae. In Caucasians, maternal anti-HPA-1a antibodies 
(abs) are responsible for the majority of cases.  No predictive factors for ICH are 
available to guide prophylactic treatment during pregnancy. In this study, we 
investigated abs from mothers with ICH-positive FNAIT and with ICH-negative 
FNAIT in order to identify serological and functional differences between the 
groups.  
Approach and Results - In an antigen capture assay, we observed a stronger 
binding of +ICH abs to endothelial cell (EC)-derived v3. By absorption 
experiments, we subsequently identified anti-HPA-1a abs of anti-v3 specificity 
in the +ICH, but not in the -ICH cohort. Only the anti-v3 subtype, but not the 
anti-3 subtype, induced EC apoptosis of HPA-1a positive ECs by caspase-3/7 
activation, mediated by reactive oxygen species. In addition, only the anti-v3 
subtype, but not the anti-3 subtype, interfered with EC adhesion to vitronectin 
and with EC tube formation. 
Conclusions - We conclude that the composition of the anti-HPA-1a antibody 
subtype(s) of themother may determine whether ICH occurs. Analysis of anti-
HPA-1a abs of the anti-v3 subtype in maternal serum has potential in the 
diagnostic prediction of ICH development and may allow for modification of 
prophylactic treatment in FNAIT. 
  
Manuscripts 
20 
 
3.3. Manuscript #3 
Immunization Against II3 and v3 in a Type 1 Variant of Glanzmann’s 
Thrombasthenia caused by a Missense Mutation Gly540Asp on 3  
Hevi Wihadmadyatami, Heike Berghofer, Lida Röder, Gregor Bein, Kathrin 
Heidinger, Ulrich J. Sachs and Sentot Santoso  
Thrombosis and Haemostasis, 2016, volume 116, pages 262-71; see attachment 
3. 
 
Abstract 
Treatment of bleeding in patients with Glanzmann’s thrombasthenia (GT) can be 
hampered by iso-antibodies against the IIb3 integrin, which cause rapid 
clearance of transfused donor platelets. Type 1 GT patients with a total absence 
of IIb3 from the platelet surface are known to be susceptible to form such 
isoantibodies. In this study, we describe a type 1 GT patient with a missense 
mutation (Gly540Asn) located in the EGF3 domain of the 3 integrin subunit. 
Cotransfection analysis in CHO cells demonstrates total absence of IIb3 from 
the surface, based on inappropriate IIb maturation. The patient’s serum was 
reactive with IIb3 and v3 integrins in a capture assay, when platelets and 
endothelial cells were used. Two specificities could be isolated from the patient’s 
serum, anti-IIb3 and anti-v3 isoantibodies. Both specificities did not interfere 
with platelet aggregation. In contrast, isoantibodies against v3, but not against 
IIb3, were able to disturb endothelial cell adhesion onto vitronectin, triggered 
endothelial cell apoptosis and interfered with endothelial tube formation. This 
intriguing finding may explain more recently observed features of fetal/neonatal 
iso-immune thrombocytopenia in children from type 1 GT mothers with 
intracranial haemorrhage, which could be related to anti-endothelial activity of the 
maternal antibodies. 
In conclusion, we give evidence that two isoantibody entities exist in type 1 GT 
patients, which are unequivocally different, both in an immunological and 
functional sense. Further research on the clinical consequences of immunization 
against v3 is required, predominantly in GT patients of childbearing age. 
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3.4. Manuscript #4 
Human Monoclonal Antibody against HPA-1a inhibits anti-HPA-1a Mediated 
Endothelial Disturbance.  
Hevi Wihadmadyatami, Tamam Bakchoul,  Gregor Bein, Behnaz Bayat, Ulrich J. 
Sachs and Sentot Santoso  
Manuscript in preparation; see attachment 4. 
 
Abstract 
In this study, we proved whether modified human monoclonal antibody 
against HPA-1a (mab 813), can prevent endothelial dysfunction induced by 
maternal anti-HPA-1a alloantibodies. For this purpose, we removed the N-linked 
carbohydrate component of mab 813 by digestion with N-glycanase. This 
modified mab 813 (termed d-813) has several advantages; can inhibit the binding 
of maternal anti-HPA-1a antibody, can pass placenta barrier, but cannot 
recognize by RES system. Thus, the use of such antibody for the prenatal 
treatment of FNAIT is feasible (Bakchoul et al. 2013). Here, we could 
demonstrate, the d-813 itself did not impair endothelial functions, but d-813 
administration prevents endothelial dysfunction mediated by maternal anti-HPA-
1a. In addition, our in vivo experiment using NOD/SCID mouse model showed 
that d-813 could also prevent platelets clearance induced by anti-HPA-1a 
antibodies. This work represents the first evidence for the use of modified mab as 
a drug for prenatal treatment of FNAIT. 
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3.5. Manuscript #5 
Alloantibody against New Platelets Alloantigen (Lapa) on GPIIb is 
Responsible for a Case of Fetal/ Neonatal Alloimmune Thrombocytopenia.  
Hevi Wihadmadyatami, Kathrin Heidinger, Lida Adriana Röder, Silke Werth, 
Martin Knorr, Gregor Bein, Ulrich J. Sachs and Sentot Santoso  
Transfusion, 2015; volume 55, pages 2920 – 2929; see attachment 5. 
 
Abstract 
Background: Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is 
caused by the destruction of platelets (PLTs) in the fetus or newborn by maternal 
platelet antibodies that crossed the placenta during pregnancy.  
Study design and method: In this study, we aim to elucidate the properties of a 
new PLT alloantigen (Lapa) that is associated with a severe case of FNAIT. 
Analysis of maternal serum with phenotyped PLTs by monoclonal antibody 
specific immobilization of platelet antigens showed positive reaction against PLT 
glycoprotein (GP) IIb/IIIa and HLA Class I expressed on paternal PLTs. 
Results: In contrast to GPIIIa-reactive anti-HPA-1a, anti-Lapa alloantibodies 
precipitated predominantly GPIIb. Indeed, a point mutation G>C at position 
2511located in Exon 25 of the ITGA2B gene was found in Lapa-positive donors. 
This mutation causes an amino exchange Gln>His at Position 806 located in the 
calf-2 domain of GPIIb. Lapa-positive individuals were not found in 300 random 
blood donors. Our expression study showed that anti-Lapa alloantibodies reacted 
with stable transfected HEK293 cells expressing the mutated GPIIb isoform 
(His806). CHO cells carrying this isoform, however, failed to react with anti-Lapa 
alloantibodies, indicating that Lapa epitopes depend on the Gln806His mutation 
and the carbohydrate composition of the GPIIb. This mutation did not hamper the 
binding of anti-HPA-3a, which recognizes a point mutation (Ile843Ser) located in 
calf-2 domain. Finally, we found that Lapa and some HPA-3a epitopes are 
sensitive to O-glycanase. 
Conclusion: This study not only underlines the relevance of rare HPAs on the 
pathomechanism of FNAIT, but also helps to understand the pitfalls of serologic 
assays to detect anti-GPIIb alloantibodies. 
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4. Discussion 
 
Immunization against platelet antigens are commonly occurring as a 
cause of immune mediated thrombocytopenia in Caucasians population, but little 
is known about the clinical relevance of platelet antibodies in Asian populations, 
especially in the multiethnic population living in Malaysia and Indonesia.  
 
Here in the first paper, we described for the first time the role of platelet 
antibodies on the mechanism of alloimmune mediated thrombocytopenia in 
Malays. By analysis of two different patient cohorts (FNAIT and PTR), we found a 
high prevalence of platelet alloantibodies reactive against HPA-3a, HPA-5a, and 
HPA-5b in mothers with FNAIT. Interestingly, severe FNAIT cases associated 
with anti-HPA-3a antibodies were observed. In contrast, anti-HPA-5b and anti-
HPA-15b alloantibodies were predominantly detected in the PTR cohort. 
Additionally, some PTR patients developed pan-reactive antibodies against 
IIb3 and platelet GPIb/IX. Based on the similar HPA allelic distribution among 
Malaysian and Indonesian populations (Asmarinah et al. 2013; Armawai et al. 
2015), immunization against HPA-3, -5 and -15 systems are expected to be the 
most critical risk for the development of FNAIT and PTR among both populations. 
In comparison to Caucasians population, immunization against HPA-1a is as a 
rare event (Armawai et al. 2015).  
 
Based on these observations, screening of platelet antibodies against 
HPA-3, -5 and -15 systems should be recommended for the diagnosis of FNAIT 
and PTR. Transfusion with HPA compatible platelets should be considered to 
treat these patients adequately. Therefore, typing of blood donors for HPA and 
installation of a national donor registry for HPA typed platelets are obligatory to 
solve this problem in near future. 
 
In Caucasians, anti-HPA-1a antibodies are the most relevant cause of 
FNAIT with ICH as the most serious complication, prenatally or postnatally. ICH 
can even occur in the fetus/neonate with normal platelet counts (Kroll et al. 2005; 
Bussel et al. 2010), indicating that low platelet counts alone are not sufficient to 
trigger the development of ICH. Other effects of anti-HPA-1a antibodies must be 
involved in the mechanism of ICH.  
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In the second paper, we found that anti-HPA-1a antibodies are 
heterogeneous, containing at least three different types of anti-HPA-1a 
alloantibodies that react with 3 alone, with IIb3 (complex epitopes formed by 
IIb and 3 subunits) or with v3 (complex epitopes formed by v and 3 
subunits). Although the Leu33Pro mutation residing on the 3 integrin subunit is 
known to control HPA-1a epitopes (Newmann et al. 1989), the presence of other 
subunits (IIb or v) seems to be  necessary for the formation of some antigenic 
determinant(s) (Valentin et al. 1995; Allen et al. 2012). Theoretically, all these 
epitopes can be recognized by the immune system. Indeed, by the use of an 
absorption approach using recombinant IIb3 immobilized onto beads and 3-
integrin transfected cells, we could identified these three types of anti-HPA-1a 
alloantibodies as interactive with IIb3 complex (termed ”type-P”; reactive with 
platelets only), 3 (termed “type-PE”; reactive with platelets and endothelial cells) 
and v3 (termed “type-E”; reactive predominantly with endothelial cells). 
Interestingly, a high prevalence of type-E antibodies was detected in FNAIT 
mothers with babies with ICH. These results indicate that type-E antibodies may 
be directly responsible for the development of ICH, whereas the other two 
alloantibody types ( type P and type PE) may promote platelet clearance (Figure 
6). 
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Figure 6:  The three different subtypes of anti-HPA-1a alloantibodies 
Antibodies type-P and type-PE are reactive against IIb3 complex or 3 alone, 
respectively, and may induce platelet clearance, while type-E antibodies reactive 
with v3 interfere with endothelial function. Both mechanisms can promote ICH, 
but the individual extent of each mechanism awaits clarifications.  
 
It has been documented that v3 is essential for endothelial proliferation 
and survival mediated by adhesion of endothelial cells onto extracellular matrix 
(Li et al. 1999). Inhibition of endothelial adhesion by v3 antagonists (e.g. 
functional inhibitory monoclonal antibodies against v3, cyclic RGD peptide, 
and peptidomimetics) that disrupt the ligation between v3 and vitronectin lead 
to cell anoikis (Edreich and Epstein, 2005) and subsequently to cell apoptosis 
(Eliceiri & Cheresh 1999;  Montgomery et al. 1994; Brassard et al. 2015; Brooks, 
1994). During this process, cell detachment can also trigger mitochondria to 
produce reactive oxygen species (ROS). It is well known that ROS can initiate 
and regulate the transcription and activation of different mediators which 
culminate in the common mechanism of cell damage via caspase pathway 
(Elmore, 2007). Additionally, the v3 integrin is expressed abundantly on 
activated endothelial cells during angiogenesis and plays a role as a key 
regulator of endothelial adhesion and migration (Somanath et al. 2009; Brooks, et 
Type P 
Type PE 
Type E 
b
b
v
Platelet 
clearance 
Endothelial 
dysfunction 
ICH 
v
Discussion 
26 
 
al. 1994; Galvagni et al. 2013). Vessel development in the brain depends on 
cross-talk between endothelial cells and perivascular astrocytes (Ballabh et al. 
2004). For this process, v integrins play an important role through the regulation 
of TGF- activation and expression of TGF-responsive genes that promote 
vessel differentiation and stabilization (Scaffidi et al. 2004; Wipff & Hinz 2008; 
Cambier et al. 2005).  
 
With respect to this pathomechanism, we found (manuscript #2) that anti-
HPA-1a antibodies against endothelial v3 (type-E) prevent endothelial 
adhesion, leading to anoikis, apoptosis of endothelial cells and disturbed vessel 
development during angiogenesis in a ROS dependent manner (Figure 6). This 
phenomenon could not be observed with anti-HPA-1a antibodies of type-P and 
type-PE. Thus, this antibody-mediated mechanism of endothelial dysfunction 
may explain brain hemorrhage in FNAIT. These findings provide new insights into 
the mechanism of severe FNAIT associated with intracranial hemorrhage and 
open the way for the development of new diagnostic method and treatment 
strategy to prevent ICH. 
 
Interestingly, same evidence was found in a patient with type 1 
Glanzmann’s thrombasthenia (GT) (manuscript #3) who ultimately failed to 
express IIb3 and v3 on his platelets surface due to a novel point mutation 
Gly540Asp located on the 3 integrin subunit. By transfection analysis, we found 
that this point mutation was directly responsible for the absence of both integrins. 
The amino acid glycine at position 540 is highly conserved across species and is 
located within a structurally important EGF3 domain of the 3 chain surrounded 
by three disulfide bonds, Cys536-544, Cys542-547 and Cys549-558 (Calvete & 
Muniz-Diaz 1993). It is well-known that type 1 GT patients with absent IIb3 
expression can develop isoantibodies against IIb3, leading to platelet 
transfusion refractoriness (Poon et al, 2006). The question whether such patients 
can develop isoantibodies against v3 was speculative. In this study, we could 
demonstrate that type 1 GT patients can also develop anti-v3 isoantibodies. 
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Figure 7: The possible mechanism of endothelial cell dysfunction mediated 
by anti-HPA-1a antibodies  
1.Anti-HPA-1a antibodies bound to endothelial v3 prevent adhesion of 
endothelial cells (ECs) onto extracellular matrix (ECM), leading to anoikis 2) 
Anoikis promotes apoptosis signaling via the external pathway (death ligand) and 
induces mitochondrial production of reactive oxygen species (ROS), and 
activation caspase 3/7 3) Caspase 3/7 triggers ECs apoptosis followed by 
disturbance of angiogenesis.  
 
 Furthermore, our functional analysis showed that this antibody specificity 
interfered significantly with endothelial functions (see manuscript #3). Whether 
these antibodies are able to contribute to platelet transfusion refractoriness 
remains unclear. However, the relevance of anti-v3 isoantibodies need to be 
considered in pregnant GT women. These antibodies can pass the placenta and 
induce fetal/neonatal isoimmune thrombocytopenia, a condition similar to FNAIT 
(Sachs 2013). Recently, Siddiq et al. (2011) reported that maternal immunization 
against platelet antigens was found in a large cohort of GT mothers, and fetal or 
neonatal death occurred only in mothers with antibodies. Anti-IIb3 
isoantibodies were also identified in association with intracranial hemorrhage 
(ICH) in two FNAIT cases of GT type 1 mothers (Ambo et al. 1998; Leticee 
2005). However, this IIb3 antibody type was also found in healthy newborns 
without any signs of bleeding (Siddiq et al. 2011; Boval et al. 2001; Sundqvist et 
al. 1981; Ito et al. 1991).  
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Several efforts have been conducted to prevent severe thrombocytopenia 
and ICH. Currently, IVIG is widely used as an effective antenatal therapy for 
FNAIT and it prevents against ICH in most pregnancies (Bussel et al. 2010). 
More recently, Widiapraja and coworkers showed that IVIG may protect cells by 
reducing the inflammation rate (Widiapradja et al. 2014; Widiapradja et al. 2012). 
 
It becomes increasingly clear that the Fc-linked glycosylation of IgG 
regulates the effector functions of IgG (Jefferis 2009). Deglycosylation of the N-
glycan attached to Asn297 inhibits recognition by Fc receptors on macrophages 
(FcRI, FcRIIa, FcRIIIa) as well as its ability to activate complement factor C1q 
(Nimmerjahn & Ravetch 2008). Interestingly, FcRn-mediated IgG transport 
through the placenta does not require carbohydrate moieties on the Fc part 
(Palmeira et al. 2012; Einarsdottir et al. 2013). Thus, removal of the N-glycan 
should not affect placental transport.  
 
Recent findings from our group demonstrated that deglycosylated mouse 
monoclonal anti HPA-1a antibodies (clone SZ21) could pass through the 
placenta and compete for the binding site of maternal HPA-1a alloantibody to 
prevent fetal platelet clearance by macrophages (Bakchoul et al. 2013). For the 
development of a drug, this monoclonal antibody was humanized (called now 
813). To analyze the effect of 813 on endothelial function, deglycosylated 813 (d-
813) was generated. Interestingly, this modified anti-HPA-1a antibody did not 
inhibit adhesion of endothelial cells onto vitronectin matrix, did not induce 
apoptosis and did not impair angiogenesis. When maternal anti-HPA-1a 
antibodies derived from ICH cases were tested, presence of d-813 antibodies 
prevented apoptosis and restored angiogenesis. Furthermore, our in-vivo 
analysis in NOD/SCID mice showed that d-813 antibodies could prevent platelet 
clearance mediated by maternal anti-HPA-1a antibodies. This observation 
indicates the therapeutic potential of d-813 for antenatal treatment of FNAIT, 
even with ICH. However, the precise mechanism how this modified monoclonal 
antibody can protect platelets and endothelial cells needs to be evaluated further. 
 
In line with our findings, Eksteen et al. (2015) recently described a new 
human monoclonal antibody against HPA-1a (named 26.4) derived from a single 
memory B cell isolated from a woman who developed anti-HPA-1a antibodies. 
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This antibody inhibits the binding of maternal anti-HPA-1a antibodies, although 
the epitopes of 26.4 are not constrained to the PSI domain alone. This is in 
contrast to d-813 that reacts with small epitopes residing on the PSI domain 
(Stafford et al. 2008). Ghevaert et al. (2008) also proved that monoclonal 
antibody B2G1 derived from the maternal B cells of a FNAIT case by phage 
display could block the binding of maternal anti-HPA1a antibodies in vitro 
(Ghevaert, et al. 2007). The question which human HPA-1a antibody; 813, 26.4 
or B2G1 is most effective in preventing platelet clearance and endothelial 
dysfunction caused by maternal anti-HPA1a antibodies is intriguing. 
 
Administration of anti-integrin β3 sera prior to injection of integrin β3 
positive platelets in an integrin β3-/- murine model of FNAIT prevented the 
formation of anti-platelet antibodies and reduced bleeding complications in 
newborn pups (Tiller et al. 2012). Currently, clinical trials for FNAIT prevention 
based on prophylaxis are underway to test the potential of anti-HPA-1a IgG to 
prevent HPA-1a immunization (Kjeldsen-Kragh et al. 2012). This project, 
however, needs a large number of women with anti-HPA-1a antibodies. Whether 
human monoclonal antibodies can replace this prophylaxis approach is an 
interesting question.  
 
 In recent years, a large number of low or rare frequency human platelets 
alloantigen has been discovered. Some of them are associated with severe 
FNAIT cases. On the last paper, we describe a new rare alloantigen term as Lapa 
located on IIb integrin subunit. Nucleotide sequencing of ITGA2B gene derived 
from the Lapa-positive father showed one nucleotide substitution G>C at position 
2511 located in exon 25 leading to amino acid substitution from glutamine to 
histidine at position 806 (Gln806His). In a population study, none from 300 
unrelated donors was found to carry the Lapa alloantigen. Transfection analysis 
mammalian cells confirmed that Gln806His mutation is directly responsible for 
the formation of Lapa alloantigenic determinant. However, we found that 
glycosylation of IIb was required for the appropriate Lapa alloantigen. This 
observation is in line with previous studies demonstrating that  HPA-3a located 
on IIb subunit, determined by a single amino acid mutation (Ile843Ser) also 
depends on the O-glycosylation of Ser847 (Calvette et al. 1993; Djafar et al. 
1993), and sialic acid residues (Goldberger et al. 1991; Wang et al. 2012). These 
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results indicate that two different types of anti-HPA-3a may develop during 
alloimmunization; type 1 recognizes carbohydrate-independent epitopes and type 
2 reacts with carbohydrate-dependent epitopes. The contribution of 
carbohydrates on the formation HPAs residing on IIb may help us to design 
better serologic assays to detect platelet reactive antibodies against IIb.  
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5. Summary 
 
Alloimmunization against HPAs leading to bleeding disorders is not only 
important for Caucasians but also Asians, especially in multiethnic Malays. This 
evidence promotes HPA typing and the installation of a national donor registry to 
improve the quality of treatment in Asia.  
 
In Caucasians, the pathomechanism how intracranial bleeding caused by 
anti-HPA-1a occurs during pregnancy in FNAIT was unclear. In this study, we 
found a high prevalence of anti-HPA-1a antibodies reactive against endothelial 
v3 (type-E) in mothers with FNAIT. In vitro, we could demonstrate that this 
subtype impairs endothelial function, and interferes with angiogenesis, indicating 
that type-E antibodies are directly responsible for the development of ICH. Our 
study showed that type-E antibody can also be formed in type 1 GT patients 
receiving platelet transfusions. Similar to FNAIT, this antibody type impairs 
endothelial function as well as angiogenesis. Thus, the presence of type-E 
antibodies in pregnant GT mothers may also cause severe FNAIT. Our study with 
a modified monoclonal antibody, 813, showed that platelet clearance and 
endothelial dysfunction mediated by maternal anti-HPA-1a alloantibodies may be 
prevented by such an approach. This interesting approach may help us to 
prevent bleeding and ICH in the fetus during pregnancy.  
 
In the last study, we showed that characterization of new platelet 
alloantigens involved in FNAIT does not only broaden our diagnostic repertoire 
but also improves our knowledge about the involvement of other molecule 
components (such as carbohydrates) on the formation of platelet alloantigenic 
determinants.  
 
Altogether, this study does not only underline the importance of 
alloantibodies in platelet clearance, but also highlights the importance of 
endothelial-reactive alloantibodies in severe bleeding such as, ICH in FNAIT 
cases. This knowledge will promote further studies including the development of 
new diagnostic methods and new treatment strategies of alloimmune mediated 
disorders.  
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6.  Zusammenfassung 
 
Eine Alloimmunisierung gegen humane Thrombozytenantigene (Human Platelet 
Antigenes, HPAs) und dadurch bedingter hämorrhagischer Diathese  findet sich 
gehäuft nicht nur bei Kaukasien, sondern auch bei Asiaten, insbesondere bei den 
multiethnischen malaiischen Völkern. Dieses erfordert eine HPA-Typisierung 
sowie eine nationale Spenderdatei, um die Qualität von 
Thrombozytentransfusionen in Asien zu verbessern. 
 
Bei der bei Kaukasiern vorkommenden fetalen/neonatalen Thrombozytopenie 
(FNAIT) war bislang der Pathomechanismus der intrakranialen Blutungen 
ungeklärt, welche während der Schwangerschaft infolge vorhandener Anti-HPA-
1a-Antikörper auftreten können. In einer eigenen Studie fanden wir bei Müttern, 
bei denen eine FNAIT diagnostiziert wurde, in hoher Prävalenz Anti-HPA-1a-
Antikörper, welche mit dem endothelialem Integrin αVβ3 (Typ E) reagierten. In 
einem In-vitro-Modell konnten wir nachweisen, dass dieser Subtyp über eine 
Beeinflussung der Angiogenese die Endothelfunktion beeinträchtigen kann. Dies 
deutet darauf hin, dass solche Typ-E-Antikörper direkt für das Auftreten 
intrakranieller Blutungen (Intracranial Hemorrhage, ICH) verantwortlich sind. 
Unsere weiteren Untersuchungen zeigen ebenfalls, dass Typ-E-Antikörper auch 
von Glanzmann-Thrombasthenie-(GT)-Typ-1-Patienten nach Thrombozyten-
Transfusionen gebildet werden können. Ähnlich wie bei der FNAIT beeinträchtigt 
dieser Antikörper sowohl die Endothelfunktion wie auch die Angiogenese. Daher 
kann das Vorhandensein von Typ-E-Antikörpern bei Schwangeren mit GT 
ebenfalls eine schwere FNAIT hervorrufen. 
In einer andern Studie mit dem modifizierten humanen Antikörper 813 konnten 
wir nachweisen, dass die durch maternale Anti-HPA-1a-Alloantikörper vermittelte 
Thrombozyten-Clearance und die endotheliale Dysfunktion durch den 
modifizierten murinen monoklonalen Antikörper d-813 verhindert werden kann. 
Dieser interessante Ansatzpunkt könnte dazu beitragen, Blutungen und damit 
auch eine ICH beim Fetus während der Schwangerschaft zu verhindern. 
 
In unseren letzten Studie haben wir gezeigt, dass die Charakterisierung neuer, im 
Zusammenhang mit der FNAIT stehender Thrombozytenantigene nicht nur 
unsere diagnostischen Möglichkeiten bezüglich dieser Krankheit  erweitert, 
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sondern auch unsere Kenntnisse über die Beteiligung anderer Moleküle (wie 
etwa Kohlenhydrate) bei der Bildung thrombozytärer Alloantigene. 
 
Insgesamt demonstrieren die Ergebnisse dieser Studien nicht nur die Bedeutung 
von Alloantikörpern bei der Thrombozyten-Clearance, sondern sie unterstreichen 
auch die Bedeutung Endothel-reaktiver Alloantikörper beim Auftreten schwerer 
Blutungen, wie etwa bei der ICH in Fällen von FNAIT. Diese Kenntnisse können 
als Grundlage dienen für weitere Forschungen in Hinblick auf die Entwicklung 
neuer diagnostischer Methoden und neuer Behandlungsstrategien bei 
Alloimmunkrankheiten. 
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Liebig-Universität Gieβen zur Sicherung guter wissenschaftlicher Praxis’’ 
niederlegt sind, eingehalten. 
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Platelet reactive alloantibodies responsible for immune 
thrombocytopenia in Malay population
Abstrak 
Latar belakang: Aloantibodi terhadap human platelet 
alloantigens (HPAs) berperan dalam terbentuknya 
platelet transfusion refractoriness (PTR) pada pasien yang 
mendapat transfusi trombosit dan gangguan pembekuan 
darah pada bayi dengan trombositopenia aloimun fetalis 
(FNAIT). Hasil penelitian kami sebelumnya, berdasarkan 
analisis distribusi alel HPAs, mengindikasikan imunisasi 
mungkin terjadi antara orang Melayu. Pada penelitian ini, 
kami mencoba untuk menganalisis frekuensi aloantibodi 
reaktif trombosit yang berperan dalam FNAIT dan PTR 
di Malaysia.
Metode: Serum dari pasien diduga FNAIT (n = 295) dan 
PTR (n = 74) dikumpulkan selama lima tahun (2008-2013) 
dan diuji untuk mengetahui adanya antibodi platelet reaktif 
dengan pemeriksaan penangkapan antigen. 
Hasil:	
	
HPA-2b (n = 1), HPA-5a (n = 1), HPA-5b (n = 1), HPA-15b 

        !"
#  $%&'    
dideteksi pada 18 serum (6,10%) yang terdiri atas anti-HPA-
1a (n = 1), anti-HPA-3a (n = 3), anti-HPA-5a (n = 6) , anti-
HPA-5b (n = 6), anti-HPA-15a (n = 1), dan anti-HPA-15b 
(n = 1). 
Kesimpulan: Penelitian ini memperlihatkan bahwa 
antibodi anti-HPA-3, -HPA-5 dan -HPA-15 merupakan 
   +/ +  :
FNAIT dan PTR di populasi Malaysia. Karena distribusi 
alel HPA yang sama terjadi antara populasi Malaysia 
dan Indonesia, imunisasi terhadap tiga sistem HPA 
ini diperkirakan menjadi risiko paling potensial untuk 
gangguan trombosit yang dimediasi aloimun di Indonesia.  
Abstract
Background: Alloantibodies against human platelet 
alloantigens (HPAs) are responsible for the development 
of platelet transfusion refractoriness (PTR) in patients 
receiving random platelets and bleeding disorder in 
babies with fetal neonatal alloimmune thrombocytopenia 
(FNAIT). Recently, our results based on the analysis of the 
allelic distribution of HPAs indicated that immunization 
may occur among Malay. In this study, we sought to 
analyze the frequencies of platelet reactive alloantibodies 
responsible for FNAIT and PTR in Malaysia.
Methods: Sera from suspected FNAIT (n = 295) and 
	

2013) and tested for the presence of platelet reactive 
antibodies by the use of antigen capture assay.
Results:  !"	
 !#
$%   &
'*+&$-*+!$-*+!&$-
*+$!&;&;<#
>?+<-&;&
$@#$%'*+$
$-*+BB-*+!@-*+!&
@-*+$!$-*+$!&$#
Conclusion:C;;<*+B-*+
!*+$!&D& <D
 &   >?+   
in Malaysian population. Since similar HPA allelic 
distribution among Malaysian and Indonesian populations 
have been observed, immunization against these three 
HPA systems are expected to be the most potential risk 
of alloimmune mediated platelet disorders in Indonesia.  
Keywords: alloimmune thrombocytopenia, transfusion     
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Human platelet alloantigens (HPAs) are immunogenic 
polymorphic forms of platelet membrane glycoproteins 
(GPs) GPIa, GPIb, GPIIb, GPIIIa and CD109. 
Meanwhile, 28 HPA biallelic systems have been 
-  [ << L    &
single amino substitution, caused by single nucleotide 
D<D E?  <  'W1 (see 
[ <D' <G""#&##;\""<"[
recent update).
Alloantibodies against HPAs are involved in three 
major clinical syndromes: fetal neonatal alloimmune 
thrombocytopenia (FNAIT), platelet transfusion 
refractoriness (PTR), and post transfusion refractoriness 
(PTP). In addition, recent evidence indicated that 
antibodies against HPAs are also importance in 
transplantation settings.2
FNAIT is caused by HPA incompatibility between 
mother and fetus. During the pregnancy, maternal 
alloantibodies cross the placenta and mediate the 
;[[#Z;-*+
1a is the most commonly involved in FNAIT (75%), 
[&*+!&&#3 In PTR cases, 
patients fail to respond adequately to an appropriate 
 [  [;# < DD;
PTR is mostly caused by antibodies against HLA 
class I antigens. However, alloantibodies against 
*+<&&B%[-
D ' *+$&  *+!&#4 PTP is a 
rare transfusion reaction characterized by sudden 
onset of thrombocytopenia. The antibodies (mostly 
*+$   <  ; 
only the destruction of donor’s platelets but also 
autologous platelets. The mechanism underlying this 
phenomenon, however, is still unclear.5
Presently, the diagnosis of alloimmune mediated 
thrombocytopenia relies on the assignment of HPA 
D&<[*+
alloantibodies. Based on the underlying SNPs, several 
molecular biological methods have been established 
 <  - <<   & <'<
;<'<<;'<;''
of HPAs.6 On account of these technologies, extensive 
studies on the gene frequency of HPAs have been 
; # *- < 
[ &  D   < 
clinical diagnostic and treatment strategy of patients 
suffering from alloimmune thrombocytopenia.
Recently, the distribution of HPA gene frequencies 
has been reported in Malaysia as well as Indonesia.7,8 
Until today, however, no data is available about 
the frequencies and the clinical relevance of HPA 
alloantibodies in these countries. In this study, we 
<'<[;[
platelet reactive alloantibodies in Malaysia, which 
are responsible for FNAIT and PTR.
METHODS
Patients
Sera from suspected FNAIT (n = 295) and PTR (n 
 	
       
$B#D&*+D
by genotyping of maternal/paternal or donor/
recipient DNA. Genomic DNA was isolated from the 
;\D-<'&<
ZDD&<D;[;
(GTI, San Diego, CA, USA and BAGene, Lich, 
Germany). PCR products were analyzed by 2% 
agarose gel electrophoresis and were visualized 
using a UV transilluminator. Informed consent 
was obtained from all subjects and the study was 
approved by the institution’s review board.
Monoclonal antibodies (Mabs) 
Mabs against glycoprotein (GP) IIb/IIIa (clone 
"!$W\ZDWD\-&"
EW\DZ;-Q->-"
 W \D Z;- Q- >-
Z$+"$@W<D'-E+-
[*]+Z##$#$;
for the antigen capture assay (see below).
Detection of platelet alloantibodies by antigen 
capture assay
Alloantibodies were analyzed using a panel of 
\ *+   *+$--B-!- 
$! [D & '; C   
by antigen capture assay, MAIPA (monoclonal 
antibody immobilized platelet antigen) as previously 
described.9,10 The principle of this assay is illustrated 
';$#
In brief, 100x109/L washed platelets of HPA 
phenotyped donors were incubated with 25μL of 
human serum for 30 min at 37°C. After washings 
with 200 μL TBS/BSA buffer (0.099M Tris buffered 
saline containing 0.2% bovine serum albumin), 
sensitized platelets were incubated with mabs for 30 
min at 37°C and washed again 3 times with TBS/
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BSA buffer. Subsequently, platelets were solubilized 
for 15 min at room temperature (RT) with 130μL 
solubilization buffer (TBS containing 0.5% Triton 
$   [;' [ $! D  
(13,000 g). The supernatants were then transferred 
>D<'D;
' ; $G!W U\ DD;<-
Pennsylvania, USA). After incubation (30 min at 
37°C) the wells are tipped out and washed 5 times 
with 125μL washing buffer (0.099M TBS containing 
0.5% NP40 and 0.2% Tween 20), and incubated with 
$] [ L O;' ' <;D
' U\ DD;<W ; $"@
for 1 h at RT. Finally, the wells were washed 5 
times with 125μL washing buffer. The reaction was 
; < $;] [ <<D
(Dako) substrate solution (15 min in the dark at RT), 
stopped by adding 100μL 0.5M H2SO4, and measured 
in photometer at 490nm (Dynex Technologies Inc., 
Virginia, USA). 
RESULTS
In total of 295 samples of suspected FNAIT cases, 
platelet antibodies against HPAs were found in 
18 sera (6.10%) by the MAIPA which consist of 
&'*+$$-*+B
B-*+!@-*+!&@-*+$!
$-*+$!&$#-
antibodies against HLA class I molecule could be 
detected in 58 samples (19.67%) (Table 1). Current 
<*]+&
not seem to play a major role on the mechanism of 
FNAIT. However, limited cases of FNAIT associated 
with HLA class I antibodies have been described.11 In 
-&'*+
   
"	
 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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$!&   B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
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16.2% of PTR cases. 
Table 2 shows the allelic distribution of HPA systems 
Q#?'[[
between these two populations could be observed. 
<*+$&[;D'Q&<
Q'<
the frequency reported among Caucasian population 
(0.024 versus ~0.133). Thus, in contrast to Caucasian, 
alloimmune mediated thrombocytopenia caused 
& *+$ & D  & LD
rare occurrence among Malay ethnics. However, 
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Figure 1. The priciple of the MAIPA assay
Alloantibody

FNAIT  
(n = 295)
PTR
(n = 74)
HLA class I 58 24
*+$ 1 
*+&  1
*+B 3 
*+! 6 1
*+!& 6 1
*+$! 1 
*+$!& 1 2
GPIIb/IIIa  11
&"  1
Table 1. The frequencies of platelet antibodies found in suspected 
FNAIT and PTR cases
HPA 
system
Gene 
frequency
Malaysia 
Gene 
frequency
Indonesia 
Gene 
frequency 
Caucasian
*+$
*+$&
0.975 
0.025
0.977
0.023
0.877
0.133
*+
*+&
0.962 
0.038
0.940 
0.060
0.943 
0.057
*+B
*+B&
0.502 
0.498
0.507
0.493
0.471 
0.529
*+

*+
&
0.995 
0.005
0.948 
0.052
1.000 
0.000
*+!
*+!&
0.950 
0.050
0.968 
0.032
0.929
0.071
*+$!
*+$!&
0.515
0.485
0.551 
0.449
0.495 
0.505
Table 2.[;[*+$*+!*+$!
Q#!-$W
Asmarinah et al 2013)
1. Stage
2. Stage
ab
Platelets
wash
ab
1x mab
wash lyse
3x
immune complex
Substrates
ColorGAH*
wash
5x5x
washGAM
Kiefel et al, Blood 1987
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the frequent allele whereas in Caucasian population 
 # E *+B"*+B&  *+
$!"*+$!&   ; &;-
alloimmunization against these HPA systems is 
expected. 
DISCUSSION 
This study was aimed to evaluate the clinical impact 
of platelet reactive alloantibodies responsible for 
the pathomechanism of FNAIT and PTR cases in 
Q# *'< 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thrombocytopenia (platelet count < 50x109/L) in the 
newborns. This is in accordance with the current 
data reported by the Japanese Society on Platelet 
Serology.12 All of the neonates was admitted to the 
NICU (Neonatal Intensive Care Unit) for close 
D'   ; 'DD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as recommended.13 Based on the delay of IVIG 
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maintain thrombocytopenia and bleeding tendency in 
these babies. Unfortunately, more improved therapy 
'D & [; < *+B '
platelets from healthy individuals was not possible 
due to a limited register of HPA typed donors in our 
National Blood Centre in Kuala Lumpur. To prevent 
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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intracranial hemorrhage during the pregnancy in 
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In accordance to previous observation, only mild 
thrombocytopenia was observed in all FNAIT cases 
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to answer, because we are unable to perform direct 
antibody testing on patient’s platelet due to limited 
amount of platelets. 
Based on the similar HPA allelic distribution among 
Malaysian and Indonesian population, immunization 
' *+B- !  $! D  L 
be the most potential risk for the development of 
FNAIT and PTR among Indonesian population. 
Therefore, screening of platelet antibodies against 
these three HPA systems should be recommended 
for the diagnosis of FNAIT and PTR. In antibody 
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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should be given to improve the treatment of these 
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compatibility between HLA antigens should also take 
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found. Providing HPA and HLA compatible platelets 
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typing of many donors for these antigen systems and 
performing national donor registry is mandatory to 
solve this problem.
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FNAIT and PTR cases in Malaysian population. 
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antigenic structures located on GPIIb and CD109, 
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some of the cases may overlook by the current 
assays. The use of fresh platelets is recommended 
to enhance the sensitivity of platelet antibody 
detection.$@$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Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a bleeding disorder of the fetus and newborn in which mater-
nal alloantibodies bind to the infant’s platelets and cause their 
destruction during pregnancy and after birth. In whites, ≈80% 
of FNAIT cases are induced by antibodies against human plate-
let antigen 1a (HPA-1a).1,2 The most devastating risk of FNAIT 
is intracranial hemorrhage (ICH), leading to death or persistent 
neurological sequelae in ≈10% of the clinically symptomatic 
cases.3,4 It is currently unclear which factors determine whether 
ICH will occur. Modality of birth, birth weight, and the pres-
ence of other bleeding symptoms are not associated with ICH, 
and the association between low platelet counts and ICH is 
loose.5,6 In subsequent pregnancies of mothers immunized 
against HPA-1a, only sibling history, but no laboratory test, has 
been shown to be predictive for the risk of ICH.7,8
HPA-1a is formed by a single amino acid substitution 
(Leu33Pro) located on the ﬂexible PSI (plexins, semaphorins, 
and integrins) domain of the integrin β3 chain.9 On platelets, 
the β3 chain forms heterodimers either with αIIb or with αv, 
which functions as a ﬁbrinogen or vitronectin receptor, respec-
tively.10 In contrast to αIIbβ3, αvβ3 is also found on endothe-
lial cells (ECs), smooth muscle cells, and different cultured 
cells.11 Several studies demonstrated that HPA-1a is consti-
tutively expressed on endothelial αvβ3.12,13 It has also been 
shown that anti–HPA-1a antibodies can affect endothelial 
integrity and the spreading capability of these cells,14 indicat-
ing that vascular damage may be involved in the pathomecha-
nism of FNAIT. However, others have reported no effect of 
anti–HPA-1a antibodies on endothelial activation and integ-
rity.15 Recently, Yougbaré et al16 demonstrated that anti–β3 
© 2016 American Heart Association, Inc.
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Objective—Fetal/neonatal alloimmune thrombocytopenia is a severe bleeding disorder, which can result in intracranial 
hemorrhage (ICH), leading to death or neurological sequelae. In whites, maternal anti–human platelet antigen-1a 
(HPA-1a) antibodies are responsible for the majority of cases. No predictive factors for ICH are available to guide 
prophylactic treatment during pregnancy. In this study, we investigated antibodies from mothers with ICH-positive fetal/
neonatal alloimmune thrombocytopenia and with ICH-negative fetal/neonatal alloimmune thrombocytopenia to identify 
serological and functional differences between the groups.
Approach and Results—In an antigen capture assay, we observed a stronger binding of +ICH antibodies to endothelial 
cell (EC)–derived αvβ3. By absorption experiments, we subsequently identiﬁed anti–HPA-1a antibodies of anti-αvβ3 
speciﬁcity in the +ICH but not in the −ICH cohort. Only the anti–αvβ3 subtype, but not the anti–β3 subtype, induced EC 
apoptosis of HPA-1a–positive ECs by caspase-3/7 activation, and mediated by reactive oxygen species. In addition, only 
the anti–αvβ3 subtype, but not the anti-β3 subtype, interfered with EC adhesion to vitronectin and with EC tube formation.
Conclusions—We conclude that the composition of the anti–HPA-1a antibody subtype(s) of the mother may determine whether 
ICH occurs. Analysis of anti–HPA-1a antibodies of the anti–αvβ3 subtype in maternal serum has potential in the diagnostic 
prediction of ICH development and may allow for modiﬁcation of prophylactic treatment in fetal/neonatal alloimmune 
thrombocytopenia.  (Arterioscler Thromb Vasc Biol. 2016;36:1517-1524. DOI: 10.1161/ATVBAHA.116.307281.)
Key Words: antibodies ◼ endothelial cells ◼ intracranial hemorrhages ◼ reactive oxygen species  
◼ thrombocytopenia, neonatal alloimmune
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isoantibodies produced in β3 knockout mice can induce ICH 
in pups by impairment of angiogenesis rather than by throm-
bocytopenia. The relevance of this ﬁnding for the develop-
ment of ICH in humans is not clear, especially because ICH is 
far less frequent in humans than observed in the animal model, 
and a booster effect as described in mice is absent in men, that 
is, likelihood of ICH does not increase with the number of 
pregnancies in humans.17 It seems likely that these differences 
are related to the fact that isoantibodies (in the murine model) 
and alloantibodies (in humans) are not alike. Furthermore, fre-
quency and natural history of ICH in humans suggest that the 
composition of the maternal anti–HPA-1a antibody repertoire 
could diverge between FNAIT cases with and without ICH.
In this study, we asked the question whether a speciﬁc anti–
HPA-1a antibody subtype exists in FNAIT cases with ICH, in 
comparison to FNAIT cases without ICH. Our results show that 
anti–HPA-1a antibodies in FNAIT cases with ICH bind spe-
ciﬁcally to the αvβ3 complex, trigger endothelial apoptosis via 
reactive oxygen species (ROS), and interfere with angiogenesis.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Anti–HPA-1a Antibodies From +ICH and −ICH 
Cases Show Different Binding Patterns
The binding of anti–HPA-1a antibodies derived from −ICH 
cases (n=18; Table 1) and +ICH cases (n=18; Table 2) to 
αIIbβ3 and αvβ3 integrins derived from HPA-1aa plate-
lets and ECs was investigated in an antigen capture assay. 
As shown in Figure 1, no signiﬁcant difference between the 
2 cohorts was observed in their binding to platelet-derived 
αIIbβ3 (A). However, a signiﬁcant difference was observed 
when binding to both platelet-derived αIIbβ3 and αvβ3 was 
analyzed (B). The differences between both cohorts became 
more signiﬁcant when sera were tested against EC-derived 
αvβ3 immobilized by monoclonal antibodies against αvβ3 
(C) and β3 (D). These results indicate that +ICH anti–HPA-1a 
might contain additional antibody speciﬁcity, most probably 
against αvβ3 compound epitope(s).
Anti–HPA-1a Antibodies From +ICH Cases 
Contain a Speciﬁc Anti–αvβ3 Subtype
To prove this hypothesis, we aimed to isolate anti-αvβ3 by 
absorbing +ICH sera with αIIbβ3-coated beads. For the evalu-
ation of this approach, monoclonal antibodies against αIIbβ3, 
Nonstandard Abbreviations and Acronyms
EC endothelial cells
FNAIT fetal/neonatal alloimmune thrombocytopenia
HPA human platelet alloantigen
ICH intracranial hemorrhage
ROS reactive oxygen species
Table 1. Clinical and Laboratory Details of –ICH Cases
No.
Mother Newborn
Anti-αvβ3 
(OD)Gravida/Para Antibody Speciﬁcity Week of Gestation Sex Platelet Nadir (G/L) ICH
Other Bleeding 
Symptoms
Bleeding 
Excluded by
1 II/I HPA-1a 28+4 M 12 No H Ultrasound 0.300
2 II/II HPA-1a 38+4 F 22 No P, H Ultrasound 0.033
3 NR HPA-1a 36+5 M 29 No P Ultrasound 0.048
4 I/I HPA-1a 40+0 M 6 No P Ultrasound 0.320
5 NR HPA-1a 40+2 F 11 No P Ultrasound 0.030
6 NR HPA-1a 28+0 F 24 No P Ultrasound 0.152
7 III/III HPA-1a 36+5 F 13 No P Ultrasound 0.324
8 I/I HPA-1a 41+0 F 5 No P Ultrasound 0.273
9 I/I HPA-1a 38+0 M 15 No P Ultrasound 0.238
10 I/I HPA-1a 41+2 M 24 No P Ultrasound 0.215
11 I/I HPA-1a 38+2 M 15 No P, H Ultrasound 0.089
12 I/I HPA-1a 40+0 F 3 No P, H Ultrasound 0.174
13 III/II HPA-1a 37+5 F 13 No P, H Ultrasound 0.084
14 III/III HPA-1a 39+3 F 18 No H Ultrasound 0.098
15 I/I HPA-1a 38+4 M 13 No P, H Ultrasound 0.167
16 IV/II HPA-1a 34+5 NR 7 No P Ultrasound 0.204
17 IV/III HPA-1a 40+0 M 18 No P Ultrasound 0.289
18 II/II HPA-1a 40+0 M 9 No P, U Ultrasound 0.245
F indicates female; H, hematoma; HPA-1a, human platelet antigen 1a; ICH, intracranial hemorrhage; M, male; NR, not reported; OD, optical density; P, petechiae; 
and U, hematuria.
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β3, and αvβ3 complexes were ﬁrst absorbed with these beads 
and tested with Chinese hamster ovary cells expressing either 
αIIbβ3 or αvβ3. Absorption removed completely anti-β3 
and anti-αIIbβ3 but not anti-αvβ3 (Figure I in the online-
only Data Supplement). Subsequently, all human sera were 
absorbed with αIIbβ3-coated beads, and the remaining anti–
HPA-1a antibodies (absorbate) were retested by antigen cap-
ture assay (Figure 2A). Absorbates from both cohorts became 
largely nonreactive with platelet-derived αIIbβ3 and αvβ3, 
with no differences between the cohorts (upper panel). In con-
trast, only sera from +ICH, but not from -ICH cases, showed 
signiﬁcant reaction with EC-derived αvβ3, conﬁrming our 
assumption that +ICH sera contain anti–HPA-1a speciﬁcally 
reactive with αvβ3 complex. Note that absorption reduced 
overall reactivity for both cohorts signiﬁcantly (in comparison 
to Figure 1), indicating that relevant amounts of anti-αIIbβ3 
and anti-β3, present in sera from both cohorts, were removed 
by absorption.
To further conﬁrm the presence of anti-αvβ3 in the +ICH 
cohort, anti–HPA-1a antibodies present in absorbates and 
antibodies eluted from αIIbβ3-coated beads (eluates) were 
investigated by immunoprecipitation using biotin-labeled 
αIIbβ3- or αvβ3-transfected Chinese hamster ovary cells 
(Figure 2B). In the absorbates, anti-αvβ3 reactivity could be 
detected in +ICH but not in −ICH cohort, and this antibody 
speciﬁcity did not show cross reactivity with αIIbβ3 (neither 
anti-αIIbβ3 nor anti-β3). In contrast, cross-reactive antibodies 
against αvβ3 and αIIbβ3 were found in eluates from both 
cohorts. All 18 immunoblots were evaluated by integrity den-
sity measurement, demonstrating that the difference between 
the +ICH cohort and the –ICH cohort for anti-αvβ3 was sig-
niﬁcant (P=0.00042) in the absorbate but nonsigniﬁcant for 
αvβ3 (P=0.13) and αIIbβ3 (P=0.48) in eluates. Taken together, 
our results suggest that 3 different subtypes of anti–HPA-1a 
antibodies can exist in FNAIT sera: anti-αIIbβ3, anti-β3, and 
anti-αvβ3. In contrast to −ICH cases, sera from +ICH cases 
contain signiﬁcant amounts of the anti–αvβ3 subtype.
Anti–αvβ3 Subtype of Anti–HPA-
1a Interferes With EC Functions
On the basis of the fact that the anti–αvβ3 subtype is present 
in sera from +ICH cases and reacts predominantly with ECs, 
we sought to investigate whether this antibody type interferes 
with EC function. All functional experiments were performed 
with IgG fractions obtained from human sera (n=9) from each 
cohort, both before (pre) and after (post) absorption with 
αIIbβ3-coated beads.
First, interference of receptor–ligand binding was ana-
lyzed by cell adhesion assay. ECs were incubated with iso-
lated IgG fractions before adhesion onto vitronectin-coated 
wells. As shown in Figure 3A, +ICH IgG signiﬁcantly inhib-
ited EC adhesion (black), whereas −ICH IgG did not (white). 
Removal of anti–HPA-1a antibodies of the anti–β3 and 
Table 2. Clinical and Laboratory Details of +ICH Cases
No.
Mother Newborn
Anti-αvβ3 
(OD)
Gravida/
Para
Antibody 
Speciﬁcity
Week of 
Gestation Sex
Platelet 
Nadir (G/L) ICH Bleeding Localization
Other Bleeding 
Symptoms
1 I/I HPA-1a 38+0 F 18 Yes Parenchymal, left frontoparietal lobe No 0.674
2 I/I HPA-1a 38+6 F 21 Yes Parenchymal, left side P, H 0.488
3 II/II HPA-1a 40+3 M 3 Yes NR P, H 0.664
4 VI/V HPA-1a 39+0 M 5 Yes Parenchymal, left temporal lobe P 0.800
5 II/II HPA-1a 37+6 F 5 Yes Subependymal, left side P, H 0.777
6 II/I HPA-1a 40+0 M 30 Yes Left thalamus and internal capsule P 0.402
7 I/I HPA-1a 39+6 M 10 Yes Periventricular, right side, and plexus cyst P, H 0.999
8 IV/II HPA-1a 34+4 NR 5 Yes Intraventricular and periventricular 0.549
9 III/II HPA-1a 36+6 F 45 Yes Parenchymal, right temporal lobe, grade IV P 0.685
10 III/III HPA-1a 41+2 F 7 Yes Parenchymal, left parietooccipital lobe P, H 0.721
11 II/I HPA-1a 36+0 F 14 Yes Parenchymal, left parietotemporal lobe P 0.689
12 II/I HPA-1a 38+0 M 17 Yes Parenchymal, right temporal lobe H, U 0.780
13 II/II HPA-1a 34+5 M 24 Yes Intraventricular P 0.548
14 NR HPA-1a NR F 12 Yes Parenchymal No 0.369
15 III/I HPA-1a 41+3 F 12 Yes Parenchymal, left parietooccipital lobe and 
right frontal lobe
P, H 0.995
16 NR HPA-1a 39+0 M 2 Yes Parenchymal P, H 0.565
17 I/I HPA-1a 38+0 M 10 Yes Porencephalic cyst, right frontal lobe P, H 0.686
18 II/I HPA-1a NR M 20 Yes Parenchymal, left and right hemisphere No 0.206
F indicates female; H, hematoma; HPA-1a, human platelet antigen 1a; ICH, intracranial hemorrhage; M, male; NR, not reported; OD, optical density; P, petechiae; 
and U, hematuria
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anti–αIIbβ3 subtypes (Figure 3A, post) had no inﬂuence on 
this effect, demonstrating that this effect was mediated by the 
anti–αvβ3 subtype.
It is known that disruption of EC adhesion onto extracel-
lular matrix results in detachment-induced apoptosis, termed 
anoikis, which is associated with increased intracellular ROS 
level.18,19 To analyze whether antibodies of the anti–αvβ3 
subtype can also trigger endothelial anoikis, the generation 
of intracellular ROS induced by anti–HPA-1a antibodies was 
ﬁrst measured by oxidation of DCFDA (2’,7’-dichlorodihy-
droﬂuorescein diacetate) using ﬂow cytometry. As shown in 
Figure 3B, only +ICH IgG (black) induced ROS, both pre and 
post absorption, indicating that the anti–αvβ3 subtype triggers 
ROS production. In the presence of AEBSF (4-(2-aminoethyl) 
benzenesulfonyl ﬂuoride hydrochloride), a speciﬁc inhibitor 
of nicotinamide adenine dinucleotide phosphate oxidase,20 
ROS production was abrogated. Similar results were obtained 
with N-acetylcysteine (data not shown).
In accordance with these observations, binding of the anti–
αvβ3 subtype triggered endothelial apoptosis as measured by 
caspase 3/7 assay (Figure 3C). In particular, the apoptosis rate 
induced by +ICH IgG remained unchanged after removal of 
the other subtypes (pre versus post; P=0.106). Apoptosis was 
conﬁrmed by morphological assessment of chromatin DNA 
cleavage (Figure 3C).
Subsequently, an endothelial tube formation assay was 
performed to analyze whether the anti–αvβ3 antibody sub-
type would also affect angiogenesis (Figure 3D). +ICH IgG 
(black), but not −ICH IgG (white), signiﬁcantly reduced 
tube length. Again, only the anti–αvβ3 subtype mediated the 
biological effect; removal of the other antibody subtypes by 
absorption had no inﬂuence on tube formation. The biological 
effect was ROS dependent and could be abrogated by AEBSF. 
Representative microphotographs are shown in Figure 3D 
(bottom). Finally, HPA-1bb ECs remained unaffected in all 
experiments in the presence of any of the IgG preparations 
(data not shown). Taken together, the anti–αvβ3 subtype 
bound speciﬁcally to HPA-1a expressed on ECs, inhibited cel-
lular adhesion to vitronectin, caused cell apoptosis (anoikis), 
and consequently disturbed angiogenesis.
Detection of the Anti–αvβ3 Subtype as a 
Potential Predictive Parameter for ICH
Once anti–HPA-1a of the β3-subtype has been removed from the 
serum, clinically relevant anti–HPA-1a of the anti–αvβ3 subtype 
can be demonstrated in an antigen capture assay (Figure 2A, 
bottom). We noticed that the use of some monoclonal capture 
antibodies results in reduced sensitivity (Figure 2A, bottom, 
left), most probably caused by competitive inhibition between 
monoclonal and human antibodies. Adjusting the current assay 
(right diagram) to 100% speciﬁcity (no false-positive detection 
of anti–αvβ3 subtype in the −ICH cohort), 1 of 18 anti–HPA-
1a of the anti–αvβ3 subtype cannot be identiﬁed in the +ICH 
cohort, resulting in a negative predictive value of 94.7%.
Discussion
The reason how and why ICH occurs in newborns with FNAIT 
is still unknown. The association between platelet count and 
ICH is weak, and ICH has been reported in FNAIT cases 
where the platelet count was within the reference range.6,21 
This indicates that biological effects of anti–HPA-1a antibod-
ies other than increased platelet turnover may be responsible 
for the development of ICH.
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Figure 1. Analysis of maternal anti–human platelet antigen 1a (HPA-1a) derived from −intracranial hemorrhage (ICH; n=18) and +ICH 
(n=18) in an antigen capture assay. HPA-1aa platelets (top) or endothelial cells (bottom) were incubated with anti–HPA-1a sera and mono-
clonal antibodies (moabs) against αIIbβ3 (a), αvβ3 (c), and β3 (b and d). After cell lysis, the moab-(αIIbβ3/αvβ3/β3)–anti–HPA-1a trimolecu-
lar complex was immobilized on microtiter wells coated with antimouse IgG. Binding of anti–HPA-1a antibodies to platelet-derived αIIbβ3, 
αIIbβ3+αvβ3, and endothelial-derived αvβ3 was detected with enzyme-labeled anti–human IgG. Statistical analysis was performed by 
Mann–Whitney U test. EC indicates endothelial cell; and OD, optical density.
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In this study, we demonstrate that maternal sera from 
+ICH cases, but not −ICH cases, contain signiﬁcant amounts 
of anti–HPA-1a antibodies, which exclusively react with the 
αvβ3 complex. Binding of this antibody subtype to ECs hin-
ders endothelial adhesion to vitronectin, leads to cell anoikis, 
and interferes with angiogenesis in an ROS-dependent man-
ner. Our results indicate that the presence of the anti–αvβ3 
subtype in maternal serum is the critical cause for the develop-
ment of fetal ICH in FNAIT.
It is known that the polymorphic residue Leu33Pro residing 
on the PSI domain of the β3-integrin subunit controls the for-
mation of HPA-1a epitopes.9 However, little is known about the 
contribution of αIIb and αv subunits to the formation of these 
epitopes. Recent studies demonstrated that some anti–HPA-1a 
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Figure 2. Identiﬁcation of an anti–human platelet antigen 1a (HPA-1a) αvβ3-speciﬁc subtype in +intracranial hemorrhage (ICH) cases after 
absorption of other subtypes with αIIbβ3 beads. A, Maternal anti–HPA-1a antibodies (n=18 per cohort) were preabsorbed with αIIbβ3 
beads to remove HPA-1a antibodies against αIIbβ3 and β3. Afterward, the absorbate was incubated with HPA-1aa platelets (top) or endo-
thelial cells (ECs; bottom) and monoclonal antibodies (moabs) against αIIbβ3 (a), αvβ3 (c), or β3 (b and d). After cell lysis, the trimolecu-
lar antigen–antibody complex was immobilized on microtiter wells coated with antimouse IgG. Binding of anti–HPA–1a antibodies was 
detected with horseradish peroxidase–labeled anti–human IgG. Statistical analysis was performed by Mann–Whitney U test. Note that 
after absorption, αvβ3-speciﬁc anti–HPA-1a remains detectable in the +ICH cohort only (c and d). This antibody speciﬁcity reacts more 
readily with αvβ3 immobilized with moab AP3 (d) than with αvβ3 immobilized with moab 23C6 (c), possibly indicating epitope interfer-
ence. B, Maternal anti–HPA-1a antibodies from the +ICH (top) and −ICH (bottom) cohorts were absorbed with αIIbβ3 beads. Unbound 
IgG (the absorbates) and bead-bound IgG (the eluates) were incubated with biotin-labeled transfected (αvβ3 and αIIbβ3) or nontrans-
fected (mock) Chinese hamster ovary (CHO) cells, as indicated. After washings, CHO cells were lysed, and the antigen–antibody complex 
was precipitated with protein-G–coupled beads and separated on 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis under 
nonreducing conditions. After blotting, precipitated proteins were visualized by the use of enzyme-labeled streptavidin and a chemilumi-
nescence system. In the –ICH cohort (bottom), all antibodies were removed by the beads as indicated by a nonreactive absorbate (left). 
Antibodies of anti-αIIbβ3/anti-β3 speciﬁcity could be eluted from these beads (right). Note that anti-β3 is capable to pull down αIIbβ3 and 
αvβ3 integrins. In contrast, in the +ICH cases (top), removal of anti-αIIbβ3/anti-β3 antibodies leaves antibodies of anti-αvβ3 speciﬁcity 
behind (left). The eluate is reactive with both integrins, indicating the presence of anti-β3/anti-αIIbβ3 (right). One representative gel from 
independent experiments (n=9) is shown. OD indicates optical density.
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Figure 3. The αvβ3-speciﬁc subtype of anti–human platelet antigen 1a (HPA-1a) interferes with endothelial function. IgG was puriﬁed from 
maternal sera from +intracranial hemorrhage (ICH) cases (n=9; black columns) and from −ICH cases (n=9; white columns) either before 
(pre) or after (post) absorption with αIIbβ3 beads and then further studied. A, Cell adhesion. Endothelial cells were incubated with puriﬁed 
IgG (20 µg/mL) and added onto microtiter wells precoated with vitronectin. After washings, adherent cells were stained with crystal violet 
and measured using an ELISA reader. Statistical analysis was performed by 1-way ANOVA followed by Bonferroni post hoc test. Cyclic 
Arg-Gly-Asp peptide (cRGD) was used as a positive control. Note that only antibodies from +ICH cases hinder endothelial cell adhesion, 
with no difference between pre and postabsorption experiments. B, Reactive oxygen species (ROS) production. Endothelial cells were 
incubated with puriﬁed IgG (20 µg/mL) in the presence of DCFDA (2’,7’-dichlorodihydroﬂuorescein diacetate). The production of ﬂuorescent 
DCF (2’,7’-dichloroﬂuorescein) correlates with cellular ROS production and was measured by ﬂow cytometry. AEBSF (4-(2-aminoethyl) 
benzenesulfonyl ﬂuoride hydrochloride) was used as an antioxidant in some experiments, as indicated. Statistical analysis was performed 
by 1-way ANOVA followed by Bonferroni post hoc test. Note that only antibodies from +ICH cases induce endothelial ROS, with no differ-
ence between pre and postabsorption experiments. C, Cell apoptosis. Puriﬁed IgG (20 µg/mL) was added to endothelial monolayers, and 
caspase 3/7 activity was measured by luminometry (top). Some experiments were performed in the presence of an ROS inhibitor (AEBSF). 
Statistical analysis was performed by 1-way ANOVA followed by Bonferroni post hoc test. cRGD was used as positive control. Note that only 
antibodies from +ICH cases induce apoptosis, with no difference between pre and postabsorption experiments. Nucleus staining of endo-
thelial cells with DAPI after incubation with anti–HPA-1a IgG postabsorption and controls was performed (bottom). Representative pictures 
(60-fold magniﬁcation) from independent experiments (n=9) per cohort are shown. D, Tube formation. Puriﬁed IgG (40 µg/mL) was added to 
endothelial cells, and tube formation was investigated by microscopy. Data are given as mean of tube length in µm+SD (top). (Continued ) 
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antibodies bound discretely to the β3 chain, and some recog-
nized complex (or compound) epitopes formed by αIIb and 
β3.22–25 Similar to αIIbβ3, point mutation Leu33Pro together 
with αv subunit may create HPA-1a compound–dependent 
HPA-1a antigenic determinants. Our structural analysis of the 
PSI domain of αIIbβ3 and αvβ3 shows distinct conformational 
states that could in theory be differentially recognized by the 
immune system (Figure II in the online-only Data Supplement). 
However, other mechanisms may play a role.
We found in our cohorts a new anti–HPA-1a antibody sub-
type that reacts with compound epitopes formed by αv and β3 
subunits. Accordingly, 3 different anti–HPA-1a subtypes may 
exist: anti-αIIbβ3 (reactive with platelets only), anti-β3 (reac-
tive with platelets and ECs), and anti-αvβ3 (predominantly 
reactive with ECs). The third subtype is produced by FNAIT 
mothers with fetal/neonatal ICH.
It has become evident that integrin αvβ3–mediated adhe-
sion to extracellular matrix is essential for EC growth and 
survival, whereas αvβ3 antagonism can induce endothelial 
apoptosis during angiogenesis.26 In fact, disruption of αvβ3 
ligation with monoclonal antibodies or peptide antagonist of 
αvβ3 caused detachment-induced endothelial anoikis19 via 
activation of caspase-3 cascade27 and impaired thereby angio-
genesis.28–30 In line with these observations, we show in this 
study that only the anti–αvβ3 subtype of anti–HPA-1a (that 
impaired αvβ3 ligation) could induce endothelial anoikis and 
affect angiogenesis.
Recently, Yougbaré et al16 demonstrated that anti–β3 anti-
bodies induce ICH in pups by impairing angiogenesis in mouse 
model of FNAIT. In this model, maternal isoantibodies were 
developed by transfusion of β3 knockout mice with wild-type 
platelets, and ICH frequency was increased with subsequent 
immunizations. In humans, however, severity of FNAIT usually 
does not increase with subsequent pregnancies,17 and a high rate 
of ICH reoccurrence is found in previous siblings with ICH.7,8 
Unfortunately, analysis of different antibody subtypes was not 
investigated in this murine model. It is conceivable that, similar 
to humans, anti-αvβ3 impaired angiogenesis in these pups.
Vessel development in the brain depends on cross talk 
between ECs and perivascular astrocytes.31 For this process, 
αv integrins play an important role through regulation of 
transforming growth factor-β activation and expression of 
transforming growth factor-β responsive genes that promote 
vessel differentiation and stabilization.32–34 A critical period 
for ICH in FNAIT is before week 28 of gestation.35 Of note, 
rapid development of premature medullary veins into shower-
like numerous vessels associated with extensive angiogenesis 
has been observed between weeks 19 and 24 of gestation.36 
Therefore, it is feasible that antibodies against αvβ3 interfere 
with these critical processes to provoke ICH, especially in the 
brain within this period. To which extent thrombocytopenia 
further modiﬁes bleeding probability and severity in the fetus 
requires further research.
In summary, our study provides evidence that human 
anti–HPA-1a of anti-αvβ3, but not of anti-β3, speciﬁcity can 
affect fetal vessel wall integrity, a mechanism that seems to 
be responsible for FNAIT-associated ICH. Our ﬁndings not 
only contribute to our understanding of FNAIT pathology 
in humans but also opens the way for new diagnostic testing 
and treatment strategies for immunized women in subsequent 
pregnancies. The absence of the anti–αvβ3 subtype could 
indicate a lower risk (or no risk) for ICH and might allow for 
modiﬁcation (or cessation) of prophylactic FNAIT treatment. 
However, larger clinical studies are necessary to evaluate the 
clinical value of the proposed diagnostic test.
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v Intracranial hemorrhage is the most serious complication of severe fetal/neonatal alloimmune thrombocytopenia, caused by maternal alloan-
tibodies against human platelet antigen-1a.
v We show here that a specific anti–human platelet antigen-1a antibody subtype reactive with αvβ3 compound epitopes expressed on endothe-
lial cells is present in intracranial hemorrhage cases.
v This antibody subtype impairs endothelial function, indicating that antiendothelial rather than antiplatelet activity is responsible for the develop-
ment of intracranial hemorrhage in fetal/neonatal alloimmune thrombocytopenia.
v Our finding has the potential of changing diagnostic and therapeutic strategies in fetal/neonatal alloimmune thrombocytopenia.
Highlights
 at U
niversitaet G
iessen on Septem
ber 6, 2016
http://atvb.ahajournals.org/
D
ow
nloaded from
 
Gregor Bein, Volker Kiefel, Jieqing Zhu, Peter J. Newman, Behnaz Bayat and Ulrich J. Sachs
Sentot Santoso, Hevi Wihadmadyatami, Tamam Bakchoul, Silke Werth, Nadia Al-Fakhri,
Fetal/Neonatal Alloimmune Thrombocytopenia
3 Antibodies Are a Major Cause of Intracranial Bleeding inβvαAntiendothelial
Print ISSN: 1079-5642. Online ISSN: 1524-4636 
Copyright © 2016 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272Arteriosclerosis, Thrombosis, and Vascular Biology 
doi: 10.1161/ATVBAHA.116.307281
2016;36:1517-1524; originally published online June 9, 2016;Arterioscler Thromb Vasc Biol. 
http://atvb.ahajournals.org/content/36/8/1517
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
http://atvb.ahajournals.org/content/suppl/2016/06/13/ATVBAHA.116.307281.DC2.html
http://atvb.ahajournals.org/content/suppl/2016/06/13/ATVBAHA.116.307281.DC1.html
Data Supplement (unedited) at:
 
http://atvb.ahajournals.org//subscriptions/
at:
is onlineArteriosclerosis, Thrombosis, and Vascular Biology  Information about subscribing to Subscriptions:
 
http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
 
document.Question and Answer
Permissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the Web
Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for 
 can be obtained via RightsLink, a service of theArteriosclerosis, Thrombosis, and Vascular Biologyin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at U
niversitaet G
iessen on Septem
ber 6, 2016
http://atvb.ahajournals.org/
D
ow
nloaded from
 
1 
 
Materials and Methods 
 
Antibodies and peptides  
Monoclonal antibody (moab) Gi5 against IIb3 complex was characterized in our laboratory.1 
Moab 23C6 against v3 complex2 and moab P2W7 against v3 were purchased from Milipore 
(Temecula, CA, USA) and Calbiochem (La Jolla, CA, USA). Moab AP3 against the common 3 
subunit4 was produced by hybridoma AP3 cell line. RGD peptide was from Bachem, Bubendorf, 
Switzerland. Moab SZ21 specific against the HPA-1a alloform of 3 was from Beckman Coulter 
(Sinsheim, Germany). A soluble recombinant IIb3 protein was produced in High Five cells.5 
 
Serum samples  
Maternal serum samples were selected from cases diagnosed with FNAIT in the Giessen 
laboratory based on the availability of adequate amounts of serum leftovers. For all selected 
samples, mothers were HPA-1a negative and had anti-HPA-1a antibodies, but no other HPA 
antibodies. Clinical data entries included neonatal brain ultrasound results, based on which the 
samples were assigned to the +ICH cohort (presence of ICH, n=18) or the –ICH cohort 
(absence of ICH, n=18). Demographic parameters (age, race) and clinical parameters as given 
in tables 1 and 2 including, neonatal platelet counts, were not statistically different between the 
+ICH and the –ICH cohort. From each cohort, 9 sera were chosen by list randomizer 
(http://www.random.org) for use in subsequent experiments. Serum samples from healthy blood 
donors were used as controls throughout the study. IgG fractions were purified using Melon Gel 
IgG Purification Kit as recommended by the manufacturer (Pierce Biotechnology, Rockford, IL, 
USA). IgG concentration was measured by Nano Drop (Thermo Scientific, Wilmington, DE, 
USA) and adjusted to a concentration of 20 μg/ml. Purified IgG was used immediately. 
Investigators in the laboratory were unaware of the clinical background of samples. 
 
Endothelial cells 
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical vein as 
described6 and maintained in endothelial basal medium-2 (EBM2; Lonza, Bazel, Switzerland). 
All experiments were performed with primary, secondary or tertiary post confluent monolayers of 
HPA-1aa or HPA-1bb genotyped HUVECs. HPA typing of HUVECs was performed by real-time 
PCR using VIC and FAM reporter probes (ABI Applied Bioscience, Washington, DC, USA) 
specific for HPA-1a and HPA-1b, respectively. 
 
Stable cell lines expressing human IIb3 and v3 integrins  
Chinese Hamster Ovary (CHO) cells expressing IIb3 were generated as described.7 CHO 
cells expressing the HPA-1a form of the v3 integrin were a generous gift from Dr. Mark 
Ginsberg (University of California, La Jolla, CA, USA) and were cultured in DMEM medium 
(PAN) supplemented with 1% non-essential amino acids (Life Technologies), 1% 
penicillin/streptomycin (Life Technologies), and 10% FCS (PAN).  
  
Characterization of HPA-1a alloantibodies by antigen capture assay 
Aliquots of 30 μl platelets (20x106 cells) or HUVEC (5x105) were incubated with 20 μl serum and 
10 μl moabs (concentration 20 μg/ml). Binding of human antibodies was analysed by MAIPA as 
described.8 Cut-offs were calculated by the use of control sera. All experiments were run in 
triplicates, and results were given as arithmetic means of optical density (OD). 
 
Production of IIb3 coated beads 
In brief, 2 ml amino-link resin beads (Thermo Scientific, Rockford, IL, USA) were coupled with 2 
ml IIbβ3 recombinant protein (0.35 mg/ml) in 200 μl coupling buffer overnight at 4°C. 
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Concentration of IIbβ3 bound to the beads was measured by bicinchoninic acid assay (BCA; 
Thermo Scientific). To verify the specificity and absorption capacity of IIb3 coated beads, 100 
μl moabs specific for IIb3 (clone Gi5), 3 (clone AP3), and v3 (clone P2W7) (concentration 
20 μg/ml) were absorbed with 100 μl IIbβ3 beads (6.8 μg IIb3/ml) overnight at 4°C. 
Absorbates were tested with v3 and IIb3 transfected CHO cells by flow cytometry (FACS 
Canto, Heidelberg, Germany) for the presence of remaining antibodies. 
 
Separation of anti-HPA-1a subtypes from human sera 
Aliquots of 100 μl IIbβ3 beads were incubated with 100 μl serum overnight at 4°C. After 
centrifugation (1 min at 10,000g), supernatant was collected, and beads were washed twice with 
500 μl isotonic saline. Antibodies bound to IIbβ3 beads were eluted with 40 μl acid buffer 
(saline containing 1.5% BSA, and 1.0% acetic acid, pH 2.8) for 10 min at RT. Eluted antibodies 
were neutralized with 3 μl 2.5M Tris buffer, pH 7.2. IgG was purified as described IgG and was 
adjusted to a concentration of 20 μg/ml before use.  
 
Analysis of different anti-HPA-1a subtypes by immunoprecipitation  
CHO cells expressing IIb3, v3 or non-transfected CHO cells were surface labelled with 2 
ml NHS-LC-Biotin (5 mmol/L; Pierce) as previously described.24 Labelled cell lysates (100 μl) 
were incubated with 35 μl adsorbate or eluate (20 μg/ml) overnight at 4°C in the presence of 50 
μl protein G beads (Gerbu Biotechnik, Heidelberg, Germany). After washings with 
immunoprecipitation buffer (50 mm Tris, 150 mm NaCl, 1% Triton X-100), bound proteins were 
eluted by adding SDS buffer for 5 min at 100 °C. Eluates were analyzed on 7.5% SDS-PAGE 
under reducing conditions. Separated proteins were transferred onto polyvinylidenfluorid 
(PVDF) membranes and developed with peroxidase-labeled streptavidin using 
chemiluminescence system (Immobilon Western Substrat, Millipore).  
 
Apoptosis assay 
Cell apoptosis was measured by the Caspase-Glo 3/7 assay (Promega, Madison, WI, USA). 
100 μl vitronectin (2 μg/mL; Athens Research & Technology, Athens, GA, USA) were coated on 
96 white well plates (Corning Incorporated, Corning, NY, USA) for 8 hours. Aliquots of 450 μl 
HUVEC (1-2x106 cells in EBM-2 medium) were incubated with cRGD (final concentration 40 
μg/ml) or purified human IgG (final concentration 40 μg/ml) and seeded onto vitronectin coated 
wells for 16 hours at 37°C, 5% CO2. 100 μl of Caspase-Glo 3/7 reagents were then added at RT 
and luminescence was measured using a fluorescence microtiter reader (FLX800, Biotek 
Instrument Winooski, VT, USA). In some experiments, 5 μl of 30 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF; Sigma) were added for 30 min at 
37°C prior to addition of IgG. 
 
Morphological assessment of apoptosis  
Aliquots of 105 HUVEC were seeded onto μ-slide well (Ibidi, Martinsried, Germany) coated with 
vitronectin (see above) together with purified human IgG (final concentration 40 μg/ml) or cRGD 
(final concentration 40 μg/ml) for 16 - 18 hours at 37°C, 5% CO2. After washings with 300 μl ice-
cold PBS pH 7.4 (PAN, Aidenbach, Germany), cells were fixed with 300 μl 4% 
paraformaldehyde (PFA; Sigma) for 15 min and incubated with 1μg/ml blue fluorescing dye 
(Hoechst 33342; Thermo Scientific, Rockford, IL, USA) for 3 min at RT. Stained chromatin DNA 
was analysed using confocal microscopy with 60x magnification (Nikon Eclipse TE2000-E, 
Tokyo, Japan).  
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ROS detection assay  
ROS produced in HUVEC was measured with 2’,7’-dichlorofluorescein diacetate (DCFDA; 
Abcam, Cambridge, UK). In brief, 105 HUVEC were seeded in 6-wells plates for 6 hours and 
cultured overnight in EBM-2 medium containing 0.5% FCS. After removal of the medium, 1.5 
mL medium containing DCFDA (final concentration, 10 mmol/L) was added. Subsequently, cells 
were incubated with mab against 23C6 or mouse IgG (5 μg/mL), cRGD (5 μg/mL), and anti-
HPA-1a or control IgG (50 μg/mL) for 1 hour at 37°C. Cells were detached with accutase 
(Sigma), fixed by adding 250 μl CELLFIX (1:10 dilution; Becton Dickinson, Heidelberg, 
Germany), and measured by flow cytometry as described above. In some experiments prior to 
stimulation with antibodies, HUVEC were treated with AEBSF for 1 hour at 37°C.  
 
Tube formation assay 
Aliquots of 50 μl ice-cold matrix gel (Biovision, Milpitas, CA, USA) were plated onto microtiter 
wells (Greiner, Frickenhausen, Germany) for 30-60 min at 37°C. 100 μl HUVEC (1-5 x 105 cells 
in EBM2 medium supplemented with 2.5% FCS) were seeded carefully onto the gel for 45 min 
at 37°C. Thereafter, thrombin (1 U; Sigma, Steinheim, Germany) or IgG (40 μg/ml) were added. 
Cells were allowed to grow for 20 hours at 37°C. Data were analysed using a F-view 
monochrome fluorescence microscope (Olympus, Tokyo, Japan) with 10x magnification. For 
quantification, data were imported as TIFF files into ImageJ (http://imagej.nih.gov/ij/) using the 
stage micrometer as calibrator. In some experiments, 5 μl AEBSF was added for 30 min at 
37 °C prior to addition of the antibodies. 
 
Adhesion assay 
Microtiter wells (Greiner Bio-one, Frickenhausen, Germany) were coated with 2 μg vitronectin 
(Athens Reasearch and Technology, Athens, GA, USA) or BSA (Serva, Heidelberg, Germany) 
in HBS buffer (119 mM NaCl, 4 mM KCl, 11 mM Glucose in 20 mM Hepes buffer) overnight at 
4°C. After washings with HBS buffer, wells were blocked with 100 μl 3% BSA. Aliquots of 
washed HUVEC (1-4 x106) were added together with purified IgG or cRGD (final concentration 5 
μg/ml) for 1 hour at 37°C. Wells were washed, adherent cells were stained with crystal violet 
(Sigma, Steinheim, Germany) and measured by a microtiter reader at 592nm (SunriseTM, 
Tecan, Maennedorf, Germany).  
 
Structural analysis 
The crystal structure of integrin IIb3 extracellular domain (PDB code 3FCS) (ref: PMID: 
19111664) was superimposed on the crystal structure of v3 extracellular domain (PDB code 
4G1M) (ref: PMID: 23106217) with PyMOL based on 3 PSI domain or 3 hybrid domain. 
 
Statistical analysis 
Statistical comparisons were made using an unpaired, 2-tailed Student’s t test or 1-way ANOVA 
followed by Bonferroni’s post-hoc test, as appropriate. A p-value <0.05 was assumed to 
represent statistical significance.  
 
Study approval 
The use of all human material was approved by the Ethics Committee of the Medical Faculty, 
Justus Liebig University, Giessen, Germany.  
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Summary
Treatment of bleeding in patients with Glanzmann’s thrombasthenia 
(GT) can be hampered by iso-antibodies against the αIIbβ3 integrin, 
which cause rapid clearance of transfused donor platelets. Type 1 GT 
patients with a total absence of αIIbβ3 from the platelet surface are 
known to be susceptible to form such isoantibodies. In this study, we 
describe a type 1 GT patient with a missense mutation (Gly540Asn) lo-
cated in the EGF3 domain of the β3 integrin subunit. Cotransfection 
analysis in CHO cells demonstrates total absence of αIIbβ3 from the 
surface, based on inappropriate αIIb maturation. The patient’s serum 
was reactive with αIIbβ3 and αvβ3 integrins in a capture assay, when 
platelets and endothelial cells were used. Two specificities could be 
isolated from the patient’s serum, anti-αIIbβ3 and anti-αvβ3 isoanti-
bodies. Both specificities did not interfere with platelet aggregation. In 
contrast, isoantibodies against αvβ3, but not against αIIbβ3, were 
able to disturb endothelial cell adhesion onto vitronectin, triggered 
endothelial cell apoptosis and interfered with endothelial tube 
formation. This intriguing finding may explain more recently observed 
features of fetal/neonatal iso-immune thrombocytopenia in children 
from type 1 GT mothers with intracranial haemorrhage, which could 
be related to anti-endothelial activity of the maternal antibodies. In 
conclusion, we give evidence that two isoantibody entities exist in 
type 1 GT patients, which are unequivocally different, both in an im-
munological and functional sense. Further research on the clinical con-
sequences of immunisation against αvβ3 is required, predominantly in 
GT patients of childbearing age.
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Glanzmann’s thrombasthenia, platelet function defect, isoimmuni-
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Introduction
Glanzmann’s thrombasthenia (GT) is a rare autosomal recessive 
bleeding disorder caused by qualitative and/or quantitative deficien-
cies of αIIbβ3, which is the major fibrinogen receptor on platelets. 
These deficiencies lead to inadequate platelet aggregation in re-
sponse to multiple physiological agonists. Based on laboratory crite-
ria, GT patients may be sub-classified into type 1 GT (αIIbβ3 pla-
telet surface expression, < 5 %), type 2 GT (> 5–20 %) and qualitative 
GT variants (1, 2). More than 150 naturally occurring mutations 
have been reported for the genes encoding αIIbβ3 (3, 4). A defect in 
either subunit (αIIb or β3) can alter the biosynthesis and/or struc-
ture of the αIIbβ3 heterodimer on the cell surface. GT patients have 
a lifelong moderate to severe haemorrhagic diathesis. Bleeding 
manifestations, which usually commence in early childhood, in-
clude easy bruising, petechiae, epistaxis, gingival bleeding, and men-
orrhagia. More severe spontaneous, unprovoked bleeding is uncom-
mon in GT patients (5), but bleeding following trauma or invasive 
procedures, including minor procedures, may become life threaten-
ing (6). Most GT patients have a significant history of red blood cell 
and/or platelet transfusions, the latter of which can trigger the pro-
duction of platelet isoantibodies against αIIbβ3, resulting in platelet 
transfusion refractoriness (7-10). Isoimmunisation of GT patients 
was also reported as a result of pregnancy (11, 12).
Notably, β3 also forms heterodimers with αv, both on platelets 
and endothelial cells (EC). Deficiency of αvβ3 has been reported 
for GT patients with β3 defects (13). The relevance of αvβ3 as an 
immuno-target in transfused GT patients has not been investi-
gated so far. Here, we have identified a type 1 GT patient with a 
missense mutation on β3 (Gly540Asp) who developed not only 
isoantibodies against αIIbβ3, but also against αvβ3. Anti-αvβ3 
isoantibodies, but not αIIbβ3 isoantibodies, were capable of inter-
fering with endothelial function and may be of particular rel-
evance in isoimmunised GT mothers during pregnancy.
Immunisation against αIIbβ3 and αvβ3 in a type 1 variant of 
 Glanzmann’s thrombasthenia caused by a missense mutation  
Gly540Asp on β3
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Material and methods
Case report
A 66-year-old male patient presented to the Haemostasis Centre 
after several episodes of critical peri-procedural bleedings requi-
ring massive transfusions. Massive transfusion protocols were 
initiated during or after intervertebral disc surgery, a biopsy of the 
prostate and partial gastrectomy. These protocols included red 
blood cell, platelets, and plasma transfusions as well as the admin-
istration of prothrombin complex and fibrinogen concentrates. He 
presented himself to our institution 12 weeks after the last massive 
transfusion related to gastrectomy. All clinical material was ob-
tained on that day. On admission, he had no signs or symptoms of 
bleeding. His Ivy bleeding time was 12 minutes (min) (reference 
less than 8 min). He had a normal coagulation screen and blood 
film, his platelet count was 150 G/l, platelet morphology was regu-
lar. In light-transmission aggregometry, his platelets were unable 
to respond to adenosine diphosphate (ADP 5–20 μM), collagen (4 
μg/ml), arachidonic acid (250–500 mg/ml), and epinephrine (2–10 
μM), but platelet agglutination in response to ristocetin (1.5 mg/
ml) was normal. Informed consent from the patient was obtained 
as per guidelines of the institutional ethics committee.
Quantification of αIIbβ3 surface expression by flow 
cytometry
Platelet-rich plasma (PRP) was prepared from acid-citrate-dex-
trose (ACD) anticoagulated blood by centrifugation at 800 g for 20 
min at room temperature (RT). The expression of glycoproteins 
α2β1, αIIbβ3, αvβ3 and GP Ib/IX on the platelet surface was 
quantified with platelet GP screen kit (Biocytek, Marseille, France) 
according to the manufacturer’s instructions on a FACSCanto flow 
cytometer (Becton Dickinson, Heidelberg, Germany).
Platelet aggregation assay
PRP was prepared from ACD anticoagulated blood by centrifu-
gation at 800 g for 20 min at RT. Platelet aggregometry was per-
formed on a PAP-8 aggregometer (Moelab, Langenfeld, Germany) 
using collagen, adenosine diphosphate (ADP), arachidonic acid, 
epinephrine, and ristocetin (all from Moelab). In some experi-
ments, antibodies were added prior to platelet aggregation.
Monoclonal antibodies and sera
Monoclonal antibodies (mabs) against αIIbβ3 complex (clone 
Gi5), against αIIb (clone Gi16) and against α2β1 (clone Gi19) were 
produced and characterised in our laboratory (14). Mabs SZ21 
and SZ22 specific for αIIb and β3 subunit, respectively, were pur-
chased from Beckman Coulter (Marseille, France). Mab against 
αvβ3 complex (clone 23C6) (15) and against αv subunit (clone 
P2W7) (16) were purchased from Millipore, Temecula, CA, USA. 
Mab against GAPDH was from Hyclon (South Logan, UT, USA). 
Anti-HPA-1a serum was obtained from a mother who gave birth 
to a child with severe neonatal alloimmune thrombocytopenia 
with intracranial haemorrhage. Serum from a healthy blood donor 
was used as control.
CHO cells expressing human β3 integrins
Chinese Hamster Ovary (CHO) cells expressing human αvβ3 inte-
grin were a generous gift from Dr. Mark Ginsberg (University of 
California, La Jolla, CA, USA) and were cultured in DMEM medi-
um (PAN-Biotech, Aidenbach, Germany) supplemented with 1 % 
non-essential amino acids (Life Technologies; Carlsbad, CA, 
USA), 1 % penicillin/streptomycin (Life Technologies) and 10 % 
foetal calf serum (FCS; PAN-Biotech). CHO cells expressing 
αIIbβ3 were developed in our laboratory (17) and maintained as 
described above.
Nucleotide sequence analysis
Full-length sequencing of ITG2B and ITGB3 was carried out as 
described previously. Nucleotide sequences of PCR primers, se-
quencing, and reaction conditions are available upon request (18). 
Briefly, αIIb and β3 coding regions of genomic DNA were PCR 
amplified with primers corresponding to intronic sequences sur-
rounding all exons of the ITG2B and ITGB3 genes. PCR was car-
ried out using a Fast-Start High Fidelity PCR system (Roche Diag-
nostic Corporation, Indianapolis, IN, USA). Prior to sequence 
analysis, all PCR products were purified with a QIAquick PCR pu-
rification kit (Qiagen Sciences, Valencia, CA, USA). Automated 
sequence analysis was performed in both directions on a genetic 
analyzer (ABI 3100; Applied Biosystems, Foster City, CA, USA).
Construction of expression vectors
A full-length construct for the β3 mutant isoform was produced by 
site-directed mutagenesis of wild-type β3 in pcDNA3.1/Zeo mam-
malian vector using Quick Change Mutagenesis Kit (Strategene, 
Heidelberg, Germany) as previously described (17). For PCR am-
plification, site directed mutagenesis primers 
(5’-TGTGCTCAGGCCATGACCAGTGCAG CTGTGG-3‘ and 
5‘-CCACAGCTGCACTGGTCATGGCCTGAGCACA-3‘) were 
used (Eurofins MWG Operon, Ebersberg, Germany). After de-
naturation for 30 seconds (sec) at 95 °C, amplification consisted of 
12 cycles (denaturation at 95 °C for 30 sec, annealing at 55 °C for 1 
min, and extension at 65 °C for 12 min). PCR products were di-
gested with Dpn endonuclease for 1 hour (h) at 37 °C, and trans-
fected into DH5α high efficiency competent E. coli (Life Technol-
ogies). Plasmid DNA from positive clones was verified by nucleo-
tide sequencing as described above.
Transfection of mutant and wild-type αIIbβ3 in 
 mammalian cells
CHO cells (American Type Tissue Collection, Rockville, MD, 
USA) were grown in alpha-MEM medium (PAN-Biotech) supple-
mented with 10 % foetal calf serum (FCS; PAN-Biotech) and were 
transfected with β3 (wild-type or mutant) together with αIIb using 
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Superfect Transfectant Reagent (Qiagen). After four weeks of cell 
culture in the presence of Zeocin and Geneticin (GIBCO BRL, 
Grand Island, NY, USA), cell lines were lysed and analysed for 
αIIbβ3 expression.
Immunoprecipitation and immunoblotting
In brief, transfected cells and platelets were surface labelled with 5 
mmol/l NHS-LC-Biotin (Pierce, Rockford, IL, USA) and were pre-
cipitated as previously described (15). Labelled cell lysates were in-
cubated with mab (20 μg/ml) or 50 μl serum overnight at 4 °C in 
the presence of 50 μl protein G beads (Gerbu Biotechnik, Heidel-
berg, Germany). After washings with immunoprecipitation buffer 
(50 mm Tris, 150 mm NaCl, 1 % Triton X-100), bound proteins 
were eluted by adding SDS buffer for 3 min at 100 °C. Eluates were 
analysed on 7.5 % SDS-PAGE under non-reducing conditions. 
Separated proteins were transferred onto polyvinylidenfluorid 
(PVDF) membranes and developed with peroxidase-labelled 
streptavidin using a chemiluminescence system (ECL, Amersham 
Biosciences, Glattbrugg, Switzerland).
Immunobloting was performed by using a total 200 μg/ml pro-
tein of unlabeled cell lysate. The lysate was separated on 7.5 % 
SDS-PAGE under non-reducing conditions, transferred onto 
PVDF membranes, and stained overnight by incubation with a 
panel of mabs (final concentration, 15 μg/ml) and visualised by the 
use of peroxidase-labelled secondary antibody and an ECL system.
Characterisation of patient’s antibodies by antigen 
capture assay
Platelets and HUVECs were used to characterise the presence of 
anti-αIIbβ3 and anti-αvβ3 isoantibodies in the patient’s serum. 
Platelets were isolated from EDTA anticoagulated blood by differ-
ential centrifugation. Aliquots of 50 μl platelet suspension (2×106 
cells) or 200 μl endothelial cells (5×105 cells) were incubated with 
20 μl serum and 10 μl mabs (final concentration 20 μg/ml). Bind-
ing of anti-HPA-1a antibodies was analysed by MAIPA as de-
scribed (19). Cut-off was calculated by the use of control sera. All 
experiments were run in duplicates, and results were given as 
arithmetic means of optical density (OD).
Separation of anti-αIIbβ3 and anti-αvβ3 isoantibodies 
using transfected cell lines
Aliquots of 1×106 CHO cells expressing αIIbβ3 or αvβ3 were incu-
bated with 100 μl of patient’s serum for 30 min at 37 °C. After cen-
trifugation for 1 min at 10,000 g, supernatant containing unbound 
antibodies (termed absorbate) was collected. Cells were then 
washed twice with 500 μl isotonic saline and resuspended in 80 μl 
isotonic saline. In order to obtain an eluate, cell-bound antibodies 
were eluted with 40 μl isotonic saline containing 1.5 % BSA, and 
1.0 % acetic acid, pH 2.8 for 10 min at RT. Eluates were neutralised 
with 3 μl 2.5M Tris buffer, pH 7.2. From both absorbates and elu-
ates, IgG was purified using MelonTM gel IgG spin purification kit 
(Thermo Fisher Scientific, Rockford, IL, USA). IgG concentration 
was measured by Nano Drop (Thermo Scientific, Wilmington, 
DE, USA) and adjusted to a concentration of 20 μg/ml. Purified 
IgG was used immediately. In some cases, sera were absorbed with 
αIIbβ3 coated beads. In brief, 100 μl αIIbβ3 beads (6.8 μg 
αIIbβ3/ml) were incubated with 100 μl serum overnight at 4 °C. 
After centrifugation (1 min at 10,000g), supernatant (termed ab-
sorbate) was collected, and beads were washed twice with 500 μl 
isotonic saline. Antibodies bound to αIIbβ3 beads were eluted as 
described above (termed eluate).
Adhesion assay
Microtitre wells (Greiner Bio-one, Frickenhausen, Germany) were 
coated with 2 μg fibrinogen (Calbiochem, Darmstadt, Germany), 
vitronectin (Athens Research and Technology, Athens, GA, USA) 
or BSA (Serva, Heidelberg, Germany) in HBS buffer (119 mM 
NaCl, 4 mM KCl, 11 mM Glucose in 20 mM Hepes buffer) over-
night at 4 °C. After washings, wells were then blocked with 100 μl 
3 % BSA for 1 h at 4 °C. Aliquots of washed HUVEC cells (1–4 
×106) were added together with mabs, purified IgG (final concen-
tration 5 μg/ml) for 1 h at 37 °C. Wells were washed once, and ad-
herent cells were stained with crystal violet (Sigma, Steinheim, 
Germany) and measured in a microtitre reader at 592 nm (Sunri-
seTM, Tecan, Männedorf, Germany).
Apoptosis assay
Cell apoptosis was measured by the Caspase-Glo 3/7 assay (Pro-
mega, Madison, WI, USA). One hundred μl vitronectin (2 μg/ml; 
Athens Research & Technology) were coated on 96 white well 
plates (Corning Incorporated, Corning, NY, USA) for 8 h. Ali-
quots of 450 μl HUVEC suspensions (1–2×106 cells in EBM-2 
medium) were incubated with mabs against αIIbβ3, αvβ3 (final 
concentration 20 μg/ml), cRGD (final concentration 20 μg/ml), or 
purified human IgG (final concentration 20 μg/ml) and seeded 
onto vitronectin coated wells for 16 h at 37 °C, 5 % CO2. One 
hundred μl of Caspase-Glo 3/7 reagents were then added at RT 
and luminescence was measured using a microtitre reader 
(FLX800, Biotek Instrument, Winooski, VT, USA).
Morphological assessment of apoptosis
Aliquots of 105 HUVEC were seeded onto μ-slide well (Ibidi, Mar-
tinsried, Germany) precoated with vitronectin (see above) to-
gether with purified human IgG (final concentration 20 μg/ml) or 
cRGD (final concentration 20 μg/ml) for 16 h at 37 °C, 5 % CO2. 
After washings with 300 μl ice-cold PBS pH 7.4 (PAN, Aidenbach, 
Germany), cells were fixed with 300 μl 4 % paraformaldehyde 
(PFA; Sigma) for 15 min and incubated with 1 μg/ml blue fluoresc-
ing dye (Hoechst 33342; Thermo Scientific, Rockford, IL, USA) for 
3 min at RT. Stained chromatin DNA was analysed using confocal 
microscopy with 60× magnification (Nikon Eclipse TE2000-E, 
Tokyo, Japan).
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Tube formation assay
Aliquots of 50 μl ice-cold gel (Biovision, Milpitas, CA, USA) were 
plated onto microtitre wells (Greiner Bio-one, Frickenhausen, 
Germany) for 45 min at 37 °C. One hundred μl HUVEC (1–5×105 
cells in EBM2 medium supplemented with 2.5 % FCS) were seeded 
carefully onto the gel for 45 min at 37 °C. Thereafter, 100 μl EBM2 
medium containing thrombin (1 U; Sigma, Steinheim, Germany) 
or mabs against αvβ3 and αIIβ3 (final concentration 40 μg/ml) or 
purified human IgG (final concentration 40 μg/ml) were added. 
Cells were allowed to grow for 20 h at 37 °C. Data were analysed 
using a F-view monochrome fluorescence microscope (Olympus, 
Tokyo, Japan) with 10× magnification. For the quantification of 
tube length, data were imported as TIFF files into ImageJ 
(http://imagej.nih.gov/ij/) using the stage micrometer as calibrator.
Alignment analysis for the IEGF-3 domain of β3
Nucleotide sequences from men, monkey, rabbit, cow, swine, 
mouse, and Drosophila melanogaster were derived from NCBI 
Gene Bank (NG_008332.1, XM_002834317.3, AF116270.1, 
JX475452.1, AF170527.1, BC125518.1, and L13305.1) and aligned 
with MEGA 6 software20.
Statistics
Statistical comparisons were made using an unpaired, two-tailed 
Student’s t-test or one-way ANOVA followed by Bonferroni’s post-
hoc test, as appropriate. A p-value <0.05 was assumed to represent 
statistical significance.
Study approval
The use of all human material was approved by the Ethics Com-
mittee of the Medical Faculty, Justus Liebig University, Giessen, 
Germany.
Results
Expression analysis of β3 integrin on patient’s 
 platelets
▶ Figure 1 A shows the flow cytometry analysis of patient’s platelet 
compared with a normal donor. In comparison to normal platelets, 
very low αIIbβ3 (1,053 ± 544 copies/platelet, n=3) and αvβ3 (755 ± 
180 copies/platelet, n=3) expression were measured on the cell sur-
face expression of our patient’s platelets. These levels, however, are 
below the limits of our test system as defined by isotype control 
(729 ± 650 copies/platelet). In contrast, normal α2β1 (4,600 ± 
1,850, n=3) and GPIb/IX expression (30,418 ± 12,000, n=3; data 
not shown) were found. The normal values for αIIbβ3, αvβ3, α2β1 
and GPIb/IX expression were 43,000 ± 12,000; 1,228 ± 400; 4,000 
± 2,800 and 38,000 ± 11,000 copies/platelet, respectively.
To confirm these findings immunoblotting analysis was per-
formed (▶ Figure 1 B). In comparison to normal platelets, only re-
sidual αIIb, but not β3 and αv subunits was detectable in cell ly-
sates of patient’s platelets. Based on these results and platelet ag-
gregation studies (see case report), type 1 GT was diagnosed.
Molecular analysis of αIIb (ITGA2B) and β3 (ITGB3) 
genes
To identify the molecular genetic defect in this patient, we isolated 
genomic DNA from the patient’s leukocytes and amplified all 
exons of ITGA2B and ITGB3 gene by PCR. Nucleotide sequencing 
analysis showed a homozygous G>A transition at position 1697 of 
Figure 1: A) Quantification of glycoproteins on the platelet surface 
by flow cytometry. Normal donor platelets (left panel) and patient pla-
telets (right panel) were incubated with monoclonal antibodies against 
αIIbβ3 (clone Gi5), αvβ3 (clone 23C6) and α2β1 (clone Gi19) as indicated. 
Mouse IgG was run as a control (Ctrl). Fluorescence-labelled donkey anti-
mouse IgG was used as secondary antibody. B) Immunobloting analysis 
of patient platelets. Platelets from patient and normal donor were lysed, 
and aliquots of cell lysates (200 μg protein) were separated on 7.5 % SDS-
PAGE under non-reducing conditions. After blotting onto PVDF membrane, 
strips were subsequently incubated with mouse IgG (lanes 1), mabs against 
β3 (clone SZ21) and αIIb (clone SZ22) (lanes 2), or mabs against β3 (clone 
SZ21) and αv (clone P2W7) (lanes 3). Bound antibodies were then visualised 
using peroxidase-labelled secondary antibody and a chemiluminescence sys-
tem.
A
B
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ITGB3, leading to a missense substitution Gly540Asp 
(GGC>GAC) in the I-EGF3 domain of β3 (▶ Figure 2). Sequenc-
ing the entire αIIb coding region showed no deviation from the 
wild-type form (not shown).
Effect of the Gly540Asp mutation on αIIbβ3 
 expression
To prove whether the Gly540Asp mutation located on β3 is di-
rectly responsible for the lack of αIIbβ3 surface expression, full-
length cDNA constructs encoding for the mutated β3 form were 
generated. A mutated β3 construct was transfected together with 
wild-type αIIb into CHO cells, and αIIbβ3 expression on the sur-
face of transfected cells was analysed by immunoprecipitation. As 
shown in ▶ Figure 3 (upper panel), CHO cells transfected with 
wild-type αIIb together with mutant β3 (Asp540) completely failed 
to express αIIbβ3 on the cell surface. Neither αIIb nor β3 specific 
bands could not be detected, even after prolonged exposure time 
(data not shown). Immunoblot analysis revealed that the mutant 
cells produced only pro-αIIb, which was not processed into mature 
αIIb, the obligatory step for αIIbβ3 surface expression. Anti-β3 de-
tected multiple bands (lane 2), most likely breakdown products 
from the β3 integrin (▶ Figure 3, bottom panel).
Development of platelet αIIbβ3 and αvβ3 
 isoantibodies
To analyse the possible development of isoantibodies due to pla-
telet transfusions, patient serum was analysed by antigen capture 
Figure 2: Nucleotide 
 sequencing analysis of 
ITGB3 gene. Results for 
nucleotides 1689 to 1704 
are shown for a healthy 
individual, the GT patient, 
and one of his children. 
The nucleotide substitu-
tion G>A at position 1697 
in exon 11 and the corre-
sponding amino acid 
change from Gly540 
(GGC) to Asp540 (GAC) 
are indicated.
Figure 3: Immunochemical analysis of CHO cells transfected with 
mutant β3. Upper panel: CHO cells were transfected either with wild-type 
β3 or mutant β3 together with wild-type αIIb constructs. Cells were surface 
labelled with biotin and precipitated with mouse IgG (lanes 1 and 3) and 
mabs against αIIbβ3 (lanes 2 and 4). Immunprecipitates were separated on 
7.5 % SDS-PAGE under non-reducing conditions and transferred onto PVDF 
membrane. Bands were then visualized using peroxidase-labelled streptavi-
din and a chemiluminescence system. Bottom panel: Transfected CHO cells 
(as above) were lysed, and cell lysates were separated on 7.5 % SDS-PAGE 
under non-reducing conditions. After blotting onto PVDF, strips were incu-
bated with mouse IgG (lanes 1), mabs against β3 (lanes 2) and αIIb (lanes 3), 
and visualised as described in Figure 1B.
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assay using mabs αIIbβ3 and αvβ3 and platelet or endothelial 
cells as targets. As shown in ▶ Figure 4 A, patient serum reacted 
with platelet αIIbβ3 as well as platelet αvβ3 (black columns). 
When tested with endothelial cells, strong anti-αvβ3 reactivity 
was observed; whereas no anti-αIIbβ3 reactivity was detected 
(this integrin is not expressed on endothelial cells). To confirm 
the presence of anti-αvβ3 isoantibodies, patient serum was incu-
bated with αIIbβ3-coated beads. After absorption with these 
beads, antibodies remaining in serum (absorbates; grey bars) still 
showed positive reaction against αvβ3 expressed on platelets and 
endothelial cells, but did no longer react with platelet αIIbβ3. 
Vice versa, analysis of antibodies eluted from the beads (eluates; 
white bars) showed strongly positive reactions with αIIbβ3 on 
platelets.
These findings indicate that this type 1 GT patient, in response 
to platelet transfusions, developed not only isoantibodies against 
αIIbβ3, but also against αvβ3. These results could be confirmed by 
immunoprecipitation analysis (▶ Figure 4 B). Similar to control 
serum (anti-HPA-1a from a FNAIT case with intracranial haemor-
rhage), patient’s serum precipitated not only αIIbβ3, but also αvβ3 
from normal platelets. As expected, both β3-integrin complexes 
could not be precipitated from patient platelets.
Functional properties of platelet αIIbβ3 and αvβ3 
isoantibodies
To study the function of anti-αIIbβ3 and anti-αvβ3 isoantibodies, 
the two different antibody specificities were separated by 
Figure 4: A) Analysis of isoantibodies by an antigen capture assay 
with platelets and endothelial cells. Platelets and endothelial cells 
(HUVEC) were incubated with patient serum (black columns) together with 
anti-αIIbβ3 (clone Gi5) or with anti-αvβ3 complex (clone 23C6). After lysis, 
the tri-molecular complex was captured by rabbit anti-mouse IgG. Human 
antibodies bound to immobilised αIIbβ3 or αvβ3 were detected with 
enzyme-labelled goat anti-human IgG and analysed by spectrophotometry 
(OD at 490/620 nm). Data are given as mean ± SD from n=3 independent ex-
periments. In addition, patient serum was absorbed with αIIbβ3-coated 
beads and the absorbate (i. e. unbound antibodies remaining in the supernat-
ant; grey columns) and the eluate prepared from the beads (i. e. antibodies 
initially bound to αIIbβ3-coated beads and then removed; white columns) 
were analysed (see Materials and methods for details). The dashed line rep-
resents the cut-off derived from the analysis of control sera (mean ± SD; n 
=3). B) Immunoprecipitation analysis of patient platelets lysate. Pla-
telets from patient and normal donor were surface-labelled with biotin and 
lysed. Labelled platelet lysates were precipitated with control serum (lanes 
1), anti-HPA-1a (lanes 2), and patient serum (lanes 3). Immunoprecipates 
were run on 7.5 % SDS-PAGE under non-reducing conditions. Separated pro-
teins were transferred onto PVDF and visualised by the use of streptavidin 
and a chemiluminescence system.
A
B
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Figure 5: A) Influence of isoantibodies on endothelial ad-
hesion. Top panel: Patient serum was incubated with αIIbβ3– or 
αvβ3-transfected cells, and eluates from these cells were used 
(5 μg/ml) to incubate HUVECs prior to adhesion onto immobi-
lised vitronectin (black columns). Serum from a healthy individu-
al was used as a control (white columns). In addition, mab 
against αIIbβ3 complex (clone Gi5), against αvβ3 complex 
(clone 23C6) and mouse IgG (5 μg/ml) were run as controls. 
After washings, adherent cells were stained with crystal violet 
and measured in an ELISA reader at 562 nm. Data are given as 
mean ± SD for n=3 independent experiments. Bottom panel: 
Representative microphotographs from the experiment are 
shown. B) Influence of isoantibodies on endothelial apop-
tosis. Upper panel: Eluates (20 μg/ml; patient given in black, 
control individual in white) were incubated with HUVEC for 18 
h. Cell apoptosis was measured by a luciferase based caspase 
3/7 assay using luminometry. Mab against αIIbβ3 complex 
(clone Gi5), against αvβ3 complex (clone 23C6) and mouse IgG 
at a concentration of 20 μg/ml were run as controls. Data are 
given as mean ± SD for n=3 independent experiments. Bottom 
panel: HUVEC nuclei were stained with DAPI; representative 
microphotographs from the experiment are shown. C) In-
fluence of isoantibodies on endothelial tube formation. 
Upper panel: Eluates (20 μg/ml; patient given in black, control 
individual in white) were incubated with HUVEC for 18 h. Tube 
formation was assessed by the use of a stage micrometer as 
calibrator. Mab against αIIbβ3 complex (clone Gi5), against 
αvβ3 complex (clone 23C6), mouse IgG at a concentration of 20 
μg/ml, and thrombin (10U) were run as controls. Data are given 
as mean ± SD for n=3 independent experiments. Bottom panel: 
Representative microphotographs from the tube formation 
assay in the presence of thrombin, control IgG, αIIbβ3 and αvβ3 
are shown.
A
B
C
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 absorbing the patient’s serum with αIIbβ3 and αvβ3 transfected 
cells. Bound antibodies, either anti-αIIbβ3 or anti-αvβ3 isoanti-
bodies, were then eluted from the cells and were tested in different 
functional tests including platelet aggregation/adhesion, endothe-
lial cell adhesion, apoptosis, and tube formation. Both specificities 
did not interfere with platelet aggregation and platelet adhesion 
onto fibrinogen (data not shown). Interestingly, anti-αvβ3 isoanti-
bodies altered endothelial cell function significantly; they in-
hibited the adhesion of endothelial cells to vitronectin (▶ Figure 
5 A), induced endothelial apoptosis (▶ Figure 5 B) and interfered 
with angiogenesis (▶ Figure 5 C). In contrast, anti-αIIbβ3 isoanti-
bodies did not exhibit any of these properties. These results dem-
onstrate that type 1 GT patients can develop anti-αvβ3 which is 
immunologically and functionally different from anti-αIIbβ3 
isoantibodies.
Discussion
In the present study, we describe a patient with Glanzmann’s 
thrombasthenia with a missense mutation Gly540Asp located on 
the β3 integrin subunit, leading to type 1 GT.
Analysis of the patient’s platelets by flow cytometry did not 
show any expression of αIIbβ3 or αvβ3 on the cell surface. Only re-
sidual αIIb was found in a lysate from patient platelets. We could 
demonstrate by transfection analysis in mammalian cells that the 
Gly540Asp mutation is directly responsible for the absence of 
Figure 6: A) Localisation 
of the Gly540Asp mu-
tation within αIIbβ3 in-
tegrin. The localisation of 
the Gly540Asp mutation in 
a model of the straighten-
ed extracellular domain of 
αIIbβ3 is shown (left), as it 
is in further detail within 
the EGF3 domain (right). 
Figures are adapted from 
Zhu et al., 2008 (32) (with 
permission). B) Extracted 
nucleotide alignment 
for the IEGF-3 domain 
of β3 from different 
species. Alignment analy-
sis was performed by 
using MEGA 6 software. 
Note that the codon for 
Gly540 is highly con-
served.
A
B
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αIIbβ3 expression on the cell surface. Apparently, Gly540 falls 
within a structurally important region of the β3 chain, since it is 
located in the EGF3 domain (▶ Figure 6 A), surrounded by three 
disulfide bonds, Cys536–544, Cys542–547 and Cys549–558 21. A 
nearby-mutation, Cys542Arg, has previously been reported to 
cause type 1 GT (22, 23). Furthermore, the amino acid Gly at posi-
tion 540 is highly conserved across species (▶ Figure 6 B).
More recently, the same mutation was discovered in a type 1 
GT patient (GT53) from Argentina (24). In contrast to our num-
bering (based on mature protein), the position of the amino acid 
exchange in this paper was stated as 566 (based on immature pro-
tein; initiating Met stated as position +1).
It is well-known that type 1 GT patients with virtually absent 
αIIbβ3 expression can develop isoantibodies against αIIbβ3, lead-
ing to platelet transfusion refractoriness (7). Mutations of β3 can, 
however, not only alter the expression of αIIbβ3, but also of αvβ3 
(13, 23, 25). Whether defective αvβ3 contributes to bleeding sever-
ity in GT patients are currently unclear (1); and the question 
whether such patients can develop isoantibodies against αvβ3 was 
purely speculative so far. To answer this question, absorption 
studies using recombinant αIIbβ3 coated on agarose beads were 
performed (▶ Figure 4 A). When absorbate (i. e. unbound anti-
bodies in the supernatant) was analysed, it did not show any reac-
tion with platelet αIIbβ3, but was strongly positive with endothe-
lial αvβ3. In contrast, the eluate (i. e. antibodies eluted from 
αIIbβ3-coated beads) exclusively reacted with platelet αIIbβ3, but 
not with platelet-derived or endothelial-derived αvβ3. These re-
sults could be further confirmed by immunoprecipitation with 
platelets from a normal donor, from which the patient’s serum pre-
cipitated both, αIIbβ3 and αvβ3. Thus, we demonstrate for the first 
time that type 1 GT patients can develop not only anti-αIIbβ3, but 
also anti-αvβ3 iso-antibodies. Whereas anti-αIIbβ3 isoantibodies 
did not have functional impact on platelets or endothelial cells, 
anti-αvβ3 isoantibodies interfered significantly with endothelial 
functions. Accordingly, the two isoantibody entities in this patient 
are unequivocally different, both in an immunological and func-
tional sense.
Theoretically, anti-αvβ3 iso-antibodies should not harm the GT 
patient himself. The question whether such antibodies are able to 
contribute to platelet transfusion refractoriness in addition to anti-
αIIbβ3 remains speculative for the moment.
However, transfer of anti-αvβ3 iso-antibodies is a relevant 
clinical condition that needs to be considered during pregnancy. 
These antibodies can pass the placenta and induce fetal/neonatal 
iso-immune thrombocytopenia, a condition that shares clinical 
features with fetal/neonatal alloimmune thrombocytopenia (25). 
Siddiq et al. recently reported on maternal immunisation against 
platelet antigens in a large cohort of GT mothers (12); fetal and 
neonatal death occurred only in mothers with antibodies. Anti-
αIIbβ3 isoantibodies were also identified in association with in-
tracranial haemorrhage (ICH) in two severely thrombocytopenic 
newborns from GT type 1 mothers (11, 26). However, maternal 
isoantibodies against αIIbβ3 were also found in healthy new-
borns without any signs of bleeding (12, 27-29). Since we have 
demonstrated that anti-αvβ3 isoantibodies hold special proper-
ties of interfering with endothelial function, it is intriguing to 
speculate whether isoanti-αvβ3 plays a role in the development 
of severe iso-antibody mediated thrombocytopenia, especially in 
cases with ICH.
It should be noted that in some GT cases, in contrast to the case 
reported here, β3 missense mutations appear to have different im-
pact on the expression and function of αIIbβ3 and αvβ3 (24, 30, 
31). Theoretically, mutated β3 in these patients may trigger the de-
velopment of autoantibodies against β3 integrins, the proof of 
which is currently lacking.
In conclusion, we have shown that in a type 1 GT patient with a 
β3 (Gly540Asp) mutation, platelet transfusions have led to the 
formation of anti-platelet iso-antibodies which include both, anti-
bodies of anti-αIIbβ3 and anti-αvβ3 specificity, with distinctive 
functional properties. We assume that iso-immunisation against 
αvβ3 may occur regularly in type 1 GT patients. Further research 
on the clinical consequences of anti-αvβ3 iso-immunisation is 
required.
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What is known about this topic?
• Patients with type 1 Glanzmann’s disease are prone to develop 
isoantibodies against αIIbβ3, the major β3 heterodimer on the 
platelet surface, as a consequence of transfusion or pregnancy.
• These isoantibodies may result in platelet transfusion refractori-
ness or, during pregnancy, in fetal/neonatal iso-immune throm-
bocytopenia.
• Isoantibodies against αvβ3, the second β3 heterodimer on the 
platelet surface, are not characterised in GT patients so far.
What does this paper add?
• Here, for the first time, isoantibodies against αvβ3 are demon-
strated in a patient with type 1 Glanzmann’s disease.
• These isoantibodies are unequivocally different to anti-αIIbβ3 
isoantibodies, both in an immunological and functional sense.
• Since these isoantibodies have significant impact on endothelial 
cell function, further research is warranted, above all in female GT 
patients of childbearing age.
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Extra Table 
What is known on this topic: 
 
• Intravenous IVIG has been used as the best choice for antenatal treatment of 
FNAIT patient with some restricted problem regarding capability to increase 
platelet count on fetal and neonatal  
• In vivo experiment showed Fab fragment from mouse monoclonal anti-HPA-1a 
(SZ21) could replacing the binding site of mother antibody against HPA-1a and 
prevent platelet clearance in circulations  
• Deglycosylated mouse monoclonal anti-HPA-1a (SZ21) pass through the 
placenta and give satisfied results to prevent platelets clearance by 
macrophages. 
 
What this paper adds: 
 
• Here, we used for the first time deglycosylated humanized chimeric monoclonal 
antibody against HPA-1a term as mab d-813  
• Based on the in vitro experiment by using endothelial cells, mab d-813 could 
prevent endothelial disturbance, additional invivo analysis showed that d-813 
may prevent platelet clearance mediated by maternal anti-HPA-1a 
• These results give new possibility that d-813 can be used as a novel antenatal 
treatment of FNAIT  
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Abstract 
In this study, we proved whether modified human monoclonal antibody 
against HPA-1a (mab 813), can prevent endothelial dysfunction induced by 
maternal anti-HPA-1a alloantibodies. For this purpose, we removed the N-linked 
carbohydrate component of mab 813 by digestion with N-glycanase. This 
modified mab 813 (termed d-813) has several advantages; can inhibit the binding 
of maternal anti-HPA-1a antibody, can pass placenta barrier, but cannot 
recognize by RES system. Thus, the use of such antibody for prenatal treatment 
of FNAIT is feasible (Bakchoul et al, 2013). Here, we could demonstrate that d-
813 itself did not impair endothelial functions, but d-813 administration prevents 
endothelial dysfunction mediated by maternal anti-HPA-1a. In addition, our in vivo 
experiment using NOD/SCID mouse model showed that d-813 could also prevent 
platelets clearance induced by anti-HPA-1a antibodies. This work represents the 
first evidence for the use of modified mab as drug for prenatal treatment of FNAIT 
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Introduction 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a serious 
condition which is occurs as a result of transplacentally maternal antibodies 
reactive with platelet antigens which have associated to fetal and neonatal 
thrombocytopenia. In healthy fetuses, the platelet count is approximately 150 × 
109/L at 10 to 17 weeks of gestation and reaches 265 ± 59 × 109/L by 30 to 35 
weeks of gestation, in contrast on the fetus and neonate which is suffering of 
FNAIT the platelet count less than 150 × 109/L and it is possible will significantly 
decreased until less than 20× 109/L. The incidence of FNAIT is estimated at 1 per 
1500-2000 live births of neonates especially in Caucasian populations (Kjeldsen-
kragh et al. 2016; Bussel 1997; Bussel et al. 2005). However, this prevalence 
rate does not include the incidence of miscarriage in FNAIT, since the rate of 
affected women is largely unknown. FNAIT carries significant risks including 
intrauterine growth restriction (IUGR), intrauterine fetal demise and the most 
serious risk of  FNAIT is intracranial hemorrhage which may have incidence is 14 
- 20% on symptomatic  infant (Mueller-Eckhardt  et al., 1989; Bussel et al., 1991, 
2005; Kaplan et al., 1991, Bertrand et al., 2011 blood). ICH may lead to death or 
persistent neurological sequel on the baby (McQuilten et al. 2011; Symington & 
Paes 2010). Occurrence of FNAIT in primiparous women is more common up to 
50% of cases, thus making the diagnosis and treatment of this disease are more 
difficult, furthermore ICH may also occur intrauterine, on the 20 weeks ages of 
pregnancy (Tiller et al. 2015; Sachs 2013), since ICH are occurring earlier its 
make antenatal treatment of FNAIT are very necessary to be applied.  
To days, injection of intravenous IgG (IVIG) with and without corticosteroid and 
also intra uterine transfusion with compatible platelet (IUPT) are being done as 
an antenatal treatment of FNAIT. IVIG treatment is relatively effective. However, 
this therapy relies on a human derived product, thus its make an open chance to 
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blood transmitted disease. In addition until today remain unclear, how is the IVIG 
protective mechanism. In a few case treatment failures have been reported, 
clinical observation show that administration of IVIG already failed to increase the 
amount of foetal or neonatal platelets counts (Bussel & Primiani 2008; Esa & Hhh 
2008; Kanhai et al. 2005; Giers et al. 2010). Administration of IUPT also have 
limitations, and IUPT may increasing the risk of iatrogenic fetal death (Birchall et 
al. 2003). Thus, there is still opening possibility to solve the weakness of FNAIT 
antenatal treatment.  
 
Material and Methods 
Monoclonal antibodies 
Monoclonal antibodies (mabs) against IIb3 complex (clone Gi5) was produced 
and characterized in our laboratory. Mab SZ22 and SZ21 was purchased from 
Beckman Coulters, Krefeld, Germany. Humanized mab SZ21 (against HPA-1a) 
were from Dongying Lida Pharmaceutical, Suzhou, China. Mab against v3 
complex (clone 23C6) was purchased from Millipore, Temecula, CA, USA. RGD 
peptide was from Bachem, Bubendorf, Switzerland. Deglycosylated mabs was 
produced by incubation of 150 μg IgG with 40 μl N-glycanase (500.000 Units/ml; 
New England Biolabs, Ipswich, MA, USA) for 2 hours at 37°C. Intravenous IgG 
(IVIG) was derived from Biotest Pharma GmbH (Dreieich, Germany). 
 
Surface Plasmon Resonance 
The surface plasmon resonance experiments were performed using a ProteOn 
XPR 36 Protein Interaction Array System (BioRad, Munich) equipped with a 
research-grade GLC ProteOn sensor chip. The ligand (mab 813) was 
immobilized covalently using amine-coupling chemistry according to the 
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suppliers’ protocol. Briefly, four parallel channels  of the chip surface were 
activated with a 1:1 mixture of 400 mM 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimid (EDAC) and 100 mM N-
hydroxysulfoxuccinimide (s-NHS) at a flow rate of 30 μl/min for 300 s. The 
capturing antibody was immobilized at a concentration of 10 μg/ml in sodium 
acetate, pH 4.5 was immobilized on all channels at densities between 3200-3500 
RU. Remaining active sides on the surfaces were blocked with 1 M 
ethanolamine. Rec. IIb3 and  v3 at concentrations 2.4 μg/ml in running 
buffer (10 mM HEPES, 150 mM NaCl, 2 mM MgCl2, 2 mM CaCl2 and 0.005% 
TWEEN 20, pH 7.4), were injected simultaneously over channels 1 and 2 and 3 
respectively, flow channel 4 was left blank to serve as a reference surface 
representing uncovered capturing antibody interactions.  
 
Adhesion assay 
Microtiter wells (Greiner Bio-one, Frickenhausen, Germany) were coated with 
vitronectin (Athens Research and Technology, Athens, GA, USA) or BSA (Serva, 
Heidelberg, Germany) in HBS buffer (119 mM NaCl, 4 mM KCl, 11 mM Glucose 
in 20 mM Hepes buffer) overnight at 4°C. After washings, wells were then 
blocked with 100 μl 3% BSA for one hour at 4°C. Aliquots of washed HUVEC 
cells (1-4 x106) were added together with mabs, purified IgG (final concentration 
5 μg/ml) for 1 hour at 37°C. Wells were washed once, and adherent cells were 
stained with crystal violet (Sigma, Steinheim, Germany) and measured in a 
microtiter reader at 592nm (SunriseTM, Tecan, Männedorf, Germany).  
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Apoptosis assay 
Cell apoptosis was measured by the Caspase-Glo 3/7 assay (Promega, Madison, 
WI, USA). 100 μl vitronectin (2 μg/mL; Athens Research & Technology, Athens, 
GA, USA) were coated on 96 white well plates (Corning Incorporated, Corning, 
NY, USA) for 8 hours. Aliquots of 450 μl HUVEC suspensions (1-2x106 cells in 
EBM-2 medium) were incubated with mabs (final concentration 20 μg/ml), and 
cRGD (final concentration 20 μg/ml), then seeded onto vitronectin coated wells 
for 16 hours at 37°C, 5% CO2. 100 μl of Caspase-Glo 3/7 reagents were then 
added at room temperature and luminescence was measured using a microtiter 
reader (FLX800, Biotek Instrument Winooski, VT, USA).  
 
Morphological assessment of apoptosis  
Aliquots of 105 HUVEC were seeded onto μ-slide well (Ibidi, Martinsried, 
Germany) precoated with vitronectin (see above) together with purified human 
IgG (final concentration 20 μg/ml), mab (final concentration 20 μg/ml) and or 
cRGD (final concentration 20 μg/ml) for 16 hours at 37°C, 5% CO2. After 
washings with 300 μl ice-cold PBS pH 7.4 (PAN, Aidenbach, Germany), cells 
were fixed with 300 μl 4% paraformaldehyde (PFA; Sigma) for 15 min and 
incubated with 1μg/ml blue fluorescing dye (Hoechst 33342; Thermo Scientific, 
Rockford, IL, USA) for 3 min at RT. Stained chromatin DNA was analysed using 
confocal microscopy with 60x magnification (Nikon Eclipse TE2000-E, Tokyo, 
Japan).  
 
Tube formation assay 
Aliquots of 50 μl ice-cold gel (Biovision, Milpitas, CA, USA) were plated onto 
microtiter wells (Greiner Bio-one, Frickenhausen, Germany) for 45 min at 37°C. 
100 μl HUVEC (1-5x105 cells in EBM2 medium supplemented with 2.5% FCS) 
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were seeded carefully onto the gel for 45 min at 37°C. Thereafter, 100 μl EBM2 
medium containing thrombin (1 U; Sigma, Steinheim, Germany) or mabs (final 
concentration 40 μg/ml) or mabs (final concentration 40 μg/ml) were added. Cells 
were allowed to grow for 20 hours at 37 °C. Data were analysed using a F-view 
monochrome fluorescence microscope (Olympus, Tokyo, Japan) with 10x 
magnification. For the quantification of tube length, data were imported as TIFF 
files into ImageJ (http://imagej.nih.gov/ij/) using the stage micrometer as 
calibrator.  
 
Analysis of d-813 in NOD/Scid mouse   
Human platelets (PLTs) from HPA-1ab donors were prepared. Briefly, blood was 
drawn into ACE and supplemented with PGE1 at 50 ng per mL. After 10 minutes 
at RT, blood was centrifuged at 200 × g for 10 minutes. Washed PLTs were 
prepared as described previously, resuspended in autologous human plasma at 
2.0 × 109 per mL, supplemented with PGE1 to 50 ng per mL, allowed to rest for 
30 minutes, and injected into the retroorbital plexus of age- and sex-matched 
NOD/SCID mice (Stock No. complexes, 001303; The Jackson Laboratory, Bar 
Harbor, ME). Thirty micrograms of mab d-813, 813 or control in 200 μL of sterile 
Dulbecco's phosphate-buffered saline was injected intraperitoneally (IP) 
immediately after introducing the human PLTs. After a blood sample was taken to 
establish baseline human PLT counts, 800 μg of maternally derived anti-HPA-1a 
or control IgG was injected IP. Blood samples of 20 to 50 μL were taken 
periodically via tail tip amputation into 1 mL of a 1:9 mixture of 3.8 percent 
sodium citrate/Tyrodes-HEPES buffer containing PGE1 at 50 ng per mL. The 
blood mixture was layered onto 2 mL of Fico/Lite PLTs (Atlanta Biologicals, 
Lawrenceville, GA) and centrifuged for 15 minutes at 350 × g, and the PLT layer 
(1 mL) added to 3.0 mL Tyrodes-HEPES buffer supplemented with 67 ng per mL 
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PGE1. PLTs were washed by centrifugation at 750 × g for 10 minutes, 
resuspended in 50 μL Tyrodes-HEPES buffer and the percentage of circulating 
human PLTs was determined by flow cytometry using FITC-labeled monoclonal 
antibody AP2. 
 
Statistics 
Statistical comparisons were made using an unpaired, 2-tailed Student’s t test or 
1-way ANOVA followed by Bonferroni’s post-hoc test, as appropriate. A p-value 
<0.05 was assumed to represent statistical significance.  
 
Results 
N-glycan modification of chimeric monoclonal antibody 813 by using PNG-
ase F 
To modify the N-glycan the humanized mab813 were deglycosylated and 
performed by using PNGase F, additionally, SDS-PAGE followed by silver 
staining was prepared to analyzed the degradation of antibodies, and as we 
expected after glycosylation native 813 are migrate more slowly compare to d-
813 (Figure 1).  
 
Deglycosylated 813 (d-813) showed similar binding affinity to unmodified 
813 
To investigate whether removing N-glycan impaired the binding affinity of 
the antibody surface plasmon resonance (SPR) was performed. In this 
experiment, we compared untreated and modified 813.  Sensor chips were 
coated with recombinant IIb3 and v3, followed by the injection of 813 and d-
813 in the different concentrations. Antibody binding was analyzed during an 
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association phase and a dissociation phase. For 813 a KD was observed to 
IIb3 and v3 is 1.54 x 10-12 and 7.43 x 10-11, which comparison to d-813 a KD 
was observed to IIb3  and v3 is 3.48 x 10-12 and 6.67 x 10-11 (Figure 2). 
Taking together, these data confirm that N-glycan removal did not impair the 
binding affinity of 813 and d-813 to the IIb3 and v3 integrin epitope.  
 
d-813 prevent endothelial disturbance mediated by maternal anti-HPA-1a 
The next experiment, we performed several functional assay to prove 
wheater d-813 may prevent endothelial disturbance mediated by maternal anti-
HPA-1a. All of the experiment are repeated three times and performed by using 
monoclonal antibody and IgG fraction derived from IIb3 coupling beads 
absorption method.  
The first experiment we performed adhesion test to prove whether 
deglycosylated 813 can prevent the binding of endothelial cells onto vitronectin 
matrix in the presence of a-HPA1a. In comparison to well established inhibitors, 
cRGD and anti-Vitronectin receptor, both native and deglycosylated 813 did not 
inhibit the binding of endothelial cells to vitronectin, additionally  by using several 
different concentration of d-813 (20, 40, 60, and 80 μg/ml), d-813 have capability 
to inhibit the effect of a-HPA-1a in the endothelial cells on the high concentration 
(Figure 3). 
Furthermore, we performed caspase 3/7 assay to prove whether 
deglycosylated 813 is able to inhibit endothelial apoptosis. In this experiments, 
we used three FNAIT ICH positive sera and shown that the presence of d-813 
can inhibit endothelial cells apoptosis induced by a-HPA1a (Figure 4A) additional 
experiment with the microscopy analysis showing also that d-813 decreasing the 
amount of endothelial cells nucleus fragmentation (Figure 4B). 
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Subsequently, we also performed tube formation assay to analyze 
whether the d-813 would also prevent anti angiogenic effect derived from 
maternal anti-HPA-1a. The results described that in contrast to the absence of d-
813, the presence of d-813 is able to inhibit the anti-angiogenic effect of anti-
HPA-1a (Figure 5A). Representative microphotographs are shown in Figure 5B 
(right panel). 
Taken together, the d-813 bound into endothelial cells and may inhibits 
cellular detachment to vitronectin, prevent cell apoptosis (anoikis), and 
consequently keep the angiogenic formation from the endothelial cells. 
 
d-813 could prevent platelets clearance mediated by maternal anti-HPA-1a 
To prove whether deglycosylated 813 may induce human platelet 
clearance untreated and deglycosylated 813 together with anti-HPA -1a were 
injected to NOD/SCID mouse prior to injection with human platelets. Periodically 
Human platelet clearances were examined in different time periods (60, 120 and 
300 minutes) by flow cytometry. Significant platelet clearance was observed with 
native 813 and anti HPA-1a. In contrast, d-813 did not induce platelet clearance 
similar to untreated control, and surprisingly giving d-813 together with anti-HPA-
1a may prevent any platelet clearance (Figure 6). 
 
Discussion 
Currently to prevent the effect because of FNAIT especially to avoid 
severe thrombocytopenia and ICH in the neonates a lot of effort already conduct. 
Since 1988 until today, IVIG is widely used as compromising and effective 
antenatal therapy for FNAIT, IVIG seems to give more protection against ICH, 
even this treatment are not guaranteed without side effect, meanwhile also on the 
persistence severe thrombocytopenia conditions the failure of the treatment still 
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presence on high-risk ICH mother  (Bussel et al. 1996; Bussel et al., 2011) that’s 
why optimal treatment regimens remain to be determined (Pacheco et al. 2011; 
Radder et al. 2004; Rayment et al. 2011). In addition, the mechanisms of IVIG in 
the treatment of immune-mediated thrombocytopenia is somehow controversial 
and debatable until today only one evidence mention how is IVIG mechanism, 
Widiapraja, and coworkers proposed that IVIG may protect the cells by reducing 
the inflammation rate (Widiapradja et al. 2014; Widiapradja et al. 2012). Recently 
in the last few year, such a preventive strategy has been proving successful in 
the murine model. Administration of anti-integrin β3 sera before injection of 
integrin β3 positive platelets in an integrin β3-/- murine model of FNAIT prevented 
the formation of anti-platelet antibodies and reduced bleeding complications in 
newborn pups (Tiller et al. 2015). Currently, clinical trials regarding FNAIT 
prevention based on prophylaxis are underway to test the potential of immunity of 
anti-HPA-1a IgG to prevent HPA-1a immunization (Kjeldsen-kragh et al. 2016), 
however, for this project the numbers of women HPA-1a alloimmunized in 
pregnancy which is needed as plasma donor is relatively small. Also, immunizing 
HPA-1a-negative individuals with HPA-1a-positive platelets would result in rare 
immunizations because transfusion of HPA-1a positive platelets rarely stimulates 
an antibody response against HPA-1a. In addition, polyclonal anti-HPA-1a IgG 
would carry the risks of the human-derived product. Therefore, monoclonal 
antibodies (mAbs) specific for HPA-1a would be very interesting for replacing 
polyclonal antibody as a source for FNAIT treatment. 
Here in our study, we try to generate deglycosylated chimeric human 
mabs specific for HPA-1a term as d813 as antenatal treatment of FNAIT. Our 
group results previously suggest that on in vivo experiments deglycosylated 
mouse monoclonal anti HPA-1a (clone NGMSZ21) may pass through the 
placenta and compete to replacing the binding site of maternal alloantibody, thus 
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may prevent fetus platelets clearance by macrophages (Bakchoul et al. 2013). 
However, this antibody are still fully derived from mouse which has more highly 
side effect consequences if fully applied to human, to eliminate the 
immunogenicity of the mabs using genetic engineering we generate chimeric 
humanized 813 by eliminating the Fc fragment from murine became human Fc 
fragment. Deglycosylated with endoglycosidase F was performed to manipulated 
sugar at the position Asn 297 with endoglycosidase F (Figure 8). Since It has 
become increasingly clear that the Fc-linked glycosylation pattern regulates 
effector functions of IgG (Jefferis, 2009), Thus deglycosylation of the N-glycan 
attached to Asn297 inhibits recognition by Fc receptors on macrophages (FcRI, 
FcRIIa, FcRIIIa) as well as its ability to activate complement factor C1q 
(Nimmerjahn & Ravetch 2008). In contrast IgG transported from the maternal 
circulation to the fetus by binding to the neonatal Fc receptor of FcRn that is 
expressed in the placental villous syncytiotrophoblast (Leach et al, 1996; 
Roopenian and Akiles, 2007) FcRn-mediated IgG transport does not require 
carbohydrate moieties on the Fc part of the antibody for binding or transplacental 
transport (Palmeira et al. 2012; Einarsdottir et al. 2013). Thus, removal of the N-
glycan should not affect placental transport.  
In line with our finding Eksteen et al. describe new mab derived from a 
single memory B cell isolated from a woman which have HPA-1a immunized 
during pregnancy named as 26.4. This antibody could inhibit binding of maternal 
polyclonal anti-HPA-1a and have high specificity and binding affinity to HPA-1a, 
but unfortunately the epitope of mAb 26.4 is not constrained to the PSI domain, 
but extends to several domains of integrin β3 in contrast d-813 have a finite or a 
limited number of epitopes on the b3 integrin. Additonally Ghevaert et al. (2008) 
also prove that mab B2G1 derived from the maternal B cells of an FNAIT cases 
by phage display can block the binding of maternal anti-HPA1a in the range 70% 
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to 95% in 18 cases of FNAIT. Base on this evidence we postulated that d-813 is 
HPA-1a specific antibodies have a sufficient affinity to block maternal antibodies 
to the HPA-1a epitope. Interestingly mAb 26.4 bound with higher affinity to 
integrin αvβ3 from trophoblasts (Eksteen et al. 2015), compared to another HPA-
1a-specific, B2G1 (Ghevaert et al. 2008). Additionally by using surface plasmon 
resonance compared to the native 813, d-813 performed the same binding 
affinity both to the IIb3 and v3.  
There is necessary to analysis the effect of d-813 both on the platelets 
and ECs, thus in vivo and in vitro experiment were performed. On the in vivo 
experiment by using NOD/SCID mouse model upon the presence of HPA-1a 
antibodies, we have shown that d-813 may prevent platelets clearance from 
circulation. Moreover in our in vitro models prior the presence of d-813, this 
antibody seems did not inhibit adhesion of the ECs into vitronectin matrix, did not 
induce any apoptosis and did not impaired tube formation in angiogenesis assay. 
When anti-HPA1a are adding to the ECs prior the presence of d-813, this 
antibody have the capability to prevent apoptosis and restore angiogenesis as 
well as on the presence of IVIG. These results convince the capability of d-813 to 
prevent endothelial dysfunction cause by HPA-1a antibodies which react to the 
v3 on the ECs especially to the brain and trophoblast. Inconclusion our 
experiment results confirm the therapeutic potential of d-813 as an alternative to 
antenatal treatment of FNAIT even how is the mechanism of the antibodies to 
give protection to the platelets and ECs need to be work out. 
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Figure legends 
Figure 1. N-glycan modification of humanized 813 term as“d-813”. 
Monoclonal antibodies 813 was treated with endonuclease F for 45 
minutes in 370C following by SDS-PAGE and visualized by silver 
staining. All of the glycan start at the position if Asp 297 were removed 
indicated by decreasing of d-813 molecular weight. 
 
Figure 2. Binding analysis of d-813 to IIb3 and v3 integrins by Surface 
Plasmon Resonance(SPR) 
Recombinant IIb3 and v3 proteins were immobilized on the 
sensor chip. Different concentrations of native and deglycosylated 813 
were injected, and the binding was recorded in real-time. SPR 
analysis showed there is no differences binding affinity between native 
and deglycosylated 813 to the IIb3 and v3 integrins 
 
Figure 3. Cell adhesion Analysis  
Endothelial cells were incubated with monoclonal antibodies (mabs) 
813, d813, mabs against v3, and purified IgG from sera HPA-1a (20 
μg/ml) and added to microtiter wells pre-coated with vitronectin. After 
washings, adherent cells were stained with crystal violet and measured 
in an ELISA reader. Statistical analysis was performed by 1-way 
ANOVA followed by Bonferroni’s post-hoc test; n.s. = not significant. 
cRGD was used as a positive control anoikis. Representative 
microphotographs of cell adhesion assay as outlined are given in the 
lower panel.  
 
 
Figure 4. Cell apoptosis.  
Monoclonal antibodies (mabs) 813, d813, and purified IgG (20 μg/ml) 
was added to endothelial monolayers and caspase 3/7 activity was 
measured by luminometry (upper panel). Some experiments were 
performed in the presence of  IVIG. Statistical analysis was performed 
by 1-way ANOVA followed by Bonferroni’s post-hoc test; n.s. = not 
significant; C = control IgG from healthy donors. mabs against v3 
was used as positive control. Nucleus staining of endothelial cells with 
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DAPI after incubation with anti-HPA-1a IgG, d-813, IVIG and controls 
were performed with representative pictures (60 fold magnification) 
(lower panel). 
 
Figure 5. Tube formation analysis 
Monoclonal antibodies (mabs) 813, d813, Purified IgG (40 μg/ml) was 
added to endothelial cells, and tube formation was investigated by 
microscopy. Data are given as mean of tube length in μm +SD (upper 
panel). Some experiments were performed in the presence of  IVIG as 
indicated. Statistical analysis was performed by 1-way ANOVA 
followed by Bonferroni’s post-hoc test; n.s. = not significant. C = control 
IgG; T = thrombin. Representative microphotographs of endothelial 
tube formation assays as outlined are given in the lower panel.  
 
Figure 6. Mab d-813 prevents anti–HPA-1a antibody-mediated platelet 
destruction in a NOD/SCID mouse model of alloimmune 
thrombocytopenia. 
Resting human platelets (HPA-1ab) were injected retroorbitally into 
NOD/SCID mice and the survival of platelets was analyzed. Results 
are shown as a median and range of experiments that were performed 
in duplicate with anti–HPA-1a antibodies from a FNAIT cases. When d-
813 was injected before the maternal anti–HPA-1a antibodies, the 
elimination of platelets was largely inhibited (orange symbols), This 
finding also presents in the administrated of d-813 (black symbol) as 
well as the control antibody alone which did not induce any relevant 
platelet destruction (green symbols). However, the injection of maternal 
anti–HPA-1a and native 813 resulted in a rapid destruction of 
circulating human HPA-1a platelets (blue symbols). 
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I M M U N O H E M A T O L O G Y
Alloantibody against new platelet alloantigen (Lapa) on
glycoprotein IIb is responsible for a case of fetal and neonatal
alloimmune thrombocytopenia
Hevi Wihadmadyatami,1,3 Kathrin Heidinger,1 Lida R€oder,1 Silke Werth,1 Astrid Giptner,1
Holger Hackstein,1 Martin Knorr,2 Gregor Bein,1 Ulrich J. Sachs,1 and Sentot Santoso1
BACKGROUND: Fetal and neonatal alloimmune
thrombocytopenia (FNAIT) is caused by the destruction
of platelets (PLTs) in the fetus or newborn by maternal
PLTantibodies that crossed the placenta during
pregnancy.
STUDY DESIGN AND METHODS: In this study, we
aim to elucidate the properties of a new PLTalloantigen
(Lapa) that is associated with a severe case of FNAIT.
Analysis of maternal serum with phenotyped PLTs by
monoclonal antibody–specific immobilization of platelet
antigens showed positive reaction against PLT
glycoprotein (GP)IIb/IIIa and HLA Class I expressed on
paternal PLTs.
RESULTS: In contrast to GPIIIa-reactive anti-HPA-1a,
anti-Lapa alloantibodies precipitated predominantly
GPIIb. Indeed, a point mutation G>C at Position 2511
located in Exon 25 of the ITGA2B gene was found in
Lapa-positive donors. This mutation causes an amino
exchange Gln>His at Position 806 located in the calf-2
domain of GPIIb. Lapa-positive individuals were not found
in 300 random blood donors. Our expression study
showed that anti-Lapa alloantibodies reacted with stable
transfected HEK293 cells expressing the mutated GPIIb
isoform (His806). CHO cells carrying this isoform,
however, failed to react with anti-Lapa alloantibodies,
indicating that Lapa epitopes depend on the Gln806His
mutation and the carbohydrate composition of the GPIIb.
This mutation did not hamper the binding of anti-HPA-3a,
which recognizes a point mutation (Ile843Ser) located in
calf-2 domain. Finally, we found that Lapa and some
HPA-3a epitopes are sensitive to O-glycanase.
CONCLUSIONS: This study not only underlines the
relevance of rare HPAs on the pathomechanism of
FNAIT, but also helps to understand the pitfalls of
serologic assays to detect anti-GPIIb alloantibodies.
F
etal and neonatal alloimmune thrombocytopenia
(FNAIT) is a severe bleeding disorder of the fetus
and newborn, which is caused by destruction of
platelets (PLTs) by maternal alloantibodies during
the pregnancy and after birth. The alloantibodies are
directed against human PLT antigen (HPA) expressed on
fetal PLTs inherited from the father.1 Six diallelic HPA sys-
tems (HPA-1, -2, -3, -4, -5, and -15) have been established.
In addition, a number of private or rare HPAs associated
with FNAIT have been reported. Meanwhile, 22 low-
frequency HPAs (HPA-6bw to -14bw and HPA-16bw to
-28bw) have been assigned. Most of them (n5 18) reside
on glycoprotein (GP) IIb/IIIa, one on GPIbb and three on
GPIa (http://www.ebi.ac.uk/ipd/hpa/).
ABBREVIATIONS: FNAIT 5 fetal and neonatal alloimmune
thrombocytopenia; GP(s) 5 glycoprotein(s); MAIPA 5
monoclonal antibody–specific immobilization of platelet
antigens; SSP 5 sequence-specific priming.
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The GPIIb/IIIa complex (also known as aIIbb3) is the
major integral PLT GP that functions as receptor for fibri-
nogen and von Willebrand factor during PLT aggregation
and adhesion.2 The biosynthesis of GPIIb/IIIa in megakar-
yocytes is complex. Posttranslational processing including
modification of carbohydrate moieties from high man-
nose to complex form, as well as proteolytic cleavage into
heavy and light chains of GPIIb is important for the matu-
ration and expression of intact GPIIb/IIIa complex on the
PLT surface.3 A conserved N-glycan at Position 15 seems
to be important for the correct folding and complex for-
mation of GPIIb/IIIa precursors.4 In addition, it is also
known that GPIIb carries an O-linked carbohydrates
structure.5 The functional role of this O-glycan in the bio-
synthesis of ITGA2B/B3, however, is unknown.
Molecular genetic studies have demonstrated that
single-amino-acid mutations on PLT integrins are respon-
sible for the formation of most HPAs.6 However, several
studies indicated that the binding sites of PLT alloantibod-
ies depend not only on the single-amino-acid mutations,
but also on the three-dimensional structure and post-
translational modification of the ITGA2B/B3 complex.7-9
Furthermore, the binding sites of PLT alloantibodies seem
to be heterogeneous; some PLT alloantibodies require an
intact GPIIb/IIIa structure, whereas others do not.10-12
In this study, we describe a case of FNAIT caused by
maternal alloimmunization against a low-frequency anti-
genic determinant on GPIIb (termed Lapa), which is not
only formed by single missense mutation (Gln806Asn), but
also depends on the O-glycosylation of GPIIb.
CASE REPORT
The index patient was born as the second child of non-
consanguine parents. The sibling born 2 years before did
not have any evidence of bleeding and has developed nor-
mally. The index patient developed hematoma and pete-
chiae directly after birth. An initial full blood count showed
a PLT count of 2 3 109/L (reference interval, 140 3
1092360 3 109/L). The patient received a PLT transfusion
with poor increment and required further transfusions for
the next 2 weeks to maintain a PLT count of higher than
503 109/L. Initial serologic workup in a regional laboratory
included a PLT antibody screen (GenProbe, Lifecodes Pak
12 enzyme-linked immunosorbent assay [ELISA], Immu-
cor, Norcross, GA) as well as a PLT cross-match by indirect
monoclonal antibody–specific immobilization of platelet
antigens (MAIPA), both of which were reported as negative.
We received a first sample 4 weeks after birth. The maternal
serum was nonreactive in the indirect MAIPA with a panel
of HPA-phenotyped PLTs except for weak reactions against
HLA Class I. The cross-match test between maternal serum
and paternal PLTs, in contrast, was clearly positive for
GPIIb/IIIa and HLA Class I. Extended serologic testing did
not reveal any known HPA specificity. Genotyping excluded
incompatibility for rare HPAs residing on GPIIb/IIIa. The
number of GPIIb/IIIa and GPIb/IX molecules expressed on
the PLTs surface of the child was found to be normal
(57,300 molecules/PLT and 36,000 molecules/PLT,
respectively).
MATERIALS AND METHODS
Antibodies
Alloantibodies against HPA-1a and HPA-3a were obtained
from a mother who gave birth to a child with FNAIT.8,13
Control AB serum was obtained from a healthy male
blood donor. Monoclonal antibodies (MoAbs) Gi5, Gi9,
and Gi18 against GPIIb/IIIa, GPIa/IIa, and PECAM-1,
respectively, were produced and characterized in our lab-
oratory.14 MoAb FMC25 against GPIb/IX complex was
purchased from AbD Serotec (Oxford, UK). MoAb against
b2-microglobulin associated with human HLA Class I
(Clone B1G6) was from Beckman Coulter (Marseille,
France), and MoAb TEA 2/16 against CD109 was pur-
chased from BD Bioscience (Heidelberg, Germany).
Characterization of PLT alloantibodies by antigen
capture assay
PLTs from the father and known HPA-phenotyped healthy
blood donors were isolated from EDTA-anticoagulated
blood by differential centrifugation and stored at 48C in
isotonic saline containing 0.1% NaN3. Antibody detection
was performed using antigen capture assay, MAIPA, using
a panel of MoAbs against PLT GPs (see above) as previ-
ously described.15
Immunoprecipitation
PLTs and HEK293 cells (see below) were surface labeled
with 5 mmol/L NHS-LC-Biotin (Pierce, Rockford, IL) and
were precipitated as previously described.16 Labeled cell
lysates (100-300 mL) were incubated with 20 to 50 mL of
serum or MoAb (20 mg/ml) overnight at 48C in the presence
of 50 mL of protein G beads (Gerbu Biotechnik, Heidelberg,
Germany). After washingswith immunoprecipitation buffer
(50 mmol/L Tris, 150 mmol/L NaCl, 1% Triton X-100),
bound proteins were eluted by adding sodium dodecyl sul-
fate (SDS) buffer for 5 minutes at 1008C. Eluates were ana-
lyzed on 7.5% SDS-polyacrylamide gel electrophoresis
(PAGE) under reducing conditions. Separated proteins were
transferred onto polyvinylidene fluoride membranes and
developed with peroxidase-labeled streptavidin and a
chemiluminescence system (ECL, Amersham Biosciences,
Glattbrugg, Switzerland).
Nucleotide sequencing analysis
Full-length sequencing of ITG2B and ITGB3 was carried
out as described previously. Nucleotide sequences of poly-
merase chain reaction (PCR) primers, sequencing, and
RARE PLT ANTIGEN AND FNAIT
Volume 55, December 2015 TRANSFUSION 2921
reaction conditions are available upon request.17 Briefly,
GPIIb and GPIIIa coding regions of paternal genomic
DNA was PCR amplified with primers corresponding to
intronic sequence surrounding all exons of ITG2B and
ITGB3. PCR was carried out using a PCR system (Fast-
Start High Fidelity, Roche Diagnostic Corp., Indianapolis,
IN). Before sequence analysis PCR products (ranged from
500-1200 bp) were purified with a PCR purification kit
(QIAquick, Qiagen Sciences, Valencia, CA). Automated
sequence analysis was performed in both directions on a
genetic analyzer (ABI 3100, Applied Biosystems, Foster
City, CA).
Genotyping by allele-specific PCR
Genomic DNA was extracted from peripheral blood leu-
kocytes derived from 5 mL of EDTA anticoagulated by
the use of a blood and tissue kit (DNeasy, Qiagen, Dues-
seldorf, Germany). One-hundred nanograms of genomic
DNA was amplified using 1.25 mL (10 pmol/mL) of allele-
specific forward primer (2492-50-GCATCCACCTTCCGG-
GAC A(or G)-30-2511) and common reverse primer
(2622-50-GATGGGCAGCCCCCAGTC-30-2605), 4 mL of
dNTP (1.25 mmol/L each nucleotide), 2.5 U of Taq Gold
polymerase (Perkin-Elmer, Norwalk, CT), and 2.5 mL of
buffer (103) in a total volume of 25 mL. Thirty-four cycles
of denaturation at 958C for 30 seconds, annealing at 628C
for 30 seconds, and extension at 728C for 30 seconds were
performed. Before PCR, samples were denatured at 958C
for 5 minutes. HGH gene was run as internal control (for-
ward primer 408-50-CAGTGGCTTCCCAACCATTCCCTT-30-
432 and reverse primer 846-50-ATCCACTCACG GATTTCT
GTTGTGTTTC-30-819). PCR products were analyzed by
2% agarose gel electrophoresis stained with ethidium bro-
mide. A 100-bp DNA ladder standard was used (Biolabs,
Ipswich, MA).
Construction of GPIIIa allelic expression vector
A full-length GPIIb cDNA in the mammalian vector
pMPSV encoding for GPIIb His806 isoform (Lap
a) was pro-
duced by site-directed mutagenesis using a mutagenesis
kit (Quick Change, Stratagene, Heidelberg, Germany) as
previously described.16 For PCR amplification, site-
directed mutagenesis primers (50-CCACCTTCCGGGACA
CTCCC AGCCCTCCGAC-30 and 50-GTCGGAGGGCTGGGA
GTGTCCCGGAGGAAGGTGG-30) encompassing nucleo-
tides (2496-2526) of GPIIb cDNA were constructed. After
denaturation for 30 seconds at 958C, GPIIb wild-type plas-
mid (20 ng) was amplified for 12 cycles (denaturation at
958C for 30 sec, annealing at 558C for 1 min, and extension
at 658C for 12 min). PCR products were digested with
DpnI endonuclease for 1 hour at 378C and transformed
into DH5a high-efficiency competent Escherichia coli bac-
teria (Invitrogen, Carlsbad, CA). Plasmid DNA from posi-
tive clones was verified by nucleotide sequencing using
reverse primer (2622-50-GATGGGCAGCCCCCAGTC
-30-2605) and forward primer (50-2418-CTGGGGACCCAA
AGTGGAGC-30-2437) as described.
Stable transfection of Lapa alloantigen in CHO and
HEK cells
CHO cells (American Type Tissue Collection, Rockville,
MD) cells were grown in a-MEM (PAN, Aidenbach, Ger-
many) supplemented with 10% fetal calf serum (FCS;
PAN) and were transfected with allele-specific GPIIb con-
structs encoding for Gln806 (wild type) or His806 (mutant)
isoform together with wild-type GPIIIa construct as previ-
ously described.16 HEK293 cells (American Type Tissue
Collection) were grown in DMEM containing 10% FCS
and 1% penicillin-streptomycin and were transfected with
GPIIb allelic constructs and GPIIIa wild-type plasmid
using Superfect as recommended by the manufacturer
(Qiagen, Hilden, Germany). Stably expressing cells were
selected with genicitin and zeocin (genicitin final concen-
tration 800 mg/mL; zeocin 250 mg/mL; GIBCO BRL, Grand
Island, NY) and were sorted by the use of fluorescein iso-
thiocyanate (FITC)-labeled MoAb against CD41 (Becton
Dickinson, Heidelberg, Germany) by flow cytometry (FAC-
SAria, Becton Dickinson).
Flow cytometric analysis of stably transfected
CHO and HEK293 cells
Transfected cells were cultured over 2 weeks, and the sur-
face expression of recombinant GPIIb/IIIa complex was
measured by flow cytometry (FACSCalibur, Becton Dickin-
son) as previously described.16 Cells were incubated with
20 mL of serum for 30 minutes at 48C or with 20 mL of
FITC-labeled MoAb against CD41 (Becton Dickinson).
After being washed with phosphate-buffered saline (PBS)
buffer containing 0.5% bovine serum albumin, cells were
labeled with FITC-conjugated anti-human IgG antibody
(dilution 1:50; Dako, Hamburg, Germany), washed, and
measured as described.
Deglycosylation of GPIIb/IIIa on PLTs and
transfected HEK cells
A total of 2 3 106 PLTs or 5 3 105 transfected HEK293 cells
were treated with 1 mL of O-glycanase (75.000 units, New
England Biolabs, Ipswich, MA) for 2 hours at 378C in a
thermomixer (Eppendorf, Hamburg, Germany). After
incubation, cells were washed two times with 100 mL of
PBS buffer. One-hundred microliters of treated and
untreated PLTs or HEK293 cells was analyzed by the
MAIPA assay as described above.
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RESULTS
Serologic and immunochemical analysis
The cross-match analysis between maternal serum and
paternal PLTs in the MAIPA assay showed clear reactions
when MoAbs against GPIIb/IIIa and HLA Class I were
used as capture antibodies, but not with MoAbs against
GPIb/IX, GPIa/IIa, PECAM-1 and CD109 (Fig. 1A). When
maternal serum was tested with a panel of HPA-
phenotyped PLTs (12 different PLT suspensions), no reac-
tion was observed (data not shown). Furthermore,
extended genotyping of GPIIb and GPIIIa polymorphisms
ruled out the presence of known rare HPAs on paternal
PLTs. These results indicated that the maternal serum
contained an alloantibody against a new low-frequency
PLT alloantigen on GPIIb/IIIa, which we termed Lapa.
When immunoprecipitation analysis was performed with
biotin-labeled paternal PLTs, maternal serum precipitated
predominantly PLT GPIIb (Fig. 1B). This band could not
be precipitated from PLTs of a normal donor.
Genetic analysis
To ascertain the molecular genetic basis underlying the
Lapa antigen, paternal genomic DNA corresponding
with the coding regions of ITGA2B and ITGB3 was
sequentially amplified by PCR using 28 sets of primers.
No point mutation was found in ITGB3 gene (data not
shown). However, nucleotide sequencing of ITGA2B
gene encompassing the full length of GPIIb transcript
showed one nucleotide substitution G>C at Nucleotide
2511 located on Exon 25 of the ITGA2B gene (Fig. 2A).
This mutation predicted the amino acid Gln (negatively
charged side group) at Position 806 in Lapa-negative
and His (positively charged side group) in Lapa-positive
individuals. This result was confirmed by nucleotide
sequence analysis of the child (data not shown). Align-
ment analysis between human, mouse, and canine
genes showed that this mutation occurred in the calf-2
domain of GPIIb.
Genotyping of family member by
PCR–sequence-specific priming
To study the paternal inheritance of Lapa, genotyping
based on allele-specific PCR was established. Allele-
specific forward primers located in Exon 25 and universal
primer in Exon 26 were designed to amplify a 247-bp PCR
product (Fig. 2A). Figure 2B shows the pedigree of the
Lapa family. In accordance with the nucleotide sequencing
results, the index neonate (III.2) as well as the father (II.2)
were typed as heterozygous Lapa, whereas the mother
(II.1) was Lapa negative. Among 10 siblings, only four
DNA samples could be obtained. Two (II.3 and II.8) were
heterozygous Lapa, and two were negative (II.4 and II.7).
This result demonstrates the codominant inheritance of
Lapa antigen in the index family. However, further analysis
by using PCR–sequence-specific priming (SSP) in 300
unrelated Caucasian blood donors did not find any Lapa-
positive individuals.
Expression study of Lapa alloantigenic
determinant on mammalian cells
Allele-specific constructs encoding wild-type GPIIb
(Gln806) or mutant GPIIb (His806) were transfected into
hamster CHO cells together with GPIIIa wild-type con-
struct to prove the role of Gln806His mutation on the
Fig. 1. (A) Serologic analysis of Lapa antibody by MAIPA.
Paternal PLTs were incubated with maternal serum together
with MoAbs against PLT GPs (anti-GPIIb/IIIa, -GPIa/IIa,
-GPIb/IX, -PECAM, -CD109, and -HLA Class I). Bound human
antibodies were then detected by the use of enzyme-labeled
secondary antibody and substrate system. Reaction was
measured at OD490/620 using ELISA microtiter reader. (B)
Immunoprecipitation analysis of anti-Lapa. Paternal and
control PLTs were surface labeled with biotin and lysed.
Labeled PLT lysates were precipitated with control serum
(Lanes 1), anti-HPA-1a (Lanes 2), and maternal serum (Lanes
3). Immunoprecipitates were run on 7.5% SDS-PAGE under
reducing conditions. Separated proteins were then trans-
ferred onto polyvinylidene fluoride membrane and visualized
by the use of streptavidin and a chemiluminescence system.
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formation of Lapa alloantigen. Surprisingly, CHO cells
transfected with mutant GPIIb construct did not show any
reaction with anti-Lapa alloantibody in flow cytometry
(Fig. 3, left panel), although intact GPIIb/IIIa could be
detected by the use of complex-dependent MoAb Gi5. To
exclude the role of posttranslational modification of
GPIIb/IIIa on different cell lines, human-derived HEK293
cells were transfected with GPIIb constructs as above. In
contrast to the results that were obtained with CHO trans-
fectants, stable transfected HEK cells expressing mutant
GPIIb/IIIa showed positive reaction with anti-Lapa alloan-
tibody (Fig. 3, right panel). In the control experiment, no
reaction was found with anti-Lapa and the wild-type
GPIIb/IIIa. Similar results were obtained by immunopre-
cipitation analysis (data not shown). These results indi-
cated that Lapa alloantigenic determinants not only
depend on the point mutation Gln806His, but also on
the posttranslational modification of GPIIb. Further-
more, study was performed to prove whether some
MoAb used as capture antibody may inhibit the binding
of anti-Lap(a) antibodies leading to false-negative reac-
tion or weak reactivity. Weak reactivity was obtained
when MoAb SZ21 and MoAb SZ22 against GPIIIa and
GPIIb, respectively, were used. This result indicated that
MoAb against GPIIb/IIIa complex is advantageous for
the detection of anti-Lap(a) antibody (Fig. S1, available
Fig. 2. (A) Nucleotide sequencing analysis of amplified GPIIb from paternal DNA. Sequencing of PCR product encompassing
nucleotides 2503 to 2518 of GPIIb gene is presented. The nucleotide exchange G>C at Position 2511 (in heterozygous state) in
Exon 25 results in Gln806 (CAG)>His806 (CAG) is shown. The positions of allele-specific primers used for PCR-SSP are indicated.
(B) Pedigree and genotyping of the Lapa family. Genomic DNA was isolated from the family member and was amplified by PCR-
SSP (see above) using human growth hormone (HGH) as internal control (439 bp). PCR products (247 bp) were visualized on 2%
agarose gel electrophoresis. Open symbols5Lapa-negative individuals; solid symbols5Lapa-positive individuals. Dotted lines5
not done; 35dead.
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as supporting information in the online version of this
paper).
Figure 4A shows the location of Lapa in the calf-2
domain of GPIIb and three putative O-glycosylation sites,
one located adjacent, only five amino acids upstream (at
S801) of the polymorphic residue 806. Two further
O-glycosylation sites (at S845 and S847) are located more
closely to the Ile843Ser mutation associated with the HPA-3
alloantigen system. To prove the role of O-glycosylation on
the expression of Lap(a) antigen, HEK-transfected cells were
treated with O-glycosidase. Nontreated and treated cells
were then tested in theMAIPA assay usingMoAbGi5 as cap-
ture antibody (Fig. 4B, left panel). When transfected cells
were treated with O-glycosidase significant reduction of
anti-Lapa binding was detected. In contrast, no change of
anti-HPA-1a binding was observed upon treatment of trans-
fectants with this enzyme. In the control experiment anti-
Lapa alloantibody did not react with wild-type GPIIb/IIIa.
Similar results were obtained with PLTs. Fresh Lapa-positive
PLTs lost their reactivity against anti-Lapa antibodies after
treatment with O-glycosidase (Fig. 4B, right panel). This
result indicated that O-glycan contributes to the generation
of Lapa alloantigenic determinants.
Reactivity of anti-Lapa with HEK-transfected cells
after a long culture period
To study the stability of Lapa for a period of time,
HEK293-transfected cells expressing Lapa alloantigenic
determinant were cultured for 6 weeks, and cells were
analyzed every week by flow cytometry (Fig. 5). A continu-
ous reduction of anti-Lapa alloantibody binding was
observed every week. After 5 weeks, cells no longer
showed any reaction with anti-Lapa alloantibody (mean
fluorescence intensity [MFI], 17.33 vs. 2.59). In contrast,
the expression of GPIIb/IIIa on the cell surface of the cells
did not change significantly within this period (MFI,
157.84 vs. 126.98), and to prove the possibility that cell
freezing may cause the reduction of Lap(a) antigen rather
than culture conditions, transfected cells were thawed
after 4 months of storage in liquid nitrogen and were
tested by the MAIPA assay as previously described. No sig-
nificant change was detected indicating that freezing-
thawing procedure did not alter the expression of Lap(a)
antigenic determinants (Fig. S1, available as supporting
information in the online version of this paper). Although
our observation indicated that PLTs or transfected cells
stored for a short period (2-5 weeks) could be used for the
detection of anti-Lap(a) antibodies in the MAIPA, the use
of fresh PLTs, transfected cells, or fresh thawed cells is
recommended.
Two different types of anti-HPA-3a
In our previous study, we found that some anti-HPA-3a
alloantibodies reacted with recombinant HPA-3a
expressed on CHO cells (Type I) and some failed to react
with these transfected cells (Type II).12 Figure 6 shows the
reactivity of Type I and Type II anti-HPA-3a alloantibodies
with HPA-3a expressed either on CHO or by HEK293 cells
(wild type). Whereas Type I HPA-3a antibodies reacted
with both transfected cells, Type II antibodies only
Fig. 3. Flow cytometry analysis of cell-expressing mutant and wild-type GPIIb/IIIa. CHO- and HEK293-transfected cells were
incubated with MoAb against GPIIb/IIIa (Clone Gi5) or anti-Lapa. Isotype mouse IgG and AB serum were run as controls in par-
allel. After being washed, cells were labeled by secondary antibody (Alexa Fluor–labeled donkey anti-mouse IgG or fluorescein-
conjugated rabbit anti-human IgG). Labeled cells were analyzed by flow cytometry. Smooth lines5negative controls; bold lines5
anti-GPIIb/IIIa and anti-Lapa reactivity.
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reacted with HPA-3a expressed on HEK293 cells, but not
on CHO cells. However, this reaction disappeared when
HEK cells were treated with O-glycosidase (Fig. 6, right
panel), similar to the phenomenon observed with anti-
Lapa antibodies (see Fig. 4B). In contrast, Type I anti-
HPA-3a still reacted with O-glycosidase–treated cells.
Finally, we tested our transfected HEK cells expressing
Lapa as well as HPA-3a (mutant) with different anti-
HPA-3a by flow cytometry. All anti-HPA-3a (n5 4) tested
showed a positive reaction with these cells, indicating
that Gln806His mutation did not alter the binding of
anti-HPA-3a (data not shown).
DISCUSSION
In this study, we report on a new rare alloantigen, Lapa,
located on PLT GPIIb, involved in a case of FNAIT.
Indeed this serum contained antibodies against HLA
Class I molecules. Although anti-HLA Class I antibodies
Fig. 4. (A) Location of Gln806His associated with Lapa mutation in the calf-2 domain of GPIIb. The positions of three putative
O-linked glycosylation sites (at Amino Acids S801, S845, and S847) and Ile843Ser mutation responsible for HPA-3 system are indi-
cated. (B) MAIPA analysis of Lapa-positive cells treated with O-glycosidase. HEK293-transfected cells and PLTs expressing Lapa
antigen were treated with O-glycosidase or PBS (as control). After being washed, cells were incubated with anti-HPA-1a,
anti-Lapa, and AB serum as negative control together with MoAb Gi5 as capture antibody. After lysis, cells that bound human
antibody were detected using enzyme-labeled goat anti-human IgG and were analyzed by spectrophotometry. Reaction was
measured at OD490/620 using an ELISA microtiter reader. (w) Untreated cells; (W) O-glycosidase–treated cells.
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are often detectable in pregnant women, their role in
NAIT is considered controversial. Husebekk and Sko-
gen18 reported 51 of 195 cases of children with throm-
bocytopenia in whom only anti-HLA Class I antibodies
were detected, indicating that anti-HLA Class I antibod-
ies may cause thrombocytopenia in the fetus and new-
born. However, the mechanism is not yet formally
demonstrated.
Examination of the nucleotide sequence of ITGA2B
derived from the Lapa-positive father showed one nucleotide
substitution G>C at Position 2511 in the heterozygous state
located in Exon 25. Whereas Lapa-negative individuals carry
glutamine at Position 806, Lapa-positive individuals bear his-
tidine at this position. In a population study, none of 300
unrelated donors was found to carry the Lapa alloantigen.
Analysis of recombinant allele-specific GPIIb/IIIa in human
mammalian cells (HEK293 cells) showed that the single-
amino-acid substitution Gln806His is directly responsible for
the formation of Lapa alloantigenic determinant(s). However,
we found evidence that glycosylation of GPIIb is required for
the proper expression of this new PLTalloantigen since anti-
Lapa was nonreactive 1) when the antigen was expressed in
CHO cells, 2) when sugars were removed from transfected
HEK cells by glycosidase treatment, and 3) when transfected
HEK cells were cultured for a longer period of time.
The fact that glycosylation patterns differ between pro-
teins synthesized in HEK293 and CHO cells is known; in
Fig. 5. The stability Lapa antigen expressed on HEK293 cells
after a long culture period. HEK293-transfected cells were
incubated by MoAb Gi5 or anti-Lapa. Isotype mouse IgG and
AB serum were run as controls in parallel. After being
washed, cells were labeled by Alexa Fluor donkey anti-mouse
IgG or fluorescein-conjugated rabbit anti-human IgG.
Labeled cells were analyzed by flow cytometry.
Fig. 6. (A) The reactivity of different anti-HPA-3a with HPA-3a–transfected cells. CHO- or HEK293-transfected cells expressing
HPA-3a were incubated with different anti-HPA-3a (Type I and Type II) containing sera or AB serum as control. After washings,
bound antibodies were labeled with fluorescein-conjugated rabbit anti-human IgG and were analyzed by flow cytometry. Smooth
line5negative control; solid line5anti-HPA-3a. Note: Type I anti-HPA-3a reacted with both CHO- and HEK-transfected cells.
Type II anti-HPA-3a reacted only with HEK-transfected cells. (B) MAIPA analysis of HPA-3a–positive HEK293 cells treated with
O-glycosidase. HEK293-transfected cells expressing HPA-3a antigen were treated with O-glycosidase (W) or PBS (w). After being
washed, cells were incubated with Type I (#1, #2) and Type II anti-HPA-3a (#3, #4). MoAb Gi5 that reacted with GPIIb/IIIa com-
plex was used as capture antibody. After lysis, cells that bound human antibody were detected using enzyme-labeled goat anti-
human IgG and were analyzed by spectrophotometry. Reaction was measured at OD490/620 using an ELISA microtiter reader.
*Significant for p<0.05 (p50.009); n.s.5not significant for p<0.05 (p50.9893).
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comparison to CHO cells, HEK293 mammalian cells are
able to synthesis N- and O-glycosylation structures of
higher complexity.19 The point mutation Gln806His associ-
ated with Lapa is located in the calf-2 domain of GPIIb,
which contains three putative O-glycosylation sites (Ser801,
Ser845, and Ser847), one of which, Ser847, was identified as
the actual site of O-glycosylation.5,20 This physical proxim-
ity is a potential explanation for the involvement of glyco-
sylation in the formation of the Lapa epitope(s). Treatment
of HEK293 cells expressing Lapa with O-glycosidase abol-
ished the binding of anti-Lapa, supporting the concept that
a correct O-glycosylation of GPIIb is involved in Lapa epi-
tope(s) formation. The question whether O-linked carbohy-
drates attached to Ser847 or to other serine residues (Ser845
or Ser806) is directly involved in the Lap
a antigen formation,
however, remains to be established.20
When transfected HEK cells were cultured for approx-
imately 6 weeks and tested every week for surface expres-
sion by flow cytometry, no change of GPIIb/IIIa surface
expression was observed. In contrast, the expression of
the Lapa antigen decreased continuously and disappeared
in Week 6. A recent study demonstrated that changing cul-
ture medium and conditions could alter glycosylation
processes of different proteins in HEK cells,19 again under-
lining the importance of correct GPIIb glycosylation for
the Lapa antigen formation.
In our previous study, we observed that some anti-
HPA-3a (six of 10) reacted with HPA-3a expressed on CHO
cells.12 The HPA-3a alloantigen is not only determined by
a single-amino-acid mutation, Ile843Ser, but also depends
on the O-glycosylation of Ser847
5,8 and sialic acid resi-
dues.7,12,21 When we retested anti-HPA-3a that failed to
react with CHO cells, positive reactions were obtained
with HPA-3a expressed on HEK cells. Furthermore, this
reactivity was destroyed when HEK cells were treated with
O-glycosidase before incubation with anti-HPA-3a. These
results indicate that two different types of anti-HPA-3a
may develop during alloimmunization: Type 1, which rec-
ognize carbohydrate-independent epitopes (reactive with
HPA-3a expressed on CHO cells and with deglycosylated
HPA-3a expressed on HEK cells), and Type 2, which recog-
nize carbohydrate-dependent epitopes (nonreactive with
HPA-3a expressed on CHO cells and nonreactive with
deglycosylated HPA-3a expressed on HEK cells).
This is a relevant observation because allele-specific
transfected cell lines expressing low-frequency HPAs have
been introduced as PLT substitutes for the detection of
PLT alloantibodies.22,23 Based on the fact that glycosyla-
tion patterns may differ and even change during cell cul-
ture, screening for PLT antibodies with such cell lines
requires careful validation.
Taken together, we have demonstrated once more the
relevance of rare HPAs residing on PLT GPIIb/IIIa in the
pathomechanism of FNAIT and the importance of per-
forming serologic cross-matches between maternal serum
and paternal PLTs in the workup of thrombocytopenic
neonates. Furthermore, we underline the contribution of
carbohydrates on the formation of Lapa and HPA-3a epi-
topes and confirm the existence of different HPA-3a anti-
gen-antibody types. This knowledge may help us to
design better serologic assays to detect PLT-reactive anti-
bodies against GPIIb. Furthermore, the question whether
some PLT antibody types reacted with different glycosyla-
ted GPIIb may impair PLT clearance or PLT function is
intriguing.
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SUPPORTING INFORMATION
Additional Supporting Information may be found in
the online version of this article at the publisher’s
website:
Fig. S1. Top: Analysis of wild type (white columns) and
mutant transfected cells (black columns) after 4
months storage in liquid nitrogen with AB serum, anti-
HPA-1a and anti-Lap(a) antibody by the MAIPA using
MoAb Gi5 as capture antibody. Note: positive reaction
of Lap(a) antibody with mutant cells could be detected
although the cells were already kept for few months in
liquid nitrogen. Bottom: Analysis of anti-Lap(a) anti-
body with mutant cells by the MAIPA assay using
MoAbs against GPIIb/IIIa complex (clone Gi5), GPIIIa
(clone SZ21) and GPIIb (clone SZ22). Note: strong
reaction was only obtained with GPIIb/IIIa specific
MoAb.
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